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A B S T R A C T
Background
Nicotine replacement therapy (NRT) aims to temporarily replace much of the nicotine from cigarettes to reduce motivation to smoke and
nicotine withdrawal symptoms, thus easing the transition from cigarette smoking to complete abstinence.
Objectives
To determine the eEectiveness and safety of nicotine replacement therapy (NRT), including gum, transdermal patch, intranasal spray and
inhaled and oral preparations, for achieving long-term smoking cessation, compared to placebo or 'no NRT' interventions.
Search methods
We searched the Cochrane Tobacco Addiction Group trials register for papers mentioning 'NRT' or any type of nicotine replacement therapy
in the title, abstract or keywords. Date of most recent search is July 2017.
Selection criteria
Randomized trials in people motivated to quit which compared NRT to placebo or to no treatment. We excluded trials that did not
report cessation rates, and those with follow-up of less than six months. We recorded adverse events from included and excluded studies
that compared NRT with placebo. Studies comparing diEerent types, durations, and doses of NRT, and studies comparing NRT to other
pharmacotherapies, are covered in separate reviews.
Data collection and analysis
Screening, data extraction and 'Risk of bias' assessment followed standard Cochrane methods. The main outcome measure was abstinence
from smoking aOer at least six months of follow-up. We used the most rigorous definition of abstinence for each trial, and biochemically
validated rates if available. We calculated the risk ratio (RR) for each study. Where appropriate, we performed meta-analysis using a Mantel-
Haenszel fixed-eEect model.
Main results
We identified 136 studies; 133 with 64,640 participants contributed to the primary comparison between any type of NRT and a placebo or
non-NRT control group. The majority of studies were conducted in adults and had similar numbers of men and women. People enrolled in
the studies typically smoked at least 15 cigarettes a day at the start of the studies. We judged the evidence to be of high quality; we judged
most studies to be at high or unclear risk of bias but restricting the analysis to only those studies at low risk of bias did not significantly
alter the result. The RR of abstinence for any form of NRT relative to control was 1.55 (95% confidence interval (CI) 1.49 to 1.61). The pooled
RRs for each type were 1.49 (95% CI 1.40 to 1.60, 56 trials, 22,581 participants) for nicotine gum; 1.64 (95% CI 1.53 to 1.75, 51 trials, 25,754
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participants) for nicotine patch; 1.52 (95% CI 1.32 to 1.74, 8 trials, 4439 participants) for oral tablets/lozenges; 1.90 (95% CI 1.36 to 2.67, 4
trials, 976 participants) for nicotine inhalator; and 2.02 (95% CI 1.49 to 2.73, 4 trials, 887 participants) for nicotine nasal spray. The eEects
were largely independent of the definition of abstinence, the intensity of additional support provided or the setting in which the NRT was
oEered. Adverse events from using NRT were related to the type of product, and include skin irritation from patches and irritation to the
inside of the mouth from gum and tablets. Attempts to quantitatively synthesize the incidence of various adverse eEects were hindered
by extensive variation in reporting the nature, timing and duration of symptoms. The odds ratio (OR) of chest pains or palpitations for any
form of NRT relative to control was 1.88 (95% CI 1.37 to 2.57, 15 included and excluded trials, 11,074 participants). However, chest pains
and palpitations were rare in both groups and serious adverse events were extremely rare.
Authors' conclusions
There is high-quality evidence that all of the licensed forms of NRT (gum, transdermal patch, nasal spray, inhalator and sublingual tablets/
lozenges) can help people who make a quit attempt to increase their chances of successfully stopping smoking. NRTs increase the rate
of quitting by 50% to 60%, regardless of setting, and further research is very unlikely to change our confidence in the estimate of the
eEect. The relative eEectiveness of NRT appears to be largely independent of the intensity of additional support provided to the individual.
Provision of more intense levels of support, although beneficial in facilitating the likelihood of quitting, is not essential to the success of
NRT. NRT oOen causes minor irritation of the site through which it is administered, and in rare cases can cause non-ischaemic chest pain
and palpitations.
P L A I N   L A N G U A G E   S U M M A R Y
Can nicotine replacement therapy (NRT) help people quit smoking?
Background
We reviewed the evidence about whether NRT helps people who want to quit smoking to stop smoking at six months or longer. NRT aims to
reduce withdrawal symptoms associated with stopping smoking by replacing the nicotine from cigarettes. NRT is available as skin patches
that deliver nicotine slowly, and chewing gum, nasal and oral sprays, inhalators, and lozenges/tablets, all of which deliver nicotine to the
brain more quickly than skin patches, but less rapidly than from smoking cigarettes.
Study characteristics
This review includes 136 trials of NRT, with 64,640 people in the main analysis. All studies were conducted in people who wanted to quit
smoking. Most studies were conducted in adults and had similar numbers of men and women. People enrolled in the studies typically
smoked at least 15 cigarettes a day at the start of the studies. The evidence is current to July 2017. Trials lasted for at least six months.
Key results
We found evidence that all forms of NRT made it more likely that a person's attempt to quit smoking would succeed. The chances of
stopping smoking were increased by 50% to 60%. NRT works with or without additional counselling, and does not need to be prescribed
by a doctor. Side eEects from using NRT are related to the type of product, and include skin irritation from patches and irritation to the
inside of the mouth from gum and tablets. There is no evidence that NRT increases the risk of heart attacks.
Quality of evidence
The overall quality of the evidence is high, meaning that further research is very unlikely to change our conclusions.
Nicotine replacement therapy versus control for smoking cessation (Review)















































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Nicotine replacement therapy
Nicotine replacement therapy versus control for smoking cessation
Patient or population: people who smoke cigarettes
Settings: clinical and non-clinical, including over the counter
Intervention: nicotine replacement therapy of any form
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes













105 per 1000 162 per 1000
(156 to 168)
Limited behavioural support




at 6+ months fol-
low-up
Follow-up: 6 to 24
months









*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%
CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.









































































































































2There are likely to be some unpublished trials with less favourable results that we were unable to identify, and a funnel plot showed some evidence of asymmetry. However,
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B A C K G R O U N D
Nicotine replacement therapy (NRT) aims to reduce motivation
to smoke and the physiological and psychomotor withdrawal
symptoms oOen experienced during an attempt to stop smoking,
and therefore increase the likelihood of remaining abstinent
(West 2001). Nicotine undergoes first-pass metabolism in the liver,
reducing the overall bioavailability of swallowed nicotine pills. A
pill that could reliably produce high enough nicotine levels in the
central nervous system would risk causing adverse gastrointestinal
eEects. To avoid this problem, nicotine replacement products
are formulated for absorption through the oral or nasal mucosa
(chewing gum, lozenges, sublingual tablets, inhalator, spray) or
through the skin (transdermal patches).
Nicotine patches diEer from the other products in that they deliver
the nicotine dose slowly and passively. They do not replace any of
the behavioural activities of smoking. In contrast the other types
of NRT are faster-acting, but require more eEort on the part of the
user. Transdermal patches are available in several diEerent doses,
and deliver between 5 mg and 52.5 mg of nicotine over a 24-hour
period, resulting in plasma levels similar to the trough levels seen
in heavy smokers (Fiore 1992). Some brands of patch are designed
to be worn for 24 hours whilst others are to be worn for 16 hours
each day. Nicotine gum is available in both 2 mg and 4 mg strengths,
and nicotine lozenges are available in 1 mg, 1.5 mg, 2 mg and 4 mg
strengths. Nicotine nasal sprays are available in either 0.5 mg or
1 mg per spray strengths, and nicotine inhalators are available in
both 10 mg and 15 mg strengths. The amount of nicotine absorbed
by the user is less than the original dose. None of the available
products deliver such high doses of nicotine as quickly as cigarettes.
An average cigarette delivers between 1 and 3 mg of nicotine and
a person who smokes 20 cigarettes per day absorbs 20 to 40 mg of
nicotine each day (Henningfield 2005).
The availability of NRT products on prescription or for over-
the-counter purchase varies from country to country. Table 1
summarises the products currently licensed in the United Kingdom.
This review was first published over 20 years ago, in 1996, and
has been regularly updated since. In previous versions, this review
addressed not only the eEect of NRT in comparison to placebo
for helping people stop smoking, but also looked at comparisons
between diEerent forms and doses of NRT, and between NRT and
diEerent pharmacotherapies. The evidence that NRT helps some
people to stop smoking is now well accepted, and many clinical
guidelines recommend NRT as a first-line treatment for people
seeking pharmacological help to stop smoking (Fiore 2008; Italy
ISS 2004; Le Foll 2005; NICE 2008; NZ MoH 2014; Woolacott 2002;
Zwar 2011). We have therefore split the previous version of the
review; this review now only looks at NRT versus placebo or no
pharmacotherapy, with the intention that, given the stability of
this comparison, this review will no longer require regular updates.
Studies which compare doses, delivery, forms, and schedules
of NRT will now be covered in a companion review, which will
continue to be regularly updated, and is in development at the
time of writing. Comparisons between NRT and other frontline
pharmacotherapies are covered in separate Cochrane Reviews
(Cahill 2016; Hughes 2014). Where they meet our other inclusion
criteria, studies of NRT in pregnancy are included in the main
analysis of this review but are covered comprehensively in a
separate Cochrane Review (Coleman 2015), which will continue to
be updated. Readers specifically interested in NRT in pregnancy
should refer to Coleman 2015.
O B J E C T I V E S
To determine the eEectiveness and safety of nicotine replacement
therapy (NRT), including gum, transdermal patch, intranasal
spray and inhaled and oral preparations, for achieving long-term
smoking cessation, compared to placebo or 'no NRT' interventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials. We also include trials where
allocation to treatment was by a quasi-randomized method, but
use appropriate sensitivity analysis to determine whether their
inclusion alters the results.
Types of participants
We include men or women who smoked and were motivated to
quit, irrespective of the setting from which they were recruited
or their initial level of nicotine dependence, or both. We included
studies that randomized therapists, rather than smokers, to oEer
NRT or a control, provided that the specific aim of the study was
to examine the eEect of NRT on smoking cessation. We have not
included trials that randomized physicians or other therapists to
receive an educational intervention, which included encouraging
their patients to use NRT, but have reviewed them separately
(Carson 2012).
Types of interventions
Comparisons of NRT (including chewing gum, transdermal patches,
nasal and oral spray, inhalators and tablets or lozenges) versus
placebo or no NRT control. The terms 'inhaler' and 'inhalator' (an
oral device which delivers nicotine to the buccal mucosa by
sucking) are used interchangeably in the literature. We have used
the term 'inhalator' throughout the rest of this review.
In some analyses we categorized the trials into groups depending
on the level of additional support provided (low or high). The
definition of the low-intensity category was intended to identify
a level of support that could be oEered as part of the provision
of routine medical care. If the duration of time spent with the
smoker (including assessment for the trial) exceeded 30 minutes
at the initial consultation or the number of further assessment
and reinforcement visits exceeded two, we categorized the level of
additional support as high. The high-intensity category included
trials where there were a large number of visits to the clinic or
trial centre, but these were oOen brief, spread over an extended
period during treatment and follow-up, and did not include a
specific counselling component. To provide a more fine-grained
analysis and to distinguish between high-intensity group-based
support and other trials within the high-intensity category, we
have therefore specified where the support included multi-session
group-based counselling with frequent sessions around the quit
date.
Previously, this review had also included studies where all
arms received NRT (e.g. testing diEerent doses, types) and
studies comparing NRT with bupropion. These comparisons are
Nicotine replacement therapy versus control for smoking cessation (Review)
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now covered elsewhere; comparisons between diEerent NRT
treatments are covered in a companion review, currently under
development, and comparisons between NRT and bupropion are
found in Hughes 2014.
Types of outcome measures
The review evaluates the eEects of NRT versus control on smoking
cessation, rather than on withdrawal symptoms. We excluded trials
that followed up participants for less than six months, except
for trials amongst pregnant women, where the interval between
enrolment and delivery may have been shorter (if less than six
months, these were excluded from the main analysis). For each
study we chose the strictest available criteria to define abstinence.
For example, in studies where biochemical validation of cessation
was available, we regard only those participants who met the
criteria for biochemically-confirmed abstinence as being abstinent.
Wherever possible we chose a measure of sustained cessation
rather than point prevalence. We regard people who were lost to
follow-up as being continuing smokers.
For the 2012 update and for this current update we collected data
on adverse events in both the included and excluded studies, where
they were reported. We have not attempted to pool these findings,
apart from one meta-analysis of reports of palpitations, tachycardia
or chest pains.
We have not included trials that evaluated the eEect of NRT
for individuals who were attempting to reduce the number of
cigarettes smoked rather than to quit in this review. They are
covered by a separate review on harm reduction approaches
(Lindson-Hawley 2016).
Search methods for identification of studies
We searched the specialized register of the Cochrane Tobacco
Addiction Group on 6 July 2017 for any reports of trials making
reference to the use of nicotine replacement therapy of any type,
by searching for 'NRT', or 'nicotine' near to terms for nicotine
replacement products in the title, abstract or keywords. The most
recent issues of the databases included in the register as searched
for the current update of this review were:
• Cochrane Central Register of Controlled trials (CENTRAL), issue
11, 2016;
• MEDLINE (via OVID) to update 20170526;
• Embase (via OVID) to week 201724;
• PsycINFO (via OVID) to update 20170529.
The search strategy for the Register is given in Appendix 1. For
details of the searches used to create the specialized register see the
Tobacco Addiction Group Module in the Cochrane Library. The trials
register also includes trials identified by handsearching of abstract
books from meetings of the Society for Research on Nicotine and
Tobacco.
For earlier versions of this review we performed searches
of additional databases: Cancerlit, Health Planning and
Administration, Social Scisearch, Smoking & Health, and
Dissertation Abstracts. Since the searches did not produce any
additional trials we did not search these databases aOer December
1996. During preparation of the first version of this review, we also
sent letters to manufacturers of NRT preparations. Since this did
not result in additional data we have not repeated the exercise for
subsequent updates.
Data collection and analysis
Selection of studies
In previous versions of this review, one review author screened
records retrieved by searches, to exclude papers that were not
reports of potentially relevant studies. For the last two updates,
two review authors independently screened references. Reports
that linked to potentially relevant studies but did not report the
outcomes of interest are listed along with the main study report in
the 'References to Studies' section. The primary reference to the
study is indicated, and for most studies the first author and year
used as the study identifier corresponds to the primary reference.
Where we extracted data for a study from more than one report we
have noted this in the Characteristics of included studies table.
Data extraction and management
Two review authors independently extracted data from the
published reports and abstracts. We resolved disagreements by
discussion or by referral to a third party. We made no attempt
to blind these review authors either to the results of the primary
studies or to which treatment participants received. We examined
reports published only in non-English language journals with the
assistance of translators.
Assessment of risk of bias in included studies
We assessed included studies for risks of selection bias (methods
of randomized sequence generation, and allocation concealment),
performance and detection bias (the presence or absence of
blinding), attrition bias (levels and reporting of loss to follow-up),
and any other threats to study validity, using the Cochrane 'Risk of
bias' tool.
Measures of treatment e>ect
We extracted smoking cessation rates in the intervention and
control groups from the reports at six or 12 months. Since not
all studies reported cessation rates at exactly these intervals, we
allowed a window period of six weeks at each follow-up point. For
trials which also reported follow-up for more than a year we used
12-month outcomes in most cases. (We note length of follow-up
for each study in the Characteristics of included studies table). For
trials of NRT in pregnant women, we extracted smoking cessation
outcomes at the closest follow-up to end of pregnancy, and also
at longest follow-up post-partum if reported. We only included
studies in pregnant women in the main analysis if they reported
results at six months or longer. Following the Cochrane Tobacco
Addiction Group's recommended method of data analysis, we use
the risk ratio (RR) for summarizing individual trial outcomes and for
estimates of pooled eEect. Whilst there are circumstances in which
odds ratios may be preferable, there is a danger that they will be
interpreted as if they are risk ratios, making the treatment eEect
seem larger (Deeks 2005).
Dealing with missing data
We treated participants who dropped out or who were lost to
follow-up aOer randomization as being continuing smokers. We
noted in the 'Risk of bias' table the proportion of participants for
whom the outcome was imputed in this way, and whether there was
either high or diEerential loss to follow-up. The assumption that
Nicotine replacement therapy versus control for smoking cessation (Review)
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'missing = smoking' will give conservative absolute quit rates, and
will make little diEerence to the risk ratio unless dropout rates diEer
substantially between groups.
Assessment of heterogeneity
To assess heterogeneity we use the I2 statistic, given by the formula
[(Q - df)/Q] x 100%, where Q is the Chi2 statistic and df is its degrees
of freedom (Higgins 2003). This describes the percentage of the
variability in eEect estimates that is due to heterogeneity rather
than sampling error (chance). A value greater than 50% may be
considered to indicate substantial heterogeneity. When there are
many trials, as in this review, the Chi2 test for heterogeneity will
be unduly powerful and may identify statistically significant but
clinically unimportant heterogeneity.
Data synthesis
We estimated a pooled weighted average of risk ratios using a fixed-
eEect Mantel-Haenszel method, with 95% confidence intervals.
Subgroup analysis and investigation of heterogeneity
In comparing NRT to placebo or control, we performed subgroup
analysis for each form of NRT. We did additional subgroup analyses
within type of NRT (gum, patch, etc.) to investigate whether
the relative treatment eEect diEered according to the way in
which smoking cessation was defined, the intensity of behavioural
support, and the recruitment/treatment setting.
Summary of findings table
Following standard Cochrane methodology, we created a
'Summary of findings' table. Also following standard Cochrane
methodology, we used the five GRADE considerations (study
limitations, consistency of eEect, imprecision, indirectness and
publication bias) to assess the quality of the body of evidence
for each outcome, and to draw conclusions about the quality of
evidence within the text of the review.
The Cochrane Tobacco Addiction Group's Glossary of smoking-
related terms is included in this review (Appendix 2).
R E S U L T S
Description of studies
Included studies
The review includes 136 studies, 18 of which are new in this update
(Anthenelli 2016; Berlin 2014; Cummins 2016; Cunningham 2016;
El-Mohandes 2013; Fraser 2014; Gallagher 2007; Graham 2017;
Hasan 2014; Heydari 2012; Heydari 2013; Johns 2017; Lerman
2015; NCT00534404; Scherphof 2014; Stein 2013; Tuisku 2016; Ward
2013). Two studies which gave diEerent doses of NRT based on
level of dependency are treated as four separate trials for the
purpose of this review (ShiEman 2002 (2 mg); ShiEman 2002 (4 mg);
ShiEman 2009 (2 mg); ShiEman 2009 (4 mg)). For this update, we
also added longer follow-up data for one previously included study
(Coleman 2012). The most recent search screened 1059 studies.
Along with the 18 new included studies, there were three ongoing
studies, and 124 studies excluded at full-text screening. The most
common reasons for exclusion were ineligible study design and
using an irrelevant comparison (NRT vs NRT rather than control).
See Figure 1 for study flow information relating to the most recent
search presented in a PRISMA diagram. Trials were conducted in
North America (62 studies), Europe (56 studies), Australasia (two
studies), Japan (two studies), South America (two studies), Iran
(two studies), in multiple regions (two studies), and in India, Syria,
Taiwan, and Thailand (one study each). The median sample size
was 257 but ranged from fewer than 50 to over 8000 participants.
We treated each of the intervention groups in the two studies
by ShiEman in 2002 and 2009 separately in the meta-analysis
(ShiEman 2002 (2 mg); ShiEman 2002 (4 mg); ShiEman 2009 (2 mg);
ShiEman 2009 (4 mg)), and listed Brantmark 1973b, CEASE 1999,
Bolliger 2000b, Wennike 2003b, Bullen 2010, Schnoll 2010 in the
Characteristics of included studies tables, despite being excluded
studies, because they provided data on adverse events.
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Figure 1.   Study flow diagram for most recent update
 
Participants
Participants were typically adult cigarette smokers with an average
age of 40 to 50. Two trials recruited adolescents (Moolchan 2005;
Scherphof 2014). Most trials had approximately similar numbers of
men and women. Six trials recruited only pregnant women (Berlin
2014; Coleman 2012; El-Mohandes 2013; Oncken 2008; Pollak 2007;
Wisborg 2000); a further four recruited only women (Cooper 2005;
Oncken 2007; Pirie 1992; Prapavessis 2007). Two trials recruited
African-American smokers (Ahluwalia 1998; Ahluwalia 2006).
Trials typically recruited people who smoked at least 15 cigarettes
a day. Although some trials included lighter smokers as well,
the average number smoked was over 20 a day in most studies.
Nicotine replacement therapy versus control for smoking cessation (Review)
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Ahluwalia 2006 recruited only people who smoked 10 or fewer
cigarettes a day and two trials recruited only people smoking 30
or more a day (Hughes 1990; Hughes 2003). One trial recruited
people with a history of alcohol dependence (Hughes 2003), one
recruited methadone-maintained smokers (Stein 2013), and one
recruited people with a history of drug abuse including opiates
or narcotics (Heydari 2013). Joseph 1996 recruited people with a
history of cardiac disease, Hasan 2014 recruited people admitted
to hospital with a cardiac or pulmonary illness, Gallagher 2007
recruited people diagnosed with psychotic-spectrum or aEective
disorders resulting in long-term mental illness and experiencing
significant symptoms and functional impairment, and Gourlay 1995
recruited relapsed smokers.
Type and dose of nicotine replacement therapy
One hundred and thirty-three studies contribute to the primary
analysis of the eEicacy of one or more types of NRT compared to
a placebo or other control group not receiving any type of NRT.
In this group of studies there were 56 trials of nicotine gum, 51
of transdermal nicotine patch, eight of an oral nicotine tablet or
lozenge, seven oEering a choice of products, four of intranasal
nicotine spray, four of nicotine inhalator, two providing patch and
gum (Hasan 2014; Stein 2013), one of oral spray (Tønnesen 2012),
one providing patch and inhalator (Hand 2002), one providing
patch and lozenge (Piper 2009), and one providing patch, gum and
lozenge (Heydari 2013).
Three studies did not contribute to the primary analysis; two were
conducted in pregnant women and did not follow up participants
at six months or longer (Berlin 2014; El-Mohandes 2013), and one
was conducted in recently relapsed smokers and is hence reported
narratively in the text (Gourlay 1995).
Most trials comparing nicotine gum to control provided the 2 mg
dose. A few provided 4 mg gum to more highly addicted smokers,
and two used only the 4 mg dose (Blondal 1989; Puska 1979). In
three trials the physician oEered nicotine gum but participants did
not necessarily accept or use it (Ockene 1991; Page 1986; Russell
1983). In one trial participants self-selected 2 mg or 4 mg doses;
we treat the two groups as separate trials in the meta-analysis
(ShiEman 2009 (2 mg); ShiEman 2009 (4 mg)). The treatment period
was typically two to three months, but ranged from three weeks
to 12 months. Some trials did not specify how long the gum was
available. Many of the trials included a variable period of dose
tapering, but most encouraged participants to be gum-free by six
to 12 months.
In nicotine patch trials the usual maximum daily dose was 15 mg for
a 16-hour patch, or 21 mg for a 24-hour patch. Thirty-two studies
used a 24-hour formulation and nine a 16-hour product; the rest did
not specify. One study oEered, among other dosage options, a 52.5
mg/24-hour patch (Wittchen 2011). If studies tested more than one
dose we combined all active arms in the comparison to placebo.
For one study we included an arm with a lower maximum dose of
14 mg but excluded a 7 mg-dose arm (TNSG 1991). The minimum
duration of therapy ranged from three weeks (Glavas 2003a, half the
participants of Glavas 2003b), to three months.
There are eight studies of nicotine sublingual tablets or lozenges.
Three used 2 mg sublingual tablets (Glover 2002; Tønnesen 2006;
Wallstrom 2000). One used a 1 mg nicotine lozenge (Dautzenberg
2001). One used 2 mg or 4 mg lozenges according to dependence
level based on manufacturers' instructions (Piper 2009), and one
used 2 mg or 4 mg based on participants' time to first cigarette of
the day (TTFC); smokers whose TTFC was more than 30 minutes
were randomized to 2 mg lozenges or placebo (ShiEman 2002 (2
mg)), whilst smokers with a TTFC less than 30 minutes had higher-
dose 4 mg lozenges or placebo (ShiEman 2002 (4 mg)). The two
groups are treated in the meta-analysis as separate trials. One
trial did not report the lozenge dose (Fraser 2014). There are four
trials of intranasal nicotine spray (Blondal 1997; Hjalmarson 1994;
Schneider 1995; Sutherland 1992), one trial of oral nicotine spray
(Tønnesen 2012), and four trials of nicotine inhalator (Hjalmarson
1997; Leischow 1996a; Schneider 1996; Tønnesen 1993).
As described above, seven studies tested combinations of patch
and a short-acting form of NRT (Hand 2002; Hasan 2014; Heydari
2013; Kornitzer 1995; Moolchan 2005; Stein 2013; Tønnesen 2000).
Six studies oEered participants a choice of products (Graham 2017;
Johns 2017; Kralikova 2009; Molyneux 2003; Ortega 2011; Pollak
2007).
Treatment setting (studies in main comparison)
Twenty-one trials in the main comparison recruited participants
from primary care practices. A further two gum trials were
undertaken in workplace clinics (Fagerström 1984; Roto 1987), and
one in a university clinic (Harackiewicz 1988). One trial recruited
through community physicians (Niaura 1994). Since participants
in these trials were recruited in a similar way to primary care,
we have aggregated them in the subgroup analysis by setting. We
also included one patch trial conducted in Veterans AEairs Medical
Centers and recruiting people with cardiac diseases in the primary
care category (Joseph 1996). We kept four trials recruiting pregnant
women in antenatal clinics in a separate category (Coleman 2012;
Oncken 2008; Piper 2009; Wisborg 2000). Six of the gum trials, two
of the nasal spray trials, an inhalator trial, an oral spray trial, and a
patch trial were carried out in specialized smoking cessation clinics
to which participants had usually been referred. Thirteen trials (five
patch, three gum, three giving a combination of products and two
giving a choice of products) were undertaken with hospital in- or
outpatients, some of whom were recruited because they had a
co-existing smoking-related illness. Three patch trials (Davidson
1998; Hays 1999; Sønderskov 1997) and one gum trial (split into
ShiEman 2009 (2 mg) and ShiEman 2009 (4 mg)) were undertaken
in settings intended to resemble 'over-the-counter' (OTC) use of
NRT. Two trials were undertaken in drug abuse treatment centres
(Heydari 2013; Stein 2013), one in schools (Scherphof 2014), and
one in a psychiatric treatment setting. The remaining trials were
undertaken in participants from the community, most of whom had
volunteered in response to media advertisements, but who were
treated in clinical settings.
Excluded studies
Thirty-four previously included studies were removed from this
update, as they did not contain a NRT-versus-control comparison.
As described in the Methods, studies which contribute to
comparisons between multiple forms of NRT are now found in
a separate Cochrane Review, in development at the time of
publication. Previously-included studies that compare NRT with
bupropion can be found in Hughes 2014. Other studies that
were potentially relevant but excluded are listed with reasons
in the Characteristics of excluded studies table. Some studies
contribute to the adverse events meta-analysis but not to the main
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analysis (e.g. due to short follow-up or short duration of time
where comparison was NRT versus control); these are listed in
the Characteristics of included studies but we do not count them
as included studies. Some studies were excluded due to short
follow-up. Some of these had as their primary outcome withdrawal
symptoms rather than cessation. We exclude studies that provided
NRT or placebo to people trying to cut down their smoking but
not to make an immediate quit attempt, and we consider them in
detail in a separate review of interventions for reduction (Lindson-
Hawley 2016). We excluded two trials in which NRT was provided
to encourage a quit attempt but participants did not need to
be planning to quit: Velicer 2006 proactively recruited people by
telephone, with those in one intervention group being mailed a
six-week course of nicotine patches if they were judged to be in
the preparation stage or in contemplation and had more pros than
cons for quitting; Carpenter 2011 encouraged all participants to
make a practice quit attempt, and gave the intervention group trial
samples of nicotine lozenges. We excluded one trial in which callers
to the NHS Quitline were randomized to be oEered free NRT or not
to receive the oEer; the control group had access to and used free
NRT and other stop-smoking medication at high levels (Ferguson
2012).
Risk of bias in included studies
Six trials are included based only on data available from
abstracts, conference presentations, or trial registries (Dautzenberg
2001; Johns 2017; Kralikova 2009; Mori 1992; Nakamura 1990;
NCT00534404), so had limited methodological details.
Overall, we judged 12 studies to be at low risk of bias (low risk of
bias across all domains), 36 at high risk of bias (high risk of bias in
at least one domain), and the rest at unclear risk of bias. The main
findings were not sensitive to the exclusion from the meta-analysis
of trials at unclear risk, or of trials at unclear and at high risk of
bias. A summary illustration of the risk of bias profile across trials
is shown in Figure 2.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
 
Thirty-nine studies (29%) reported allocation procedures in
suEicient detail to be rated as being at low risk for their attempts
to control selection bias, by using a system of treatment allocation
which could not be known or predicted until a participant is
enrolled and assigned to a study condition. Twenty-four of these
low-risk trials (62%) also reported adequate sequence generation
procedures. Most studies either did not report how randomization
was performed and allocation concealed, or reported them in
insuEicient detail to determine whether a satisfactory attempt
to control selection bias had been made (rated as being at
unclear risk). A small number of nicotine gum trials randomized to
treatment according to day or week of clinic attendance (Page 1986;
Richmond 1993; Russell 1983), or to birth date (Fagerström 1984),
and were consequently rated as being at high risk of bias. In one
study (Gallagher 2007), study staE oversaw allocation and hence we
rated this at high risk of bias. One study randomized by physician
and there was no information about avoidance of selection bias in
enrolment of smokers (Nebot 1992), so we also rated this as being
at high risk.
We judged 44 of the included studies to be at low risk of
performance and detection bias (33%). We judged 23 (17%) to
be at high risk of bias in this domain, most commonly because
they were not blinded (although we judged some studies which
were not double-blind to be at low risk in this domain due to
other study factors). Forty-three trials did not have a matched
placebo control (24 gum trials, nine patch trials, six choice of
product trials, three combination trials, and one lozenge trial). A
further two had both a placebo and a non-placebo control which
we combined for the meta-analysis control group (Buchkremer
1988; Russell 1983). Approximately one-third of the trials reported
some measure of blinding, but we did not assess whether the
integrity of the procedure was tested, in line with the CONSORT
guidelines (CONSORT 2001). Where they are done, assessments
of blinding integrity should always be carried out before the
clinical outcome has been determined, and the findings reported
(Altman 2004). Mooney 2004 notes that few published trials report
this information. While those that do provide some evidence
that participants are likely to assess their treatment assignment
correctly, it is insuEicient to assess whether this is associated with
diEerences in treatment eEects. Further, there may be an apparent
breaking of the blinding in trials where the treatment eEect is
marked, for either an intended outcome or an adverse event, but
participants who successfully decipher assignment may disguise
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their unblinding actions (Altman 2004). It is also possible that those
who believe that they are receiving a placebo may be more likely to
stop trying to quit.
Definitions of abstinence varied considerably. Eighty-nine trials
(66%) reported some measure of sustained abstinence, which
included continuous abstinence with not even a slip since quit day,
repeated point prevalence abstinence (with or without biochemical
validation) at multiple follow-ups, or self-reported abstinence for a
prolonged period. Thirty-nine (29%) reported only point prevalence
abstinence at the longest follow-up. In six studies it was unclear
exactly how abstinence was defined. In four trials, participants
who smoked two or three cigarettes a week were still classified as
abstinent (Abelin 1989; Ehrsam 1991; Glavas 2003a; Glavas 2003b).
Sensitivity analyses excluding these four trials made no diEerence
to the overall findings. Most studies reported follow-up at least
12 months from start of treatment. FiOeen gum trials, 19 patch
trials, four combination trials, and one lozenge trial in the primary
analysis had only six months follow-up. We report the findings of a
subgroup analysis by type of abstinence and length of follow-up in
the Results section.
One hundred and seventeen (87%) of the trials used biochemical
validation of self-reported smoking cessation at longest follow-
up. The most common form of validation was measurement of
carbon monoxide (CO) in expired air. The 'cut-oE' level of CO used
to define abstinence varied from less than 4 to 11 parts per million.
Some of the 21 trials that did not validate all self-report at longest
follow-up did use biochemical confirmation at earlier points, or
validated some self-reports. The main findings were not sensitive
to the exclusion of 17 studies contributing to that analysis that did
not attempt to validate all reported abstinence (Ahluwalia 1998;
Buchkremer 1988; Clavel-Chapelon 1992; Daughton 1991; Fraser
2014; Graham 2017; Huber 1988; NCT00534404; Otero 2006; Page
1986; Puska 1979; Roto 1987; Sønderskov 1997; Tuisku 2016; Villa
1999; Wisborg 2000; Wittchen 2011).
E>ects of interventions
See: Summary of findings for the main comparison Nicotine
replacement therapy
Any type of NRT versus placebo or no NRT control, six months
or longer follow-up
Analysis 1.1 included 131 trials (133 comparisons), with over 64,000
participants (Summary of findings for the main comparison). A
small number of trials contributed to more than one subgroup and
two trials were treated as two separate studies in the analyses. Each
of the six forms of nicotine replacement therapy (NRT) significantly
increased the rate of cessation compared to placebo or no NRT, as
did a choice of product. The pooled risk ratio (RR) for abstinence
for any form of NRT relative to control was 1.55 (95% confidence
interval (CI) 1.49 to 1.61; 64,640 participants). The I2 statistic was
39%, indicating that little of the variability was attributable to
between-trial diEerences. The risk ratio and 95% CI for each type
are tabulated below.
 
Type of NRT RR 95% CI I2 N of stud-
ies
N of participants Interven-
tion/Control
Gum 1.49 1.40 to 1.60 40% 56* 10,596 / 11,985
Patch 1.64 1.53 to 1.75 24% 51 13,773 / 11,981
Inhalator 1.90 1.36 to 2.67 0% 4 490 / 486
Intranasal spray 2.02 1.49 to 2.73 0% 4 448 / 439
Tablets/lozenges 1.52 1.32 to 1.74 71% 8* 2326 / 2113
Oral spray 2.48 1.24 to 4.94 N/A 1 318 / 161
Choice of product 1.37 1.25 to 1.52 42% 7 4179 / 4109
Patch and inhalator 1.07 0.57 to 1.99 NA 1 136 / 109
Patch and lozenge 1.83 1.01 to 3.31 N/A 1 267 / 41
Patch and gum 1.15 0.64 to 2.06 50% 2 173 / 86
Patch, gum and
lozenge
15.00 2.00 to 112.54 N/A 1 212 / 212
* includes 1 study treated as 2 for analysis; N/A: not applicable
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Although the estimated eEect sizes varied across the diEerent
products, confidence intervals were wide for the products with
higher estimates which had small numbers of trials. One subgroup
based on product type had a confidence interval which did not
overlap with the pooled estimate; this group consisted of only
one study in which only one participant in the control group had
successfully quit smoking (Heydari 2013). In the tablets/lozenges
subgroup, the I2 statistic was 71%, indicating substantial statistical
heterogeneity. In all trials in this subgroup, more participants quit
in the intervention arm than in control, but in one study new for this
update the point estimate was considerably lower (RR 1.08) (Fraser
2014); this study drove the observed statistical heterogeneity.
Twelve studies had lower quit rates in the treatment than in the
control group at the end of follow-up (all of which had confidence
intervals which crossed the line of no eEect), and in a further 73%
of trials the 95% confidence interval for the RR included 1 (i.e. the
trials did not detect a significant treatment eEect). Many of these
trials had small numbers of smokers, and hence insuEicient power
to detect a modest treatment eEect with reasonable certainty.
One large trial of nicotine patches for people with cardiovascular
disease had lower quit rates in the intervention than in the control
group (Joseph 1996); at six months the quit rates were 14% for
active patch and 11% for placebo, but aOer 48 weeks there had been
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Figure 3.   Forest plot of comparison: 1 Any type of NRT versus placebo/no NRT control, outcome: 1.1 Smoking
cessation at 6+ months follow up.
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Figure 3.   (Continued)
 
Sensitivity to definition of abstinence
For nicotine gum and patch we assessed whether trials that
reported sustained abstinence at 12 months had diEerent
treatment eEects from those that only reported a point prevalence
outcome, or had shorter follow-up (Analysis 2.1; Analysis 2.2).
Subgroup categories were sustained abstinence at 12 months or
more, sustained abstinence at six months, point prevalence or
unclear definition at 12 months, and point prevalence/unclear
at six months. For nicotine gum 32/55 studies (56 comparisons)
(58%) reported sustained 12-month abstinence and the estimate
was similar to that for all 55 studies: sustained 12-month RR 1.43,
95% CI 1.31 to 1.56 (13,737 participants), compared with RR 1.49,
95% CI 1.40 to 1.60. The highest estimate was for the subgroup
of eight studies reporting sustained abstinence at six months,
where confidence intervals did not overlap: RR 2.77, 95% CI 2.14 to
3.59; 4187 participants. This seems to be attributable to one study
(ShiEman 2009 (2 mg); ShiEman 2009 (4 mg)), and is unlikely to be
of methodological or clinical significance. For nicotine patch, 21/49
studies (43%) reported sustained 12-month abstinence, and the RR
was also similar to that for all 49 studies: sustained 12-month RR
1.52, 95% CI 1.34 to 1.74 (7622 participants), compared with RR 1.64,
95% CI 1.53 to 1.75 (25,754 participants) overall). For patch studies
there was no evidence that the RRs diEered significantly between
subgroups.
Sensitivity to intensity of behavioural support
All trials provided the same behavioural support in terms of
advice, counselling, and number of follow-up visits to the active
pharmacotherapy and control groups, but diEerent trials provided
diEerent amounts of support. We conducted subgroup analyses by
intensity of support for gum and patch trials separately (Analysis
3.1; Analysis 3.2). There was no evidence of a significantly diEerent
eEect between groups. For nicotine gum the RR was similar
across all three subgroups. The control group quit rates varied as
expected, averaging 3.5% with low-intensity support, 9% with high-
intensity individual support and 11.7% with group-based support.
Nicotine patch trials showed the same pattern; the RRs were
similar for each subgroup and the average control group quit rates
were 9.0% with low-intensity support, 9.5% with high-intensity
individual support and 17.0% with group-based support.
Sensitivity to treatment settings
We conducted further subgroup analyses for each type of setting
in which smokers were recruited or treated (with type of NRT as a
subgroup beneath setting). The pooled RR for trials in community
volunteers where care was provided in a medical setting was 1.62
(95% CI 1.53 to 1.72, 65 trials, 24,597 participants; Analysis 4.1)
and was similar to that of trials conducted in smoking clinics (RR
1.70, 95% CI 1.48 to 1.96, 12 trials, 3300 participants; Analysis
4.2), trials conducted in primary care settings (RR 1.50, 95% CI
1.33 to 1.69, 24 trials, 11,974 participants; Analysis 4.3), trials
conducted in hospitals (RR 1.39, 95% CI 1.24 to 1.55, 13 trials, 7037
participants; Analysis 4.4), and trials conducted in settings similar
to 'over the counter' (OTC) (RR 1.40, 95% CI 1.26 to 1.55, 9 trials,
13,163 participants; Analysis 4.5). Pooled results from four trials in
antenatal clinics were lower than in other settings (RR 1.22, 95%
CI 0.92 to 1.62, 1675 participants; Analysis 4.6); this was the only
setting in which results did not show a statistically significant eEect
of the intervention. In a meta-regression we checked whether there
was any evidence of interaction between the treatment setting and
type of NRT used. The eEect of nicotine gum was highest in the
OTC setting and this seems to be attributable to the same study
that contributed heterogeneity in the abstinence subgroup analysis
above (ShiEman 2009 (2 mg); ShiEman 2009 (4 mg)).
Control group quit rates varied by setting; the lowest rates were
found in OTC (8.4%) and primary care (6.9%) studies, and the
highest rate in smoking clinics (14.3%). Falling within this range,
control group rates were 9.3% in antenatal clinics, 12.5% in
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community volunteers where treatment was provided in a medical
setting, and 12.3% in hospitals.
Sensitivity to risk of bias and study methods
Excluding those studies at high risk of bias did not significantly alter
the point estimate for the main comparison: RR 1.61, 95% CI 1.52
to 1.69, analysis not shown. Similarly, restricting the main analysis
to only those 12 studies at low risk of bias across all domains
led to results consistent with the main analysis: RR 1.53, 95% CI
1.37 to 1.71, analysis not shown. Removing those studies without
biochemical validation did not substantially influence the eEect
estimate: RR 1.62, 95% CI 1.55 to 1.70, analysis not shown, nor did
restricting the analysis to only placebo-controlled studies: RR 1.61,
95% CI 1.53 to 1.70, analysis not shown.
Relapsed smokers
Although many of the trials reported here did not specifically
exclude people who had previously tried and failed to quit with
NRT, one trial recruited people who had relapsed aOer patch and
behavioural support in an earlier phase of the study but were
motivated to make a second attempt (Gourlay 1995). This study
did not detect an eEect on continuous abstinence (RR 1.25, 95% CI
0.34 to 4.60, analysis not shown), although it did detect a significant
increase in 28-day point prevalence abstinence (RR 2.49, 95% CI
1.11 to 5.57). Quit rates were low in both groups with either
definition of abstinence.
Adverse events
We have made no systematic attempt in this review to synthesize
quantitatively the incidence of the various adverse events reported
with the diEerent NRT preparations. This was because of the
extensive variation in reporting of the nature, timing and duration
of symptoms. In the included studies, attrition rates in NRT groups
were generally similar to or lower than in control groups. Appendix
3 summarises the main adverse events reported in the included and
excluded studies, where the data were available.
The most common adverse events usually reported with nicotine
gum include hiccoughs, gastrointestinal disturbances, jaw pain,
and orodental problems (Fiore 1992; Palmer 1992). The only
adverse event that appears to interfere with use of the patch is skin
sensitivity and local skin irritation; this may aEect up to 54% of
patch users, but it is usually mild and rarely leads to withdrawal
of patch use (Fiore 1992). The major adverse events reported
with the nicotine inhalator and nasal and oral sprays are related
to local irritation at the site of administration (mouth and nose
respectively). For example, symptoms such as throat irritation,
coughing, and oral burning were reported significantly more
frequently with participants allocated to the nicotine inhalator
than to placebo control (Schneider 1996); none of the experiences,
however, were reported as severe. With the nasal spray, nasal
irritation and runny nose are the most commonly reported adverse
events. In the study of oral spray, hiccoughs and throat irritation
were the most commonly reported adverse events (Tønnesen
2012). Nicotine sublingual tablets have been reported to cause
hiccoughs, burning and smarting sensation in the mouth, sore
throat, coughing, dry lips and mouth ulcers (Wallstrom 1999).
Adolescents report similar adverse events to adults (Bailey 2012).
A review of adverse events based on 35 trials with over 9000
participants did not find evidence of excess adverse cardiovascular
events amongst those assigned to nicotine patch, and the total
number of such events was low (Greenland 1998). A meta-analysis
of adverse events associated with NRT included 92 RCTs and
28 observational studies, and addressed a possible excess of
chest pains and heart palpitations among users of NRT compared
with placebo groups (Mills 2010). The authors report an OR of
2.06 (95% CI 1.51 to 2.82) across 12 studies. We replicated this
data collection exercise and analysis where data were available
(included and excluded) in this review, and detected a similar but
slightly lower estimate, OR 1.88 (95% CI 1.37 to 2.57; 15 studies;
11,074 participants; OR rather than RR calculated for comparison;
Analysis 6.1). Chest pains and heart palpitations were an extremely
rare event, occurring at a rate of 2.5% in the NRT groups compared
with 1.4% in the control groups in the 15 trials in which they were
reported at all. A recent network meta-analysis of cardiovascular
events associated with smoking cessation pharmacotherapies
(Mills 2014), including 21 RCTs comparing NRT with placebo, found
statistically significant evidence that the rate of cardiovascular
events with NRT was higher (RR 2.29 95% CI 1.39 to 3.82). However,
when only serious adverse cardiac events (myocardial infarction,
stroke and cardiovascular death) were considered, the finding was
not statistically significant (RR 1.95 95% CI 0.26 to 4.30). A sensitivity
analysis demonstrated that lower-level events, predominantly
tachycardia and arrhythmia, accounted for the observed increased
risk of cardiovascular events. Chest pains and palpitations are the
only clinically significant adverse events to emerge from the trials,
and no evidence of significant harm has been identified.
When first licensed there was concern about the safety of NRT in
smokers with cardiac disease (TNWG 1994). A trial of nicotine patch
that recruited smokers aged over 45 with at least one diagnosis
of cardiovascular disease found no evidence that serious adverse
events were more common in smokers in the nicotine patch
group (Joseph 1996). Events related to cardiovascular disease,
such as an increase in angina severity, occurred in approximately
16% of participants, but did not diEer according to whether or
not they were receiving NRT. A review of safety in people with
cardiovascular disease found no evidence of an increased risk
of cardiac events (Joseph 2003). This included data from two
randomized trials with short-term follow-up that we excluded from
the present review (Tzivoni 1998; Working Group 1994), and a case-
control study in a population-based sample. An analysis of 187
smokers admitted to hospital with acute coronary syndromes who
received nicotine patches showed no evidence of diEerence in
short- or long-term mortality compared to a propensity-matched
sample of smokers in the same database who did not receive
NRT (Meine 2005). A subgroup analysis within a network meta-
analysis of cardiovascular events (Mills 2014), found no increased
risk of cardiovascular events with NRT amongst individuals with
predisposing conditions that placed them at an increased risk of
having an event (RR 1.24, 95% CI 0.77 to 2.02). Another recent
network meta-analysis in people with cardiovascular disease found
a slightly higher number of cardiovascular events with NRT but was
not able to draw quantitative conclusions due to the low number of
trials reporting adverse events and the variation in adverse event
definitions used (Suissa 2017).
The six trials assessing NRT use in pregnant women did not
detect significant increases in serious adverse events amongst the
treatment groups (Berlin 2014; Coleman 2012; El-Mohandes 2013;
Oncken 2008; Pollak 2007; Wisborg 2000). The eEects of NRT use
on neonatal health are discussed further in a separate Cochrane
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Review, which found no statistically significant diEerences in rates
of any serious adverse events between treatment and control
groups (Coleman 2015). As mentioned previously, this separate
review covers this topic comprehensively and will be regularly
updated, so interested readers should refer to Coleman 2015
for more information on the adverse events profile of NRT in
pregnancy.
D I S C U S S I O N
This review provides high-quality evidence from trials including
over 64,000 participants that oEering nicotine replacement therapy
(NRT) to dependent smokers who are prepared to try to quit
increases their chance of success over that achieved with the same
level of support but without NRT. This applies to all forms of NRT
and is independent of any variations in methodology or design
characteristics of trials included in the meta-analysis. In particular
we did not find evidence that the relative eEect of NRT was smaller
in trials with longer follow-up beyond our six-month minimum for
inclusion. We did not compare end-of-treatment risk ratios with
post-treatment follow-up, and relapse rates may be higher in active
treatment participants once they stop using NRT products, but later
relapse is probably unrelated to NRT use (Etter 2006).
The absolute eEects of NRT use will depend on the baseline quit
rate, which varies in diEerent clinical settings. Studies of people
attempting to quit on their own suggest that success rates aOer
six to 12 months are 3% to 5% (Hughes 2004). Use of NRT might
be expected to increase the rate by 2% to 3%, giving a number
needed to treat for an additional beneficial outcome (NNTB) of 56.
If, however, the quit rate without pharmacotherapy was estimated
to be 15%, either because the population had other predictors of
successful quitting or received intensive behavioural support, then
another 8% might be expected to quit, giving an NNTB of 11.
Intensity of additional support and treatment setting
We did not detect important diEerences in relative eEect within
patch or gum studies by our classification of level of support.
A letter prior to the previous update of this review identified
inconsistencies in the classification of low- and high-intensity
support in this review (Walsh 2007). In response, we changed the
classification of a small number of trials. This did not alter the
conclusion that intensity of support does not appear to be an
important moderator of NRT eEect.
We also did not detect diEerences in relative eEect according to
the setting of recruitment and treatment. This subgroup analysis
had considerable overlap with the support subgroup since, for
example, people recruited in primary care settings typically had
lower-intensity support.
There has been continuing debate about the amount of evidence
for the eEicacy of NRT when obtained OTC without advice or
support from a healthcare professional (Hughes 2001; Walsh 2000;
Walsh 2001). The small number of placebo-controlled trials in
settings intended to replicate OTC settings support the conclusion
that the relative eEect of NRT is similar to settings where more
advice and behavioural support is provided, although quit rates
in both control and intervention groups have been low. One
other meta-analysis supports the conclusion of eEicacy, although
it diEers in its inclusion criteria (Hughes 2003). In addition to
the same three trials comparing nicotine patch to placebo in an
OTC setting (Davidson 1998; Hays 1999; Sønderskov 1997), that
review includes one study excluded here due to short follow-up
(ShiEman 2002a). It also pools four trials comparing NRT provided
OTC to NRT provided under prescription. We exclude one trial
that compared both gum and patch in these settings, but was
not randomized (ShiEman 2002b), and another that has not been
published and for which we have been unable to obtain reliable
data for inclusion (Korberly 1999). The abstract reported that there
were no significant diEerences in quit rates between users of
nicotine patch who purchased it through a non-healthcare facility,
and those receiving it on prescription. It has also been suggested
that the 'real world' eEectiveness of NRT declines or disappears
once it becomes available to purchase without requiring contact
with a health professional who can oEer behavioural support and
guidance on appropriate use (Kotz 2014; Pierce 2002). A comparison
of two cross-sectional surveys in California found that quit rates
for self-selected NRT users were higher than rates for non-users
prior to OTC availability, but aOer the switch to OTC this diEerence
disappeared (Pierce 2002). In addition, a prospective cohort study
found that the odds of cessation in people who had used OTC
NRT were lower than in people who had not used any cessation
pharmacotherapy or accessed a national stop-smoking service (OR
0.69, 95% CI 0.49 to 0.94) (Kotz 2014). However, these observational
studies are at risk of residual confounding from unmeasured
confounders, such as psychological factors, as participants self-
selected their treatment. These studies are also at risk of bias,
as unaided quit attempts are less likely to be recalled than those
involving NRT.
A report of a prospective cohort study questioned the eEectiveness
of NRT outside of the clinical trial setting aOer finding no diEerence
in relapse rates between smokers trying to quit who used NRT and
those who did not use NRT (Alpert 2012). However, the design of
this study has been criticized for not addressing initial quit rates in
the two groups (Stapleton 2012). Furthermore, two multi-country
prospective cohort studies observed that NRT users had higher
quit rates than non-users (Kasza 2012; West 2007), although in the
former study this eEect was limited to NRT patches, with no eEect
detected for oral nicotine products. Again, these are observational
studies and are at risk of confounding and bias.
Trials in special populations
Trials generally restricted recruitment to adults over the age of
18; in a small number of trials the age range was not specified.
Two relatively small studies in adolescents did not detect an
eEect of NRT on quitting at six months or longer (Moolchan 2005;
Scherphof 2014). A separate Cochrane Review of tobacco cessation
interventions for young people did not detect an eEect of NRT,
although confidence intervals were wide and did not preclude the
possibility of a clinically important eEect (Fanshawe 2017). This is
likely to remain an active area of research.
This review previously conducted a separate analysis on a subgroup
of studies evaluating NRT in pregnant women. This is covered
by a separate Cochrane review (Coleman 2015) which provides
more comprehensive analysis of these studies and will be regularly
updated (whereas this review is now marked as stable and will
no longer be updated). Therefore, readers interested in this topic
should refer to (Coleman 2015).
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Evidence for di>erential treatment e>ects in di>erent
subgroups
We made no attempt to conduct separate analyses for any
subgroups of trial participants, because subgroup results are
uncommon in trial reports, and where data cannot be obtained
from all studies there is a risk of bias from using incomplete
data. Munafó 2004a has reported the results of a meta-analysis
of nicotine patch by sex. The researchers were able to include
data from 11 out of 31 eligible trials (35%) and 36% of study
participants. They found no evidence that the nicotine patch was
more eEective for men than for women, as has been hypothesized;
although men showed a somewhat bigger benefit from NRT at
12 months, the diEerence was not significant. There was also no
diEerence in average placebo quit rates between men and women,
which has been reported in some studies. In a commentary some
additional data were identified (Perkins 2004), but this did not alter
the conclusions (Munafó 2004b). A second meta-analysis of any
type of NRT reported that in women the odds ratio for cessation
declined with increasing length of follow-up, with a non-significant
diEerence at 12 months (Cepeda-Benito 2004). Amongst men the
odds ratio declined less over time and remained significant. Based
on a further subgroup analysis, they also reported that the decline
in long-term eEicacy in women was greater in trials with low-
intensity support than with high-intensity support, suggesting that
the more intensive support helped prevent late relapse in women
who had initially received NRT. Although there was no evidence of
bias, the review could only include a subset of published studies,
so the finding should be regarded as hypothesis-generating. All
review authors agreed that trials are underpowered to identify
any interaction between treatment and any type of individual
characteristics, and recommended public archiving of data from
studies, as well as new research specifically designed to test group-
by-treatment interactions. At the moment there does not appear to
be suEicient evidence of clinically important diEerences between
men and women to guide treatment matching.
Re-treating relapsed smokers
Whilst end-of-treatment success rates may be quite high, many
people relapse aOer the end of therapy. There is suggestive
evidence that repeated use of NRT in people who have relapsed
aOer an initial course may produce further quitters, although the
absolute eEect is small (Gourlay 1995). A subgroup analysis in
another trial indicated that the relative eEect of treatment with
nicotine patch compared to placebo was at least as high for people
who had used NRT before (Jorenby 1999, reported in Durcan 2002).
The authors noted that there was no way to distinguish between
people who had completely failed to quit using NRT and those who
had been initially successful but relapsed.
Limitations of the evidence base
Two possible limitations to this evidence base need to be borne
in mind: risk of bias in individual studies and publication bias. For
the former, although we judged most of our included studies to be
at unclear or high risk of bias in at least one domain, restricting
the analysis to only those studies at low risk of bias overall did
not significantly alter the pooled eEect. For the latter, we tried to
partly address any shortcomings from having limited our analysis
to reported data by approaching investigators, where necessary,
to obtain additional unpublished data or to clarify areas of
uncertainty. Although we took steps to minimize publication bias by
writing to the manufacturers of NRT products when this review was
first prepared, the response was poor and we have not repeated this
exercise, although we have searched clinical trials registries. It is
therefore possible that there are some unpublished trials, with less
favourable results, that we have not identified despite our eEorts to
do so. A funnel plot (Figure 4) shows some evidence of asymmetry
for trials in the main comparison; however, given the large number
of trials in the review, the funnel plot does not suggest that results
would be altered significantly were smaller studies with lower RRs
included. A meta-analysis has also demonstrated that nicotine gum
and patch studies that received pharmaceutical industry funding
have on average slightly higher eEect sizes than other studies
aOer controlling for some trial characteristics (Etter 2007). The
practical eEect of these considerations is that the magnitude of the
eEectiveness of NRT may be smaller than our estimates suggest.
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Figure 4.   Funnel plot of comparison: 1 Any type of NRT versus placebo/no NRT control, outcome: 1.1 Smoking
cessation at 6+ months follow up.
 
A possible further limitation relates to length of follow-up. This
review excludes studies with less than a six-month follow-up from
the start of treatment; the outcome used reflects the eEect of
NRT aOer the end of active treatment. A comparison of abstinence
rates during treatment and abstinence at one year suggests that
the relative eEect of NRT declines once active therapy stops
(Fagerström 2003), i.e. people who quit with the help of NRT are a
little more likely to relapse aOer they discontinue treatment than
those on placebo. The relative eEect of NRT could continue to
decline even aOer a year of follow-up. However, a meta-analysis
comparing one-year and long-term outcomes in 12 NRT trials with
follow-up beyond one year suggested that the relative eEicacy did
not change, with similar relapse rates in the active and placebo
groups, but further relapse does reduce the absolute diEerence in
quit rates (Etter 2006).
Stability of the evidence base
This review was first published in 1996. Despite the number of
included studies more than doubling over this time, the eEect
estimate has remained remarkably stable, and our intention is that
this publication is the final time the Cochrane Tobacco Addiction
Group will review the evidence comparing NRT to placebo or to no
pharmacotherapy. This is not to say that all questions about NRT
have been answered; evidence is still needed comparing diEerent
forms, doses, and durations of NRT, comparing NRT to other
pharmacotherapies, and testing NRT in special populations where
we may reasonably hypothesize that its eEectiveness diEers from
that in the general population (e.g. pregnant women, adolescents).
Further studies are also needed of electronic cigarettes containing
nicotine, which some consider a form of NRT (but which we
have never included in this review). However, we will cover these
in separate reviews which we will continue to update regularly
(Cahill 2016; Coleman 2015; Fanshawe 2017; Hartmann-Boyce
2016; Hughes 2014). In summary, based on 20 years of research and
136 randomized controlled trials in over 64,000 participants, we
believe the question of whether NRT helps people to quit smoking
to be definitively answered. We consider that further research
is highly unlikely to change our confidence in the eEect of NRT,
and funders and researchers should give careful thought before
pursuing further studies comparing established forms of NRT with
control.
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A U T H O R S '   C O N C L U S I O N S
Implications for practice
1. All of the commercially available forms of nicotine replacement
therapy (NRT), i.e. gum, transdermal patch, nasal spray,
inhalator, oral spray, lozenge and sublingual tablet, are eEective
as part of a strategy to promote smoking cessation. They
increase the rate of long-term quitting by approximately 50% to
60%, regardless of setting. These conclusions apply to smokers
who are motivated to quit. There is little evidence about the role
of NRT for individuals smoking fewer than 10 to 15 cigarettes a
day.
2. The form of delivery of NRT is unrelated to eEectiveness, so other
considerations such as preferences, availability, or cost might
determine the form of NRT chosen.
3. The eEectiveness of NRT, in terms of the risk ratio, appears to
be largely independent of the intensity of additional support
provided. Intensive behavioural support is not essential for NRT
to be eEective. However, it should be noted that the absolute
increase in success rates attributable to the use of NRT will be
larger when the baseline chance of success is already raised by
the provision of intensive behavioural support.
4. NRT causes non-ischaemic chest pain and palpitations in a
minority of users but there is no evidence of an excess of serious
cardiac problems, even in people with established cardiac
disease.
5. NRT commonly leads to minor adverse reactions which reflect
irritation of the site of use of the form of NRT. These reactions
are usually not severe enough to prompt discontinuation of
treatment
Implications for research
There is high-quality evidence that nicotine replacement therapy
increases quit rates at six months or longer in adults motivated to
quit. We consider that further research is highly unlikely to change
our confidence in the eEect of NRT in this population.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Country: Switzerland
Recruitment: 21 primary care clinics
Participants 199 primary care patients
40% female, average age 41, average cpd 27
Participants were motivated to quit.
Interventions 1. Nicotine patch, 24 h, 12 weeks with weaning; 21 mg smokers of > 20 cpd, 14 mg for < 20 cpd
2. Placebo patch
Level of support: low (number of visits unclear)
Outcomes Sustained abstinence at 12 months (0 to 3 cigarettes/week)
Validation: expired CO
Notes Methods in Lancet paper, final follow up in Muller 1990.
Sources of support not reported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Method not stated
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk "Double-blind", no further details. 75% of NRT group and 76% of placebo




Low risk Dropouts similar between groups (NRT 20, placebo 21); 36/41 dropouts contin-
ued to smoke, but all 41 counted as treatment failures in ITT analysis






Recruitment: hospital in- and outpatients
Participants 410 African-American smokers
Average age 47, FTND 6
Participants were motivated to quit
Interventions 1. Nicotine patch (21 mg with weaning, 10 weeks)
2. Placebo patch
Ahluwalia 1998 
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Level of support: high (1 h initial visit and brief follow-up visits)
Outcomes Prolonged abstinence at 6 months (self-report of no smoking since end of treatment)
Validation: none
Notes Study funded by American Cancer Society Career Development Award, Marion Merrell Dow Inc, and
Emory Medical Care Foundation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A "computer-generated random numbers table with a block size set at 20"
Allocation concealment
(selection bias)
Low risk Study staE blinded - see below
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "Both study staE and patients were blinded to patch treatment"





Low risk Losses similar between groups at 6 months: NRT 53, placebo 58. Counted as






Participants 755 African-American light smokers (≤ 10 cpd)
67% female, average age 45, average cpd 8
Participants were motivated to quit
Interventions Factorial trial, behavioural interventions collapsed for this review
1. Nicotine gum (2 mg), recommended use tailored to cpd. Highest 10/day for 4 weeks, tapering for 4
weeks
2. Placebo gum, 8 weeks
Level of support: high: 3 in-person visits at randomization, week 1, week 8, and phone contact at week
3, week 6, week 16, content based on either motivational interviewing or health education principles
Outcomes PP abstinence at 6 months (7-day PP)
Validation: cotinine ≤ 20 ng/ml
Notes Study funded by National Cancer Institute; products supplied by Glaxo-SmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomization codes were generated in blocks of 36". For counselling
support "a sealed envelope with pre-assigned randomization numbers was
drawn"
Ahluwalia 2006 
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Allocation concealment
(selection bias)
Low risk Quote: "Study staE ... were blinded"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "Study staE and participants were blinded". "Assignment to MI coun-




Low risk Participants receiving active gum and HE counselling were more likely to re-
main in the study, but interaction not statistically significant. Losses to follow




Methods Countries: Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Denmark, Finland, Germany, Mexico,
New Zealand, Russian Federation, Slovakiam South Africa, Spain, USA
Recruitment: community (media advertisements, posters, fliers)
Participants 8144 smokers (≥ 10 cpd), treatment-seeking, exhaled CO > 10 ppm at screening. Participants in the psy-
chiatric disorder cohort had to have a current or lifetime stable psychiatric diagnosis
44% men, mean age 46, mean CPD 20.7, mean FTND 5.8
Interventions 1. Varenicline, 1 mg x 2/day (1 week titrated, then 11 weeks full dose)
2. Bupropion SR, 150 mg x 2/day (titrated for 3 days, then full dose for 11 weeks)
3. Nicotine patch, 21 mg x 7 weeks, 14 mg x 2 weeks, 7 mg x 2 weeks (11 weeks, 24 v 16 h not specified)
4. Triple-dummy placebo for each arm of the trial (12 weeks)
Level of support: high (counselling (up to 10 mins) at all contacts: up to 15 face-to-face visits and 11
telephone visits)
Outcomes 6 months continuous abstinence weeks 9 to 24
Validation: CO < 10 ppm
Notes New for 2017 update. For this review, arm 3 v 4 only
Trial funded by Pfizer and GlaxoSmithKline
Some data extraction and risk of bias taken from Cahill 2016. N quit extrapolated from percentages giv-
en
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "computer-generated randomisation schedule ... using a block size of 8
(1:1:1:1 ratio) for each of the 20 diagnosis by region combinations"
Allocation concealment
(selection bias)
Low risk Quote: "Investigators obtained participant identification numbers via a web-
based or telephone call-in drug management system"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "Study product kit codes did not allow deciphering of randomised
treatment or block size. As such, participants, investigators, and research per-
sonnel were masked to treatment assignment"
Anthenelli 2016 
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"The triple dummy design feature required participants to take study medica-
tion as masked tablets dispensed in separate varenicline and bupropion pill
bottles each with matching placebo along with with either applying active or




Low risk All losses fully accounted for; ITT analysis conducted throughout. 790/1025






Participants 200 smokers (≥ 15 cpd)
6% female, average age 39, average cpd 24
Participants were motivated to quit
Interventions 1. Gum (2 mg) x 8 boxes
2. Placebo gum x 8 boxes
Level of support: high (weekly visits with physician, unspecified frequency and duration)
Outcomes PP abstinence at 6 months
Validation: CO
Notes Support level reclassified as high, 2008
Study funded by Merrel Dow (Bangkok, Thailand), with products supplied by A.B. Leo, Helsinborg, Swe-
den
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The subjects were randomly assigned"
Allocation concealment
(selection bias)
Unclear risk Insufficient information
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. "Neither the investigators nor the subjects knew




Low risk Significant differences between NRT (20 dropouts) and placebo (37 dropouts;
P < 0.01) at 6 months
Other bias High risk 10/93 quitters did not provide CO validation, but distribution not reported. All
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Recruitment: multicentre, advertisements and letters from participating healthcare settings
Participants 403 pregnant smokers (≥ 5 cpd) at 9 to 20 weeks amenorrhoea, motivated to quit
100% female, average age 29, average cpd 11, median FTND 4.5, median gestational age 17 weeks
Interventions 1. Nicotine patch, 16 h, from TQD to delivery. Daily dose 10 to 30 mg/day based on salivary cotinine, ad-
justed at 6 and 12 weeks post-randomization
2. Placebo on same schedule
Level of support: high (1 h behavioural counselling at baseline, at least 10 mins counselling at following
6 visits)
Outcomes Continuous abstinence at 20 weeks post-TQD
Validation: CO ≤ 8 ppm
Notes New for 2017 update
2-month cessation data post-delivery also collected but not reported. Data at 20 weeks post-TQD in-
cluded in Analysis 5.1.1. Not included in main analysis because follow-up was less than 6 months
Funding: Ministry of Health, France and Assistance publique-Hôpitaux de Paris
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “A computer generated randomisation list (allocation ratio 1:1) in
blocks of four was prepared and kept double blinded.”
Allocation concealment
(selection bias)
Low risk Quote: “…the randomisation number was attributed automatically at the
completion of the randomisation visit. A statistician…who was fully indepen-
dent of the trial, prepared the random, computer generated allocation se-
quence. The randomisation code was kept in a sealed envelope in a safe. A
copy of the randomisation code was kept separately in case of a serious ad-
verse event necessitating exposure of a participant’s group assignment. Inves-
tigators, members of the coordination centre, hospital pharmacists, and the
study statistician were kept blinded until the code was opened before witness-
es on 19 February 2013.”
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: “All study staE (investigators, pharmacists, members of the coordina-
tion centre and of the drug safety monitoring board, laboratory staE, statis-
tician) were double blinded to treatment allocation.” “The placebo patches
were manufactured by the same company, with specific quality control guide-
lines to ensure double blinding.” “Determinations of saliva cotinine levels
were carried out blinded. The investigators were not aware of the results” “Da-




High risk 92/203 and 113/199 withdrew, 107/203 and 123/199 not followed up at every
visit (needed for strictest measure)
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Recruitment: community volunteers invited to attend a smoking cessation clinic
Participants 182 smokers (included pipe and cigar users, smoked at least once a day)
57% female, average age 42, average tobacco use 21 g/day
Participants were volunteers, but motivation not required or assessed
Interventions 1. Gum (4 mg) for at least 1 month
2. Placebo gum (containing pepper) for 1 month or more
Level of support: high (group therapy, 5 x 1-h sessions, TQD at session 1)
Outcomes Lapse-free abstinence at 12 months (24 months also reported, no validation)
Validation: CO < 10 ppm
Notes Lapse-free abstinence used since 2008
Study funded by Icelandic Ministry of Health and Social Security
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Assignment was by group (6 to active gum, 6 to placebo); whether randomized
or not is unclear
Allocation concealment
(selection bias)
Unclear risk Probably. "Each subgroup knew they would either get nicotine gum or a place-
bo"
Blinding (performance
bias and detection bias) 
All outcomes




Low risk 7/59 claiming abstinence at 12 months were not CO-confirmed (4 missing and
3 > 10 ppm), and counted as continuing smokers
Other bias Low risk 44/92 in NRT group were highly nicotine-dependent, compared with 28/90 in






Participants 159 smokers (≥ 1 cpd)
44% female, average age 42, average tobacco use 25 g/day
Participants had to be motivated to quit
Interventions 1. Nicotine nasal spray (NNS) ad lib use. Each dose (2 squirts) delivered 1 mg nicotine. Maximum dose 5
mg/h and 40 mg/day. Recommended duration of use 3 months
2. Placebo nasal spray containing piperine to mimic sensory effect of nicotine
Level of support: high (Group therapy 6 x 1-h sessions)
Outcomes Sustained abstinence at 1 year (continuous abstinence from quit day, follow-up also at 2 years)
Validation: CO < 10 ppm at each of 5 follow-ups
Notes Abstinence at 24 months 15/79 vs 11/78. OR 1.4
Blondal 1997 
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Study funded by Icelandic Ministry of Health and Social Security, with consumables supplied by Phar-
macia & Upjohn
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes

















Methods Country: UK (95 centres)
Recruitment: hospital chest clinics (80%) and inpatient wards
Participants 1618 clinic patients age 18 to 65 with a smoking-related illness (pulmonary or vascular)
39% female, average age 49, average cpd 24
Interventions 1. Brief advice from physician
2. Brief advice + booklet
3. Brief advice + booklet + placebo chewing gum
4. Brief advice + booklet + nicotine chewing gum (2 mg for up to 3 months, up to 6 months on request)
Level of support: low (1 month and 3 month follow-up visits)
Outcomes Sustained validated abstinence at 6 months and 12 months
Validation: Venous carboxyhaemoglobin
Notes Includes both placebo and no-placebo groups. 4 vs 1 + 2 + 3 used in main comparison. 4 vs 3 has lower
OR (0.8) but does not alter MA notably
Study was funded by Health Education Council and Lundbeck Ltd
Br Thor Society 1983 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Physician opened envelope at first treatment session
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "Placebo and nicotine gums were indistinguishable in appearance and





Low risk Lower losses from gum groups (10 and 10) than from Advice groups (24 and
24), but 18 VA and VAB participants were prescribed Nicorette in error; remov-
ing these made differences non-significant














50% female, average age 35, average cpd 29
Participants were motivated to give up
Interventions 1. Nicotine patch (24 h/day, 8 weeks, 15 cm with weaning) + behavioural therapy
2. Placebo patch + behavioural therapy
3. Behavioural therapy alone
Level of support: high (9 weekly group sessions)
Outcomes Abstinence (not stated how assessed) at 12 months
Validation: none
Notes Placebo and no-placebo groups. 1 vs 2 + 3 used in main comparison
Study was funded by Deutsche Forschungsgemeinschaft
Risk of bias
Bias Authors' judgement Support for judgement
Buchkremer 1988 
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Random sequence genera-
tion (selection bias)
Unclear risk Quote: "smokers were randomly assigned ... Randomization included match-
ing by age, sex and initial cigarette consumption"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind; "checked by questioning both the training person-
nel and the probands of nicotine- and placebo-groups". No significant differ-

















Recruitment: primary care (45 GPs in 11 centres)
Participants 836 primary care patients agreeing to try to stop smoking after brief advice from their doctor
61% female, average age 39
Interventions 1. Nicotine gum (2 mg) x 6 boxes
2. Placebo gum x 6 boxes
Level of support: low (no further face-to-face contact, ⅔ received a letter after 1 month)
Outcomes Sustained abstinence at 12 months
Validation: CO
Notes Study funded by Chest, Heart and Stroke Association; discounted Nicorette gum supplied by Lunbeck,
free chewing gum by Wrigleys
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "in a double-blind random fashion". Control participants were recruit-
ed sequentially after the gum cohort had been assembled
Allocation concealment
(selection bias)
Unclear risk Not stated
Campbell 1987 
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Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk 37% losses at 12 months






Participants 212 patients with smoking-related diseases
44% female, 53% aged 50+, 61% smoked > 15 cpd
Interventions 1. Nicotine gum 2 to 4 mg (3 months)
2. Placebo gum
Level of support: high (support at 2, 3, 5 weeks, 3 months, 6 months)
Outcomes Sustained abstinence at 12 months
Validation: CO
Notes Study was supported by Pharmacia LEO
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "those who had agreed were given packages of identical appearance
randomly containing either nicotine (2 mg) or placebo gum"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes










Recruitment: hospital inpatients and outpatients
Participants 234 adult smokers (> 1 cpd in previous week) (172 outpatients, 62 inpatients) Stratified on FTND. Partic-
ipants were motivated to quit
54% female, average age 49
Campbell 1996 
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Interventions 1. Nicotine patch (21 mg, 24 h, 12 weeks with dose tapering)
2. Placebo patch
Level of support: high (counselling at 2, 4, 8,12 weeks)
Outcomes Continuous abstinence at 12 months
Validation: CO
Notes Originally included as Burton 1992 which was an abstract of the same trial
Study was funded and supplied by Ciba-Geigy Ltd
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Participants stratified by inpatient/outpatient status, and outpatients also by
FTND score. Participants "were randomized"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes




Low risk 57 NRT and 56 placebo participants did not complete the 12-week course. By















Participants 64 smokers (> 15 cpd)
70% female, average cpd 29/22
Interventions 1. Nicotine patch (21 mg, 12 weeks incl weaning)
2. Behaviour therapy only (no placebo)
Level of support: High (group therapy weekly for 9 weeks)
Outcomes Sustained abstinence, 12 months post-treatment and all previous points (EOT, 1, 3, 6 months)
Cinciripini 1996 
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Validation: CO < 6 ppm at each point
Notes 121 smokers recruited but only the first 64 followed up for 1 year. 6-month quit rates for whole cohort
were approximately 53% vs 30% (personal communication 2004)
Study was supported by a DHHS grant, and by Ciba Geigy Corporation and Marion Merrell Dow
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Sixty-four participants ... were randomly assigned"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes











Participants 427 smokers (≥ 5 cpd)
51% female, average age 34, average cpd 22 for intermediate group (Clavel 1984). Participants were
motivated to quit
Interventions 1. Nicotine gum (2 mg) x 1 box
2. Control group (time lock-controlled cigarette case)
(Acupuncture arm not included in this review)
Level of support: High (3 x 1 h group therapy sessions in first month)
Outcomes Sustained abstinence at 13 months
Validation: "Smoking cessation adjusted using exhaled CO figures from published trials"
Notes Classification of support corrected to high in 2008 update
Study was supported by the Haut Comité d'Aide à la Lutte Contre le Cancer, and Laboratoire Léo, Swe-
den
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Treatment ... was allocated by balanced randomisation"
Allocation concealment
(selection bias)
Unclear risk Not stated
Clavel 1985 
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Blinding (performance
bias and detection bias) 
All outcomes




High risk Those still smoking at 1 month were not followed and were counted as fail-
ures, as were the 6% non-responders. Half the abstainers were visited at home






Participants 996 smokers (≥ 10 cpd)
45% female, average age 34
Interventions Factorial trial with active/placebo acupuncture arms, collapsed for this review
1. Nicotine gum (2 mg) for up to 6 months, max 30/day
2. Placebo gum (contained 1 mg unbuffered nicotine)
Level of support: high (3 acupuncture session at 0, 7, 28 days)
Outcomes Abstinence at 13 months (1-month quitters followed up). 4-year follow-up reported in 1997 with differ-
ent 1-year results
Validation: none at 1 year
Notes Question over inclusion because placebo contained small amount of nicotine
Abstinence at 4 years 30/481 vs 32/515
Study was supported by CIBA-GEIGY
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Participants were randomly allocated"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes




High risk Only participants abstinent at 1 month were followed up. 2 participants were
lost between months 9 and 12, and 32 between year 1 and year 4. Losses "were






Recruitment: pregnant women attending hospital clinics
Coleman 2012 
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Participants 1050 pregnant women at 12 to 24 weeks gestation smoking ≥ 5 cpd
Average age 26, average cpd at time of recruitment 14, average cpd before pregnancy 20
Interventions 1. Nicotine patch 15 mg/16 h for 8 weeks (participants given 4 week supply at outset, if not smoking at 4
weeks given another 4-week supply)
2. 'Visually identical' placebo on same schedule
Level of support: high. Behavioural cessation support ≤ 1 h at enrolment + 3 phone calls (on quit date,
3 days after quit date, 4 weeks after quit date). If collecting another 4-week supply of NRT/placebo, par-
ticipants given another face-to-face session
Outcomes Continuous abstinence from quit date to delivery and prolonged abstinence at 2 years from delivery.
Lapses of up to 5 cigarettes (on 5 occasions) permitted
Validation: at delivery: salivary cotinine < 10 ng/ml, CO ≥ 8 ppm, primary outcomes required saliva coti-
nine validation, with or without CO. At 2 years, no validation
Notes Funded by NIHR Health Assessment Technology Programme
Similar rates of adverse pregnancy and birth outcomes in both groups; at 2 years, infants born to
women who used NRT during pregnancy were more likely to have unimpaired development
Low compliance in both arms (7.2% active treatment and 2.8% placebo group reported using patch for
more than 1 month)
Longer-term follow-up data (2 year post-delivery) added for 2017 update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "computer-generated sequence, in random permuted blocks of ran-
domly varying size and with stratification by recruiting site"
Allocation concealment
(selection bias)
Low risk Quote: "eligibility criteria were entered into a secure online database before
randomization"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "identically packaged study patches were dispensed, and all partici-











Participants 439 female smokers (≥ 10 cpd)
Average age 38, average cpd 23
Interventions 1. Nicotine gum (2 mg), 10 to 12 pieces/day recommended, for 9 weeks, weaning last 3 weeks
2. Placebo gum
Cooper 2005 
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Level of support: high. 13 x 1-h weekly cognitive behavioural group sessions. Reduction prior to TQD
week 5
(3rd arm tested phenylpropanolamine gum, not included in review)
Outcomes PP abstinence at 12 months
Validation: CO < 10 ppm
Weight change in quitters was also a primary outcome in the trial
Notes First included as Cooper 2003. Published report from 2007
Sources of support not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Eligible participants ... were randomized"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk Dropouts not reported, all analyses conducted as ITT. Dropouts (if any) count-





Recruitment: inpatients at participating hospitals (multicentre)
Participants 1270 hospitalied smokers (excl. obstetrics, surgery and behavioural health patients), smoked in last 30
days and at least 6 cpd on days smoked
57% male, average age 50, average cpd 15
Interventions 1. NRT patches for 8 weeks, doses based on cpd. If 6 cpd to 10 cpd: 14 mg for 6 weeks, 7 mg for 2 weeks.
If > 10 cpd: 21 mg for 4 weeks, 14 mg for 2 weeks, 7 mg for 2 weeks. (NS if 16-h or 24-h patches)
2. No NRT
Level of support: varied. All were provided quitline number. Hospital systems, individual hospitals, and
even individual units had their own approach to usual care for smokers, with differences in providing
counselling or prescribing quitting aids during hospitalisation. There was no attempt to constrain these
activities. Some participants in the NRT and the no-NRT groups also received counselling due to factor-
ial design (2 x 2 factorial design: NRT/counselling/NRT and counselling/usual care). Counselling was by
the Quitline service. Authors tested for an interaction between NRT and counselling and this was not
significant, therefore results collapsed for this review
Outcomes 7-day PP at 6 months
validation: saliva cotinine < 10 ng/ml
Notes New for 2017 update
Cummins 2016 
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Funding: National Cancer Institute (CA159533)
N quit extrapolated from percentages given. Not included in support subgroups as support varied by
study centre
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “randomly assigned by computer to one of four groups”
Allocation concealment
(selection bias)
Low risk Recruiters “entered study-related information into a secure website that ran-
domised the subject.”
Blinding (performance
bias and detection bias) 
All outcomes




Low risk NRT 205/637, no-NRT 208/633 dropout < 50%. (return of saliva kits at 6 months





Recruitment: by random digit dialling
Participants 1000 smokers (≥ 10 cpd)
51% female, average age 49, average cpd 18, mean FTND 5
Interventions 1. Nicotine patches. 5 weeks total, tapered: 3 weeks 21 mg, 1 week 14 mg, 1 week 7 mg (unclear if 16 or
24 h)
2. No intervention
Level of support: low; no support provided (patches mailed to intervention participants)
Outcomes 30-day PP at 6 months
Validation: Saliva cotinine < 15 µg/L
Notes New for 2017 update
Total n followed up from author correspondence
Funding: Canadian Institutes of Health Research, Centre for Addiction and Mental Health, Canada
Foundation for Innovation, Ontario Ministry of Research and Innovation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants randomized "using a random number generator contained in
the computer assisted telephone interview program" This was "conducted in
Cunningham 2016 
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Low risk As above
Blinding (performance
bias and detection bias) 
All outcomes
High risk The participants knew which group they were in, although the interviewers
were masked to the experimental group at each follow-up point "(ensured










Recruitment: community volunteers at 2 sites
Participants 158 smokers (at least 1 pack cpd)
53% female, average age 42, average cpd 33
Interventions 1. Nicotine patch (15 cm2, 4 weeks) worn for 16 h/day
2. Nicotine patch (15 cm2, 4 weeks) worn for 24 h/day
3. Placebo patch, 4 weeks
Level of support: unclear and differed between sites
Outcomes Sustained abstinence at 6 months
Validation: None after 4 weeks (CO at 2 to 4 weeks)
Notes 1 + 2 vs 3 in Analysis 1.1. Not used in support intensity subgroup analysis
Study was funded by ALZA Corp, Palo Alto, CA, through a contract with the Merrel Dow Research Insti-
tute, Cincinnati, OH
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "All 158 study-eligible volunteers were randomly assigned"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes





Unclear risk Dropouts (if any) not reported; included as treatment failures in our analysis;
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Methods Country: USA (21 sites)
Recruitment: patients at family practices - self-referred to study or recruited by physician
Participants 369 smokers (> 20 cpd)
Average age 37, average cpd 27 to 30; participants were variously motivated to quit
Interventions 1. Nicotine patch (21 mg, 16 h, 10 weeks with weaning)
2. Placebo patch
Level of support: low (Nicoderm Committed Quitters Programme support booklet + follow-up visit 1
week after quit day)
Outcomes Sustained abstinence (continuous self-reported from quit day) at 12 months
Validation: CO ≤ 8 ppm and saliva cotinine < 20 mg/mL
Notes There were differences in quit rates between self-referred and physician-selected recruits and between
smokers recruited during an illness and at another visit
Study was funded by Marion Merrell Dow Inc
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a random code was generated" for equal numbers of active and place-
bo within blocks of 10
Allocation concealment
(selection bias)
Low risk See above
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Losses low at 3 months (1.1%), 6 months (1.6%) and 12 months (2.2%). Those






Participants 433 smokers (excludes 25 from ITT population)
52% female, average age 39, average cpd 21
Interventions 1. Nicotine lozenge (1 mg, 8 to 24/day, 6 weeks + 6 weeks weaning for quitters)
2. Placebo lozenge
Level of support: not stated
Outcomes PP abstinence at 26 weeks
Validation: CO < 10 ppm
Notes Based on published abstract
Study was funded by Novartis Consumer Health
Risk of bias
Dautzenberg 2001 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk Method not stated
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Higher losses in placebo than active group (44% vs 37%); analyses conducted




Methods Country: USA (4 centres)
Recruitment: community volunteers in shopping malls (OTC setting)
Participants 802 smokers (> 20 cpd) who scored 5+ on a questionnaire assessing motivation
54% female, average age 39, average cpd 29
Interventions 1. Nicotine patch (22 mg, 24 h, for up to 6 weeks)
2. Placebo patch
Level of support: low (self-help book provided. Participants visited mall weekly to obtain patches. CO
levels were monitored)
Outcomes Sustained abstinence at 24 weeks (from week 2)
Validation: Expired CO ≤ 8 ppm at each weekly visit, but 24 week quit based on self-report
Notes 541/802 did not complete the 6 weekly visits
Study was funded by Elan Pharmaceutical Corporation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a computer-generated randomization schedule"
Allocation concealment
(selection bias)
Low risk See above
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Losses were included as failures. 67.5% withdrew before study completion;
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Methods Country: Switzerland
Recruitment: University (primary care)
Participants 112 smokers at 2 universities
Average age 26, average cpd 23
Interventions 1. Nicotine patch (21 or 14 mg/24 h, 9 weeks, tapered)
2. Placebo patch
Level of support: high (no counselling)
Outcomes Sustained abstinence at 12 months (0 to 3 cigarettes per week)
Validation: urinary cotinine
Notes Study funding not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk Method not stated
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk Dropouts included as failures. 36% dropped out of active group, and 55% out
of placebo group
Other bias Unclear risk Abstinence defined as 0 to 3 cigarettes a week, with CO < 12 ppm. Relapse de-





Recruitment: healthcare (3 prenatal care sites)
Participants 52 pregnant (< 30 weeks gestation) smokers motivated to quit, self-identified as ethnic minority
100% female, average age 28, average cpd 6, mean gestational age at baseline 9 weeks
Interventions 1. Nicotine patch, 10 weeks. Dose based on baseline salivary cotinine: if baseline salivary cotinine level
≥ 100 ng/ml then 21 mg patches for 2 weeks, 14 mg patches for 4 weeks and 7 mg patches for 4 weeks.
If baseline salivary cotinine level 20 to 99 ng/ml then 14 mg patches for 6 weeks and 7 mg patches for 4
weeks
2. No pharmacotherapy
Level of support: high (6 individual in person counselling visits)
Outcomes Abstinence since last visit (approximately 3 weeks) at 20 weeks
El-Mohandes 2013 
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Validation: CO ≤ 8 ppm
Notes New for 2017 update
Does not contribute to primary analyses as follow-up < 6 months. 20-week abstinence (pre-delivery) in-
cluded in Analysis 5.1.1
Funding: Eunice Kennedy Shriver National Institute of Child Health and Human Development
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Using a 1:1 ratio, women were randomized to either the NRT patch
and continued CBT (Group 1) or CBT only (Group 2)… The web-based database
management system was programmed to randomize after entering the neces-
sary data to verify eligibility and administration of the baseline survey.”
Allocation concealment
(selection bias)
Low risk Quote: “The web-based database management system was programmed to
randomize after entering the necessary data to verify eligibility and adminis-
tration of the baseline survey.”
Blinding (performance
bias and detection bias) 
All outcomes
High risk Quote: “Telephone interviewers were blinded to group assignment.” “The in-




High risk At the strictest quit timepoint (salivary continine levels at final visit), 34/52 par-
ticipants lacked data (> 50%). If already delivered before 20 week follow-up,





Recruitment: smoking cessation clinic
Participants 100 consecutive smokers; 43 referred by physician, 57 applied by phone to SC clinic
59% female
Interventions 1. Nicotine gum (2 mg) for at least 4 weeks
2. Placebo gum for at least 4 weeks
Level of support: high (individual counselling, average 7.7 sessions)
Outcomes PP abstinence at 6 months
Validation: CO
Notes Study funding source not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "patients were randomly assigned... in blocks of ten"
Allocation concealment
(selection bias)
Unclear risk No information
Fagerström 1982 
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Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "All patients were told that the chewing gum they received contained
nicotine"; participants did not know that they were involved in a study
"the experimenter's guess of nicotine or placebo gum was in the direction of




Low risk 4 early dropouts (3 active, 1 placebo) excluded from analysis; all other





Recruitment: general practices and industrial clinics (primary care)
Participants 145 smokers motivated to quit
56% female, average age 40 years, average cpd 19
Therapists: 10 Swedish GPs, 3 Swedish industrial physicians
Interventions 1. Short follow-up (advice plus 1 appointment)
2. Long follow-up (advice plus 2 appointments, phone call + letter)
3. Short follow-up plus nicotine gum (2 mg or 4 mg)
4. Long follow-up plus nicotine gum
Level of support: low
Outcomes Sustained abstinence at 12 months (and at 1, 6 months)
Validation: 15% deception rate detected by expired CO > 4 ppm in a random subset of claimed non-
smokers at 6 months. Self-reported 12 month rates used in MA
Notes 3 and 4 vs 1 and 2 in Comparison 1
Study funding not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Quote: "Patients were randomly assigned" by birthdate; participants born 1st
to 20th received active gum, 21st to 31st no gum. Those born on even dates got
long follow-up, odd dates short follow-up.
Allocation concealment
(selection bias)
High risk Not used
Blinding (performance
bias and detection bias) 
All outcomes




High risk Only participants abstinent at 1 follow-up were seen again for the next one. All
losses counted as failures
Other bias High risk Physicians selected for the study were personal acquaintances of the author,
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Methods Country: UK
Recruitment: smoking cessation clinic
Participants 352 smokers, no other demographic data
Interventions 1. Gum (2 mg) given for 5 weeks
2. Placebo gum given for 5 weeks
Level of support: high (10 group therapy sessions)
Outcomes PP abstinence at 12 months
Validation: Blood carboxyhaemoglobin
Notes Study was supported by LEO Laboratories, Sweden
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "Allocation was carried out by external staE, using a random selection
procedure unknown to the authors"
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk Significantly higher losses from placebo (47.7%) than from active group






Participants 88 smokers (> 15 cpd), motivated to quit.
Interventions 1. Nicotine patch (22 mg/24 h, 8 weeks, no weaning)
2. Placebo patch
Level of support: high (intensive group counselling)
Outcomes PP abstinence at 6 months (7-day PP)
Validation: CO
Notes Reported in same paper as Fiore 1994b
Studies supported by Elan Pharmaceutical Research Corporation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a pregenerated computer sequence" and stratified by FTQ score
Fiore 1994a 
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Allocation concealment
(selection bias)
Low risk See above
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Ten placebo and 1 active participant failed to complete the NRT course. 25 par-






Participants 112 smokers (> 15 cpd)
Interventions 1. Nicotine patch (22 mg/24 h, 6 weeks including weaning)
2. Placebo patch
Level of support: high (8 weekly 10 min to 20 min individual counselling)
Outcomes PP abstinence at 6 months (7 days PP)
Validation: CO
Notes Reported in same paper as Fiore 1994a.
Studies supported by Elan Pharmaceutical Research Corporation.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a pregenerated computer sequence" and stratified by FTQ score
Allocation concealment
(selection bias)
Unclear risk See above
Blinding (performance
bias and detection bias) 
All outcomes




Low risk 29% did not complete treatment phase and were included as failures (15 on






Setting: community volunteers (telephone recruitment)
Participants 1044 smokers aged 18 to 65, able to quit for 24 h, and without serious illness. Motivated to maintain ab-
stinence
Fortmann 1995 
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42% female, average age 40, average cpd 20
Interventions 1. Nicotine gum (2 mg, 1/h, at least 10/day and not more than 30/day)
2. Self-help materials
3. Nicotine gum plus materials
4. Incentive alone
All groups offered incentive of USD 100 for quitting at 6 months
Level of support: low
Outcomes PP abstinence at 12 months
Validation: CO < 9 ppm/salivary cotinine < 20 ng/ml
Notes Until 2008 only groups 1 and 4 compared. Since the trial was factorial and shows no evidence of inter-
action, both gum groups now used; 1 and 3 vs 2 and 4. The RR is unaltered but CIs narrow
Study was funded by the National Heart, Lung, and Blood Institute
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Method not stated
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk 3.9% dropped out at 6 months, and 6.2% at 12 months. Unclear whether






Recruitment: community (individuals who spontaneously accessed smokefree.gov portal)
Participants 1034 smokers of ≥ 5 cpd, motivated to quit, no prior use of smokefree.gov website
68% female, average age 39, average cpd 19.3, mean FTND 5.3
Interventions 1. Nicotine mini-lozenge for 2 weeks (mailed). 162 lozenges received (dosage not given but based on
time to first cigarette), instructed to use 6 to 10 lozenges per day
2. No pharmacotherapy or placebo
Level of support: variable (factorial study resulting in 32 distinct experimental conditions, behavioural
elements varied on quitline counselling, messaging, brochures)
Outcomes 7-day PP at 7 months (by e-mail)
Validation: none
Notes New for 2017 update
Fraser 2014 
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Factorial trial, NRT versus no NRT compared in main analyses, other factors related to behavioural sup-
port (authors tested for interaction. No interaction found between NRT and behavioural components,
results therefore collapsed for our analysis)
N quit extrapolated from percentages given
Funding: Matthews Media Group, National Cancer Institute
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Through automated system: “Randomization occurred immediately after the
confirmation call, and participants completing this step were sent an automat-
ed email welcoming them to the study and outlining services they would re-
ceive (based on their randomization).”
Allocation concealment
(selection bias)
Low risk Automated, see above
Blinding (performance
bias and detection bias) 
All outcomes
High risk No blinding of participants. “Follow-up interviewers were blind as to treat-




Low risk At 7 months, 828/1034 participants were followed up (> 50%). Dropout for each
group not given but states follow-up across 5 different treatment factors 76%





Recruitment: 3 psychiatric case management sites in La Frontera, Arizona
Participants 180 smokers, aged 18+, English-speaking, smoked at least 10 cpd for at least 3 years, CO > 10 ppm. Di-
agnosed with DSM-IV Axis 1 psychotic-spectrum or affective disorders resulting in long-term mental ill-
ness and experiencing significant symptoms and functional impairment
52% male, average age 43, av FTQ 6.1, average cpd 24.8
Interventions 1. Contingency reinforcement (CR): Weekly visits weeks 1 to 4 (Phase 1), fortnightly weeks 6 to 12
(Phase II), monthly weeks 16 to 24 (Phase III). Payments USD 25 for baseline assessment and USD 5 per
visit, plus USD 20 per abstinent visit in Phase I, USD 40 in Phase II, USD 60 in Phase III, and USD 80 if ab-
stinent at 36-week follow-up. Max payable USD 580 for attendance + abstinence. At each visit weight,
pulse rate, smoking status, intention to quit, withdrawal symptoms, CO, BP measured
2. CR + NRT: As CR Group, plus 16-week course of 21 mg NRT patches (16 h or 24 h not stated), plus sup-
porting instructions
3. Control: Visits at baseline and weeks 20 and 36, plus encouraged to use the community smoker
helpline, ALA and ACS self-help information
Level of support: high (contingency reinforcement)
Outcomes PP abstinence at week 36
Verified by expired CO < 10 ppm and by salivary cotinine < 15 ng/mL
Notes New for 2017 update. Analysis compares 2 vs 1; 3 not included as comparison with NRT confounded
Not required to commit to cessation, but 98% expressed interest either in quitting or in reducing
Gallagher 2007 
Nicotine replacement therapy versus control for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Additional information supplied by the author. N quit extrapolated from percentages given
Study funded by Arizona Biomedical Research Commission.
Risk of bias and some data extraction from Cahill 2015
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




High risk Study staE oversaw allocation
Blinding (performance
bias and detection bias) 
All outcomes




Low risk No significant differences between groups: Attrition for CR at weeks 20 and 36






Participants 106 adult smokers (excludes 81 not beginning treatment)
65% female, average age 36, average cpd 25
Interventions 1. Gum (2 mg) for 3 to 4 months
2. Placebo gum for 3 to 4 months
Level of support: high (group therapy, 7 sessions over 3 months)
Outcomes Sustained abstinence at 6 months
Validation: CO ≤ 7 ppm
Notes Sources of support not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "La asignación a los grupos de estudio se realizaba aleatoriamente al
acudir a la primera entrevista"
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind ("doble ciego")
Incomplete outcome data
(attrition bias) 
Low risk Dropouts reported at 1, 3 and 6 months. Analyses appear to be ITT-based,
counting dropouts as failures
García 1989 
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Participants 608 smokers, aged > 20, smoking > 5 cpd
51% female, average cpd 23
Interventions 1. 4 mg nicotine gum (recommended 9 to 15 pieces), weaning from 2 months
2. 2 mg nicotine gum, use as 1
3. Placebo gum
All received brief counselling (5 to 10 mins) at each study visit (1, 7, 14, 30 days, 2, 3, 6, 9, 12 months)
Level of support: high
Outcomes Sustained abstinence at 12 months (relapse defined as 7+ consecutive days or episodes of smoking)
Validation: CO ≤ 8 ppm
Notes 4 + 2 mg doses combined in main comparison
Study was funded by National Institute of Drug Abuse and Department of Veterans Affairs. Gum sup-
plied by Marion Merrell Dow
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk No further detail
Blinding (performance
bias and detection bias) 
All outcomes










Participants 223 patients presenting to primary care doctors and smoking at least 1 cpd (not selected by motiva-
tion)
Interventions 1. Support from physician plus offer of nicotine gum prescription (2 mg)
2. Support from physician (no placebo)
Level of support: low (enrolment, quit day, offer of 4 support visits, 2 in week 1, 1 month, 2 months)
Outcomes Sustained abstinence at 12 months (for 3 months)
Gilbert 1989 
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Validation: salivary cotinine
Notes ˜30% of gum group did not use any, 14% of support only group did use gum. ˜70% attended quit day
visit, ˜43% attendance for follow-up visits
Study was funded by US National Insititutes of Health
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "physicians were presented with a sealed envelope indicating treat-
ment allocation by the receptionist"; "allocation was balanced within each
block of four patients for each physician"
Blinding (performance
bias and detection bias) 
All outcomes
High risk No placebo gum used. Control group participants could request gum, and




Unclear risk Follow-up at 1 year of 91.5%; those lost to follow-up were included as failures
Other bias Unclear risk Participants using gum were required to pay for their prescription
Participants claiming abstinence were visited for validation test without being





Recruitment: hospital health professionals
Participants 112 healthcare professionals smoking at least 1 cpd. 26% had FTND score 6+
66% female, average age 34, average cpd: 24
Interventions 1. Nicotine patch, 24 h, 25 mg/15 mg/8 mg starting dose depending on baseline cpd. 3 weeks
2. Placebo patch
Level of support: low (visits to pick up patch at 7, 14, 21 days, no details about advice given)
Outcomes Sustained abstinence (3 or fewer cigarettes/week) at 1 year (5-year abstinence also reported, not used
in MA)
Validation: CO < 11 ppm
Notes Study was supported by Novartis
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Glavas 2003a 
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Allocation concealment
(selection bias)
Low risk Quote: "each examinee received a presealed envelope, labeled after random
numbering, which contained either 8 transdermal nicotine system patches or
matching placebo stickers"
Blinding (performance
bias and detection bias) 
All outcomes











Interventions 1. Nicotine patch, 24 h, 25 mg/15 mg/8 mg starting dose depending on baseline cpd. 6 weeks
2. Nicotine patch, 24 h, 25 mg/15 mg starting dose depending on baseline cpd. 3 weeks
3. Placebo patch. 6 weeks
4. Placebo patch 3 weeks
Level of support: low
Outcomes Abstinence at 6 months after EOT
Validation: CO < 11 ppm
Notes Both durations pooled for main comparison
Study funding information not reported
Author supplied additional details in personal communication
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Low risk Quote: "presealed numbered envelopes"
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Quote: "The envelopes were prepared well in advance and the distribution was




Unclear risk Not stated
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Methods Country: USA
Recruitment: community volunteers
Participants 241 smokers (≥ 10 cpd), motivated to quit
54% female, average age 42, average cpd 29
Interventions 1. Nicotine sublingual tablet (2 mg). Recommended dosage 1 tablet/h for smokers with FTND < 7, 2
tablets/h for scores ≥ 7. After 3 months treatment, tapering period of 3 months if necessary
2. Placebo tablet
Level of support: high (brief counselling at all visits 1, 2, 3, 6 weeks, 3, 6,12 months)
Outcomes Sustained abstinence at 12 months
Validation: CO < 10 ppm
Notes Study was funded by Pharmacia & Upjohn
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a computer-generated randomization code"
Allocation concealment
(selection bias)
Low risk Quote: "subjects were sequentially randomized"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "All tablets were identical in appearance... each placebo tablet con-











Participants 629 smokers (> 15 cpd) who had relapsed after transdermal nicotine and behavioural counselling in an
earlier phase of the study
Minimal additional support
Interventions 1. Nicotine patch 30 cm2 (21 mg/24 h) for 4 weeks, 20cm2 (14 mg/24 h) for 4 weeks, 10 cm2 (7 mg/24 h)
for 4 weeks.
2. Placebo patch
Outcomes Sustained abstinence at 6 months
Validation: expired CO < 10 ppm
Notes Does not contribute to main comparison. Test of patches vs placebo in recently relapsed smokers. Re-
sults given in text.
Study was funded by Ciba-Geigy Australia, the Anti-Cancer Council of Australia and the Victorian
Health Promotion Foundation
Gourlay 1995 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "Subjects were randomised"
Blinding (performance
bias and detection bias) 
All outcomes









Recruitment: smoking cessation website
Participants 5290 current smokers
61% female, average age 42, average cpd 17, mean FTND 5.3
Interventions 1. 4 weeks of NRT patch, gum or lozenge depending on participant preference, mailed to participants.
Standard dosing protocol as per labelling instructions
2. No NRT
Level of support: low (use of interactive website. Some participants also received web-based social net-
work intervention. 2 x 2 factorial design. No evidence of interaction between NRT and web-based social
network intervention, therefore results collapsed for our analysis)
Outcomes 30-day PP at 9 months
Validation: none
Notes New for 2017 update
9-month data obtained from authors
Funding: National Cancer Institute
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “randomisation is stratified by gender and baseline motivation to quit.




Low risk Central computer-based allocation
Graham 2017 
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Blinding (performance
bias and detection bias) 
All outcomes
High risk Participants were not blinded but if research staE contacted participants by











51% female, average age 42, average cpd 33, average FTND 7.8
Interventions 1. Nicotine gum (2 mg), tapered from week 12. Active gum groups further randomized to chew 7, 15 or
30 pieces of gum
2. No gum
Level of support: high (1 pre-quit group counselling session, 14 clinic visits in 10 weeks)
Outcomes Continuous abstinence at 6 months (up to 3 cigarettes allowed)
Validation: CO ≤ 10 ppm. Saliva thiocyanate in week 2
Notes No placebo. Long-term abstinence rates not affected by amount of gum, so these groups collapsed for
comparison with no-gum condition
Study was funded by National Institute of Drug Abuse, and supported by Marion Merrell Dow
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk "Random assignment", stratified by dependence measures
Blinding (performance
bias and detection bias) 
All outcomes









Recruitment: community volunteers and physician referrals
Participants 120 smokers (77 in arms contributing to MA)
47% female, average age 38, average cpd 31
Hall 1985 
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Interventions 1. Intensive behavioural treatment (14 group sessions over an 8-week period)
2. Combined - 2 mg nicotine gum (period of use not specified) and intensive behavioural treatment
3. Low-contact behavioural treatment (4 meetings over 3 weeks) and 2 mg gum
Level of support: high
Outcomes Abstinence at 12 months
Validation: CO < 10 ppm and blood thiocyanate < 85 mg/mL
Notes No placebo. 2 vs 1 in main comparison. 3 not used in MA. Quit rate higher than arm 1
Study was funded by National Institute of Drug Abuse and Department of Veterans Affairs
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "Subjects were randomly assigned within time constraints to one of the
three treatment conditions"
Blinding (performance
bias and detection bias) 
All outcomes










Participants 139 adult smokers
47% female, average age 39, average cpd 30
Interventions 2 x 2 factorial trial of gum and behavioural support
1. Nicotine gum (2 mg) up to 12 months
2. Placebo gum up to 12 months
Both levels of behavioural support classified as high intensity and collapsed in analysis (both group-
based, 14 x 75-min sessions, or 5 x 60-min sessions)
Outcomes PP abstinence at 12 months
Validation: CO < 8 ppm and serum thiocyanate < 95 mm/l
Notes Study funded by National Institute of Drug Abuse and Department of Veterans Affairs
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Hall 1987 
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Allocation concealment
(selection bias)
Unclear risk Quote: "Within their time constraints, subjects were randomly assigned to 5 to
6 member groups across conditions"
Blinding (performance
bias and detection bias) 
All outcomes











Participants 207 smokers of which 6 excluded from analyses because of protocol breaches
52% female, average age 40, average cpd 24
Interventions 2 x 2 factorial trial of gum and psychological treatment
1. Nicotine gum (2 mg) for 8 weeks, 1 piece/h for 12 h/day recommended
2. Placebo gum, same schedule
Both levels of behavioural support classified as high intensity and collapsed in analysis (both group-
based, 10 sessions over 8 weeks, TQD session 3)
Outcomes Sustained abstinence at 12 months (abstinent at all assessments)
Validation: CO ≤ 10 ppm at 8, 12, 26 weeks and urinary cotinine ≤ 60 ng/ml at 52 weeks
Notes Psychological treatment arms collapsed, no evidence of a significant interaction
Study was funded by National Institute of Drug Abuse and Department of Veterans Affairs.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "Patients were stratified according to depression history and number
of cigarettes smoked per day; they were then randomly assigned from within
stratified blocks"
Blinding (performance
bias and detection bias) 
All outcomes











Nicotine replacement therapy versus control for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Recruitment: hospital in- or outpatients referred by hospital doctor
Participants 245 patients with smoking-related disease
46% male, typically aged 50+, smoking 15+ cpd; participants were motivated to try and quit
Interventions 1. Nicotine patch (initially 30 or 20 mg based on smoking rate) and inhaler for 3 weeks including patch
tapering. Same counselling as control
2. Individual counselling, 4 sessions in 4 weeks. No placebo
Level of support: high
Outcomes Sustained abstinence at 12 months (abstinent at all assessments)
Validation: CO < 10 ppm
Notes No placebo. Compliance with NRT was low, 28% did not use, 30% used full supply
Used in main comparisons
Study was funded from one author's endowment fund
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
High risk Quote: "randomised, according to month of entry"; unequal months, with im-
balance in favour of NRT group
Blinding (performance
bias and detection bias) 
All outcomes









Recruitment: primary care (University Health Centre)
Participants 197 smokers (151 used in MA), motivated to quit
63% female, average age 36, average cpd 26
Interventions 1. Nicotine gum (2 mg, 6 weeks initial supply, suggested tapering after 3 months, available for 6
months) plus self-help manual
2. Self-help manual
3. Control (booklet)
Level of support: low (single appointment with doctor or nurse, length not specified)
Outcomes Sustained abstinence at 12 months
Validation: CO in all participants, cotinine and carboxyhemaglobin in a subsample of participants
Notes No placebo. Arm 3 not included in MA control group - it had a lower quit rate so inclusion would in-
crease the gum treatment effect
Risk of bias
Harackiewicz 1988 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "randomly assigned to one of three conditions"
Blinding (performance
bias and detection bias) 
All outcomes





Low risk 11% of participants did not return for any follow-up, and were not included in







Participants 122 (81 to relevant arms) smokers admitted with a cardiac or pulmonary illness
48% female, average age 55, average cpd 20
Interventions 1. Patch and gum/lozenges as per participant preference. Patch dose dependent on cpd prior to hospi-
talization; exact dose not specified but participants smoking 10 to 20 cpd on 21 mg/day initially
2. No NRT
Level of support: high. 90-min individualized hypnotherapy session with a certified hypnotist and a to-
bacco treatment specialist, plus self-help materials and counselling (intensive counselling for 30 mins
in hospital, with 5 follow-up 15-min phone calls with additional counselling at 1, 2, 4, 8, and 12 weeks
after hospital discharge)
Outcomes 7-day PP at 6 months
Validation: Urinary cotinine < 15 ng/ml
Notes New for 2017 update
Funding: Norman H. Read Charitable Trust Foundation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: “We randomized participants to one of three treatment groups: NRT
only (NRT), hypnotherapy only (H), and a group receiving both hypnotherapy
and NRT (HNRT)… Randomization assignments were performed in permut-
ed blocks of three (ratio 1:1:1) with assignments sequentially numbered” Not
clear how sequence generated
Allocation concealment
(selection bias)
Low risk Quote: “Randomization assignments were performed in permuted blocks of
three (ratio 1:1:1) with assignments sequentially numbered, and schedule was
maintained independent of the study by the project coordinator. Randomized
Hasan 2014 
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assignments were concealed from both patients and research staE until pa-
tients had signed the informed consent document and were enrolled in the
study"
Blinding (performance
bias and detection bias) 
All outcomes
High risk Quote: “Due to the nature of the intervention conditions, counselors could not
be blinded to the modality of intervention.” “Our analysis is somewhat limit-
ed by the fact that comparing two vastly different modalities such as hypnosis
and pharmacotherapy represents a randomization challenge, as participants









Methods Country: USA (3 sites)
Recruitment: community volunteers
Participants 958 smokers, > 15 cpd, motivated to quit
50% female, average age 44, typically smoked 21 to 40 cpd
Interventions 1. Nicotine patches (22 mg, 24 h for 6 weeks) purchased by participants, open-label
2. Nicotine patches (22 mg, 24 h for 6 weeks) provided, double-blind
3. Placebo patches provided
The intervention replicated an OTC environment, with no counselling intervention and minimal study
recording. Weekly visits required for CO measurement and adverse experience recording, but study
sites were not in medical centres and there was no advice, counselling or interaction with medical per-
sonnel
Level of support: low
Outcomes Abstinence at 6 months (7-day PP)
Validation: CO ≤ 8 ppm
Notes 1 and 2 vs 3 in patch vs placebo comparisons
Study was supported by Elan Pharmaceutical Research Corp
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Computer-generated random schedule"
Allocation concealment
(selection bias)
Low risk 2-stage process. 1. random allocation to 1 of 2 trials, i.e. open-label pay trial or
placebo-controlled. 2. Those in placebo trial were then assigned "by means of
a computer-generated code, in blocks of 20".
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "The randomization code was not revealed to any of the investigators




Unclear risk Participants who missed follow-up visits classified as failures. Dropout rates
not reported
Hays 1999 
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Participants 322 smokers > 10 cpd, scoring ≥ 4 on FTND, no serious illness. Only those who were ready to quit after 4
weeks of behavioural treatment were randomized
43% female, average age ˜38, average cpd 33 for high dependence, 16 for low dependence
Interventions Low-dependence smokers (FTND 4 to 6):
1. 2 mg nicotine gum
2. Placebo gum
High-dependence smokers (FTND 7 to 11):
1. 4 mg nicotine gum plus
2. 2 mg nicotine gum
Level of support: high for all (12 group sessions over 6 weeks + 6 weekly maintenance sessions)
Participants also randomized to starting medication with increasing dose for 1 week before TQD, or to
start at full dose on TQD - there was no blinding for this
Outcomes Sustained abstinence at 2 years (1 year also reported)
Validation: expired CO < 6 ppm
Notes Low-dependence smokers included in comparison 1
Relapse between 1 and 2 years similar between low-dependence groups. Higher relapse in 4 mg high
dependence than 2 mg
No information on support or funding
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk Stratified on dependency scores, to determine dosage. Then "randomly as-
signed"
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk 68 participants dropped out in Phase 1 (weeks 1 to 2) and 10 participants in
Phase 2 (weeks 4 to 6), i.e. before randomization. Dropout rates not reported,





Setting: Smoking cessation clinics
Participants 272 treatment-seeking participants: Brief advice (91), NRT (92), varenicline (89).
41.2% women, mean age 42.5 years, mean FTND 5.5
Interventions 1. NRT: 8 weeks of 15 mg/24 h NRT patches
Heydari 2012 
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2. 8 weeks of 1 mg x 2/day varenicline (titrated 1st week)
3. Control group: no pharmacotherapy
Level of support: high (all received brief (5 mins) education and counselling at 4 x weekly sessions.)
Outcomes 12 months PPA, in person or by phone, verified by expired CO (cut-oE value not given)
Notes New for 2017 update. Our analyses only include 1 vs 3
Funding: Masih Daneshvari Hospital Research Institute, Tehran
Risk of bias and some data extraction taken from Cahill 2016
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes




Low risk No attrition: "Participants entered the study of their own accord and none leO
the study"
Other bias Unclear risk Abstinence-by-gender data (Table 2) appears to contain an error for women on






Recruitment: drug abuse treatment centres
Participants 424 smokers ("habitual smokers" ≥ 1 year), history of drug abuse including opiates or narcotics for ≥ 1
year prior to referral to drug treatment centre
100% male, average age 44, average cpd NS (majority smoked 11 to 30 cpd), mean FTND 5.3
Interventions 1. NRT patch, gum and lozenges over 6 weeks. Step down 30 mg, 20 mg and 10 mg patches, and supply
of 4 mg chewing gum and 1 mg pills
2. No pharmacotherapy or placebo
Level of support: high (individual behavioural therapy, further detail not provided)
Outcomes Abstinence at 6 months (type of measure not specified)
Validation: exhaled CO (cut oE not specified)
Heydari 2013 
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Notes New for 2017 update.
Not included in Analysis 4 as only study to be conducted in drug abuse treatment setting
Funding: not specified, NRT provided free of charge by Meliora Health Corporation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “424 persons were assigned in a simple randomisation process into




Unclear risk No details provided
Blinding (performance
bias and detection bias) 
All outcomes
High risk Quote: “researchers informed clinicians as to the type of treatment to admin-










Recruitment: smoking cessation clinic
Participants 206 smokers
56% female, average age 42, average cpd 24
Interventions 1. Nicotine gum (2 mg) (no restrictions on amount or duration of use)
2. Placebo gum
Level of support: high (6 group sessions in 6 weeks)
Outcomes Sustained abstinence at 12 months
Validation: CO
Notes No information on support or funding
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk 26 groups "were randomly assigned"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Both therapists and nurse distributing gum were blinded to assignment of
groups. Placebo gum was flavoured with capsaicin to mimic nicotine
Hjalmarson 1984 
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Low risk 3 dropouts from each cohort during follow-up; they were counted as smokers.






Recruitment: smoking cessation clinic
Participants 248 smokers
57% female, average age 45, average cpd 22
Interventions 1. Nicotine nasal spray (0.5 mg/spray) used as required up to 40 mg/day for up to 1 year
2. Placebo spray
Level of support: high (8 x 45- to 60-min group sessions over 6 weeks with clinical psychologist)
Outcomes Sustained abstinence at 12 months
Validation: CO < 10 ppm
Notes Study was supported by Kabi Pharmacia AB, Sweden
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "Subjects ... were randomized" to 26 groups
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "Procedure was blind to both subject and therapist", but where more
than 1 household member was enrolled all members got the same treatment
(6 couples thus affected, 3 in active and 3 in placebo). At 12 months, 60% of re-









Recruitment: smoking cessation clinic
Participants 247 smokers (> 10 cpd) who had previously made a serious attempt to stop using nicotine gum, and
were motivated to quit
64% female, average age 48, average cpd 21
Interventions 1. Nicotine inhaler (recommended minimum 4/day, tapering after 3 months, use permitted to 6
months)
2. Placebo inhaler
Level of support: high (8 group meetings over 6 weeks)
Hjalmarson 1997 
Nicotine replacement therapy versus control for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Outcomes Sustained abstinence at 12 months
Validation: CO < 10 ppm at 2 and 6 weeks and 3, 6, 12 months
Notes Study was funded by Pharmacia & Upjohn, Sweden
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "All numbers were on a list for random allocation to medication"
Allocation concealment
(selection bias)
Low risk Participants received "a subject number consecutively" at the first group ses-
sion
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "The randomization was blinded to both the participant and the thera-
pist", but members of the same household received the same treatment. At 12











Participants 225 smokers (109 contribute to MA)
No demographic information
Interventions 1. Nicotine gum alone
2. Behaviour therapy, 5 weekly group meetings
3. Nicotine gum (no details of dose) and behaviour therapy
Level of support: high
4. 6-month waiting-list control
Outcomes Abstinence at 12 months
Validation: none
Notes 3 vs 2 in comparison 1. No placebo. Quit rates derived from graphs. The nicotine-alone group was not
used in the MA; quit rates were higher than intervention 2
Study funding and support not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "225 interested subjects ... were randomly assigned"
Huber 1988 
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Blinding (performance
bias and detection bias) 
All outcomes










Participants 315 daily smokers, motivated to quit
56% female, average age 37, average cpd 29
Interventions 1. Nicotine gum (2 mg for 3 to 4 months)
2. Placebo gum
Level of support: low (29 to 35 mins at 1st visit including nurse and physician advice and materials, fol-
low-up appointment 1 to 2 weeks later)
Outcomes Sustained abstinence at 12 months
Validation: salivary cotinine < 15 ng/mL or thiocyanate < 1.6 mmol/L
Notes Time spent at 1st visit is marginal for inclusion in low-intensity support category
Study was funded by National Institute on Drug Abuse; gum supplied by Merrel-Dow Research Institute
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk A 4th random digit (1 to 9) was added to their 3-digit subject ID number. Only
exception was members of same household got the same treatment
Allocation concealment
(selection bias)
Low risk 2:1 randomization scheme. Quote: "Subjects were assigned randomly in a dou-
ble-blind manner"
Blinding (performance
bias and detection bias) 
All outcomes












Participants 78 smokers, motivated to quit
54% female, average age 34 to 44, average cpd 24 to 30
Hughes 1990 
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Interventions 1. Placebo gum
2. 1 mg nicotine gum (unbuffered formula, available dose approximately 0.5 mg)
3. 2 mg nicotine gum
4. 4 mg nicotine gum
Gum use not recommended for longer than 3 months
Level of support: low (similar to Hughes 1989a)
Outcomes Sustained abstinence at 6 months
Validation: Independent observer report
Notes 2 + 3 + 4 vs 1 in Comparison 1. Excluding the lowest dose would increase the treatment effect
Study was funded by National Institute on Drug Abuse
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "Subjects were randomly assigned"
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Quote: "in a double-blind manner"; participants guessed which group they









Methods Country: USA (12 sites), Australia (1 site)
Recruitment: community volunteers and referrals
Participants 1039 smokers (≥ 30 cpd) who had made a prior quit attempt, motivated to try again
50% male, average age 43, average cpd 38
Interventions 1. 42 mg nicotine patch (24 h, 6 weeks + 10 weeks tapering)
2. 35 mg nicotine patch
3. 21 mg nicotine patch
4. Placebo patch
Level of support: high (group behaviour therapy for 7 weeks, brief individual counselling at 5 dose-ta-
pering meetings. Self-help booklet)
Outcomes Prolonged abstinence at 6 months (from 2 weeks post-quit) verified at each follow-up visit
(12-month follow-up only completed for 11/13 sites)
Validation: CO ≤ 10 ppm
Notes All doses pooled in Analysis 1.1 against placebo
6-month abstinence rates used in analyses since not all centres completed 12-month follow-up due to
sponsor termination of study. Denominators confirmed by author
Study was funded by National Institute on Drug Abuse, ALZA and Hoechst Marion Roussel
Hughes 1999 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "Subjects were randomly assigned in a double-blind manner"
Blinding (performance
bias and detection bias) 
All outcomes




High risk Early termination by sponsor, resulting in incomplete long-term follow-up da-






Participants 115 smokers with a history of alcohol dependence, motivated to quit, ≥ 30 cpd
68% male, average cpd 30
Interventions 1.Nicotine patch (21 mg, 24 h, 6 weeks + 4 weeks tapering + 2 weeks placebo)
2. Placebo patch 12 weeks
Level of support: high (Group behaviour therapy x 6, brief individual counselling x 3)
Outcomes Sustained abstinence at 6 months (from 2 weeks post-quit)
Validation: CO ≤ 10 ppm at each follow-up visit
Notes Unadjusted ORs used in MA not significant, significant when adjusted for smoking variables
Study was supported by GlaxoSmithKline, and funded by National Institute on Drug Abuse
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "Subjects were randomly assigned"
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk Quote: "we assumed that missing data indicated smoking". Losses reported,
but not distribution across groups
Hughes 2003 
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Participants 62 adult smokers (> 20 cpd); only accepted if willing to make a quit attempt
53% female, average age 39, average cpd 30
Interventions 1. Nicotine patch (30 mg 24 h, 6 weeks + option of further 12 weeks ± tapering)
2. Placebo patch (continuing smokers at 6 weeks were offered active patch)
Level of support: high (brief advice from nurse co-ordinator at 6 weekly visits)
Outcomes Sustained abstinence at 12 months (quit by week 6, and all subsequent visits)
Validation: CO ≤ 8 ppm
Notes Study was in part supported by Elan Pharmaceutical Research Corporation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "subjects were assigned randomly"
Blinding (performance
bias and detection bias) 
All outcomes




Low risk 4 dropouts from each group in first 6 weeks; smoking status of all dropouts as-






Participants 240 adult smokers (> 20 cpd), motivated to quit
53% female, average age 43, average cpd 30
Interventions 1. Nicotine patch (22 mg/24 h, 8 weeks, no tapering)
2. Placebo patch
Level of support: high (nurse counselling at 8 weekly visits, weekly phone calls to week 12)
Outcomes Abstinence at 12 months (no puE since 9-month visit)
Validation: CO ≤ 8 ppm
Notes Study was supported by Lederle Laboratories, NY
Risk of bias
Bias Authors' judgement Support for judgement
Hurt 1994 
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Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "subjects were randomly assigned to active or placebo patches"
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Quote: "subjects with missing information or who dropped out... were consid-





Setting: primary care (19 general practices)
Participants 1686 smokers (> 15 cpd), not necessarily motivated to quit.
55% female, average age 43, average cpd 24
Interventions 1. Nicotine patch (21 mg/24 h, 12 weeks incl tapering)
2. Placebo patch
Level of support: high (brief advice from nurse at 4 study visits)
Outcomes Sustained abstinence at 12 months (from week 1)
Validation: Salivary cotinine or CO
Notes 8-year follow-up in Yudkin 2003, OR remained similar
Study supported by Ciba-Geigy Pharmaceuticals
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Low risk Quote: "prior random allocation of study numbers to each intervention group
and by sequential allocation of a study number to patients on entry"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Participants and nurses blinded to patches but not to support materials. Par-
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Recruitment: primary care (6 general practices)
Participants 200 adult smokers who had failed to stop smoking during a previous study of the effect of physician ad-
vice
No demographic information
Interventions 1. Nicotine gum (2 mg) for 3 months+
2. Placebo gum
Level of support: low (follow-up visits at 2, 4, 12 weeks for data collection, no counselling reported)
Outcomes PP abstinence at 6 months
Validation: expired CO ≤ 12 ppm
Notes Study was funded by Oxford District Research Committee and NuEield Dominions Trust, and supported
by Lundbeck Ltd
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The codes were balanced to give equal numbers of patients receiving
either the active gum ... or a placebo".
Allocation concealment
(selection bias)
Low risk Quote: "allocated to next available of ten alphabetical codes" from lists held in
each practice
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Treatments were "identical in appearance and packaging". "No one doctor or
member of staE was likely to see sufficient numbers of patients to be able to









Recruitment: smoking cessation clinic
Participants 116 clinic attenders, motivated to quit
55% female, average age 41/38, average cpd 31/27 (P < 0.05)
Interventions 1. Nicotine gum (2 mg) unrestricted amount for at least 3 months
2. Placebo gum (1 mg unbuffered nicotine)
Level of support: high (group therapy 6 x 1 h weekly)
Outcomes Sustained abstinence at 12 months (6-month and 12-month PP)
Validation: CO (small number by confirmation from friend/relative only)
Notes The placebo gum was intended to match the active gum in taste but deliver minimal amounts of nico-
tine
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "treated in groups of about ten, taken in order from the waiting list"
Blinding (performance
bias and detection bias) 
All outcomes




Low risk One sparticipant lost to follow-up counted as a failure





Recruitment: smoking cessation clinic
Participants 293 adult smokers (> 10 cpd) in relevant arms
54% female, average age 42, average cpd 21 to 22
Interventions 1. Nicotine gum (2 mg for 3 months)
2. Silver acetate chewing gum (not used in MA)
3. Standard chewing gum
Level of support: high (9 group meetings over a year, weekly to week 4)
Outcomes Sustained abstinence at 12 months
Validation: CO
Notes 12 month data reported in Jensen 1990, used from 2008
Sources of support not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "smokers were randomised to 24 smaller groups and each group was
randomly allocated to treatment". No further information
Blinding (performance
bias and detection bias) 
All outcomes





Unclear risk 21 trial-wide losses reported, but not included in the analyses. Distribution not
stated, so not possible to include those lost to follow-up in the final denomina-
tor
Jensen 1991 
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Participants 300 (200 to relevant arms) smokers prone to lung cancer (previous lung disease/family history of lung
cancer/past cancer treatment/lowered immunity/previous smoking-related cancers/exposure to cer-
tain chemicals/radon gas)
Other characteristics unknown
Interventions 1. NRT: patch, gum, inhalator, sublingual tablet or nasal spray for 6 weeks (no further detail provided)
2. No NRT
Level of behavioural support: low (20 mins intervention, no further detail given)
Outcomes PP (length NS) at 12 months
Validation: CO < 10 ppm
Notes New for 2017 update
Conference abstract only so limited information available, hence only in primary analysis
N quit extrapolated from percentages given
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes








Methods Country: USA (4 sites)
Recruitment: community volunteers
Participants 893 smokers, motivated to quit, (> 15 cpd)
52% female, average age 42 to 44, average cpd 25 to 28
Interventions 1. Nicotine patch (21 mg/24 h for 6 weeks, tapered for 2 weeks) and sustained release bupropion 300
mg for 9 weeks from 1 week before quit day
2. Bupropion 300 mg and placebo patch
Jorenby 1999 
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3. Nicotine patch and placebo tablets
4. Placebo patch and placebo tablets
Level of support: high, < 15 min individual counselling session at each weekly assessment. 1 phone call
3 days after quit day
Outcomes Abstinence at 12 months (primary outcome for study was PP abstinence; this analysis uses continuous
abstinence since quit day)
Validation: Expired CO < 10 ppm at each clinic visit
Notes 3 vs 4 in main analyses
Study was funded by Glaxo Wellcome
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)
Unclear risk Quote: "subjects were randomly assigned to one of four treatments with use of
an unequal-cell design... Randomization was not balanced within sites"
Blinding (performance
bias and detection bias) 
All outcomes




Low risk 311 discontinued treatment, with 177 withdrawing completely from the trial.





Methods Country: USA, multicentre trial
Recruitment: 10 Veterans Affairs Medical Centers
Participants 584 smokers (> 15 cpd) with a history of cardiac disease. Patients with cardiac events within the last 2
weeks were excluded
Interventions 1. Nicotine patch, (21 mg/24 h for 6 weeks, 14 mg for 2 weeks, 7 mg for 2 weeks)
2. Placebo patch
Level of support: High (self-help pamphlets and brief behavioural counselling on 3 occasions)
Outcomes PP abstinence at 6 months (Joseph 1996), 12 months (Joseph 1999)
Validation: CO ≤ 10 ppm
Notes Study was funded by Hoechst Marion Roussel
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Participants were randomly assigned in blocks of 10
Joseph 1996 
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Blinding (performance
bias and detection bias) 
All outcomes










Participants 64 adult smokers
72% female, average age 44, average cpd 32
Interventions 1. Nicotine gum (2 mg) for 7 weeks
2. Skills training
3. Skills training plus nicotine gum
Level of support: high (group therapy)
Outcomes Sustained abstinence at 10½ months
Validation: CO
Notes 1 + 3 vs 2 used in comparison. 3 vs 2 would increase effect
Study was funded by the National Institute of Health, and supported by Merrell-Dow Pharmaceuticals
Inc
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Participants "were blocked on sex and Fagerström score and assigned ran-
domly to treatment group".
"Therapists were assigned randomly to treatment conditions"
Blinding (performance
bias and detection bias) 
All outcomes
High risk No blinding reported. "Interpretation of this data is hampered by the lack of a










Recruitment: community volunteers who had abstained from smoking for 48 h
Participants 1218 adult smokers
Killen 1990 
Nicotine replacement therapy versus control for smoking cessation (Review)









Cochrane Database of Systematic Reviews
52% female, average age 43, average cpd 25
Interventions 1. Nicotine gum (2 mg, 8 weeks) ad lib dosing
2. Nicotine gum on a fixed dose
3. Placebo gum
4. No gum
Each group was also factorially randomized to 1 of 3 psychological interventions (all high support)
Outcomes PP abstinence at 12 months (7-day PP)
Validation: cotinine, except participants who moved away
Notes Quit rates were higher on fixed dose than ad lib gum
Quit rates identical (18%) in placebo and no-gum groups at 12 months
Study was funded by National Cancer Institute
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "randomly assigned"
Blinding (performance
bias and detection bias) 
All outcomes




Low risk 8 deaths removed from final analyses. Participants moving out of the area








˜50% female, average age ˜45, average cpd ˜23
Interventions 2 x 2 factorial design, comparison between video & self-help manuals and manuals alone collapsed
1. Nicotine patch (21 mg/24 h) for 8 weeks, 14 mg for 4 weeks, 7 mg for 4 weeks
2. Placebo patch
3. Nicotine patch and video (The video was shown at initial visit and a copy supplied for home use)
4. Placebo patch and video
Level of support: low (All treatment groups received a self-help treatment manual designed to develop
self-regulatory skills
Outcomes Sustained abstinence at 12 months (7-day PP at 6 and 12 months)
Validation: saliva cotinine < 20 ng/ml with the exception of participants living outside the area
Notes There was evidence of an interaction between NRT and video/self-help conditions but this does not al-
ter the MA so the conditions are combined from 2007. Both self-help conditions treated as low intensity
- classifying video as high intensity would marginally reduce effect in high-intensity subgroup
Killen 1997 
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Study was funded by National Heart, Lung, and Blood Institute, and supported by Hoechst Marion
Roussel Inc and Blue Shield Management
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Participants "were randomized to treatment conditions"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "Assignment to the patch condition was double-blind"; participants in-




Low risk Participants leaving the area (10) were excluded from analyses; all other un-






Participants 374 healthy smokers (> 10 cpd for > 3 years), motivated to quit
61% male, average age 40, average cpd 25
Interventions 1. Nicotine patch (12 weeks 15 mg/16 h, 6 weeks 10 mg, 6 weeks 5 mg) and nicotine gum (2 mg, as re-
quired)
2. Nicotine patch and placebo gum
3. Placebo patch and placebo gum. Level of support: high (nurse counselling)
Outcomes Sustained abstinence at 12 months
Validation: CO < 10 ppm
Notes Contributes data to main comparison (2 vs 3)
Study was supported by Pharmacia Consumer Pharma
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk See below
Allocation concealment
(selection bias)
Low risk Quote: "randomized list generated by a computer program". Randomization
balanced between companies 2:2:1
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "The investigator and the subjects were completely blind concerning
treatment". "unblinding was never requested during the whole study"
Incomplete outcome data
(attrition bias) 
Unclear risk Withdrawals counted as treatment failures. All analyses conducted on ITT ba-
sis. Dropout and withdrawal rates not reported
Kornitzer 1995 
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Methods Country: Czech Republic
Recruitment: community volunteers "wanting to reduce"
Participants 314 smokers (≥ 15 cpd)
58% female, average age 46, average cpd 25
Interventions 1. Choice of 4 mg nicotine gum (up to 24/day) or 10 mg inhaler (6 to 12 daily) for up to 6 months with
further 3 months tapering
2. Placebo gum or inhaler
Common components: brief behavioural cessation/reduction support at clinic visits (9 scheduled)
Outcomes Sustained abstinence at 12 months
Validation: CO < 10 ppm
Notes Trial also included assessment of reduction. Reduction outcomes contribute to Cochrane Review on
harm reduction
Study details are taken from a conference abstract. Published 2009
Study supported by Pharmacia CHC, Sweden
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes










Participants 222 smokers (> 20 cpd). (2 excluded from analysis having received incorrect prescription)
55% female, average age 44, average cpd 26
Interventions 1. Nicotine Inhaler (10 mg). Advised to use 4 to 20 cartridges/day for 3 months. After this tapering was
encouraged until 6 months
2. Placebo inhaler
Participants received advice and watched a video showing proper use of the inhaler
Level of support: high (brief individual smoking cessation support at each study visit, 10 in all)
Leischow 1996a 
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Outcomes Sustained abstinence at 12 months
Validation: CO < 10 ppm at each follow-up
Notes Study was funded by Pharmacia Upjohn, Sweden
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "the randomization code was generated by computer"
Allocation concealment
(selection bias)
Low risk Quote: "subjects were sequentially and randomly assigned"
Blinding (performance
bias and detection bias) 
All outcomes








Methods Country: USA and Canada
Recruitment: community (multicentre)
Participants 1246 (826 to relevant arms) smokers of at least 10 cpd for at least 6 months
44% female, average age 46, average cpd 18, mean FTND 5.3
Interventions 1. NRT patch, 11 weeks. 21 mg for 6 weeks, 14 mg for 2 weeks, 7 mg for 3 weeks
2. Placebo
Level of support: high (1 h in-person pre-quit group behavioural counselling, brief (˜15 minute) tele-
phone counselling at weeks 0, 1, 4, 8)
Outcomes 7-day PP at 12 months
Validation: CO < 8 ppm
Notes New for 2017 update
Funding: National Institute on Drug Abuse, National Cancer Institute, National Human Genome Re-
search Institute, National Institute on General Medical Sciences, Abramson Cancer Center at the Uni-
versity of Pennsylvania, Commonwealth of Pennsylvania Department of Health, Canadian Institutes of
Health Research, Canada Foundation for Innovation, Ontario Ministry of Research and Innovation. Pfiz-
er Inc. provided varenicline and placebo pills at no cost
N quit extrapolated from percentages given
As combination of group and indiv. support, not included in support subgroup analyses
Risk of bias
Lerman 2015 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not specified
Quote: "biostatistician, independent of study investigators, developed the ran-
domisation procedure which was integrated into a centralised data manage-
ment system. Subjects were randomised to the treatment arms in a 1:1:1 ra-
tio. Randomisation was stratified by baseline NMR status and study site, and




Low risk Allocation was done by centralised data management system
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Double-blinding of researchers and participants "participants, study investiga-
tors, and personnel…were masked to treatment arm allocation and NMR sta-










Recruitment: hospitalised patients willing to make a quit attempt
Participants 185 smokers (≥ 10 cpd), motivated to quit
46% female, average age 43 to 44, cpd 23 to 24
Interventions 1. Minimal intervention, 2 to 3 mins motivational message and self-help pamphlet
2. As 1. plus placebo patch. Nurse provided brief telephone counselling at 1, 3, 6 and 24 weeks
3. As 2. plus nicotine patch (22 mg/ 24 h for 3 weeks, tapered to 11 mg for 3 weeks)
Level of support: low (since initial support was brief and further contacts in 2 were by phone
Outcomes PP abstinence at 6 months Validation: CO ≤ 10 ppm
Notes 3 vs 1 + 2 used in MAs
Study was funded by Elan Pharmaceutical Research Corporation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk See below
Allocation concealment
(selection bias)
Low risk Quote: "using a predetermined computer-generated randomization code"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "Both patients and study staE were blinded with respect to patch dose"
Lewis 1998 
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Recruitment: smoking cessation clinic
Participants 216 smokers
Average cpd 28 to 30
Interventions 1. Nicotine gum (dose not stated) for 1 month
2. Placebo gum
Level of support: high (group support)
Outcomes Sustained abstinence at 12 months
Validation: CO
Notes Reclassified as high support 2008
Study was funded by el Fondo de Investigaciones Sanitarias de la Seguridad Social, la Sociedad Es-
pañola de Patologia Respiratoria, and los Laboratorios PENSA-ESTEVE
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "asignados al azar"
Blinding (performance
bias and detection bias) 
All outcomes











40% to 43% female, average age 44 to 46, average cpd 25 to 26
Interventions 1. Nicotine gum (2 mg) at least 10/day for at least 3 months
2. Placebo gum
3. Control
Level of support: high (weekly individual counselling for 1 month)
Malcolm 1980 
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Outcomes Sustained abstinence at 6 months
Validation: venous carboxyhaemoglobin ≤ 1.6%
Notes Study was supported by AB Leo & Company, Helsinborg, Sweden
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "randomly allocated"
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk Only the 1-month quitters were followed up at 6 months (77/82 participants)
Other bias Unclear risk 16 participants with dentures who could not chew gum were allocated to Con-






Participants 293 adult smokers. Average cpd not stated. 58% smoked > 25 cpd
Interventions 1. ALA Freedom from Smoking clinic program plus nicotine gum (2 mg for 3 months)
2. ALA Freedom from Smoking clinic program alone (no placebo gum)
Level of support: high (group)
Outcomes PP abstinence at 12 months
Validation: salivary thiocyanate
Notes Study was supported by Merrell-Dow Pharmaceuticals
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Quote: "Participants were randomly assigned .... Assignment to condition was
by clinic group rather than individual subject".
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Not relevant, as no placebo gum used
McGovern 1992 
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Participants 274 smokers (182 in relevant arms) admitted to medical and surgical wards, smoked in last 28 days
60% male, average age 60, median cpd 17, 81% had previous quit attempt
Interventions 1. Choice of NRT products (15 mg 16-h patch/2 mg or 4 mg gum, 10 mg inhalator/2 mg sublingual
tablet, 0.5 mg spray), Brief (20 min) bedside counselling from a research doctor or nurse
2. Brief counselling only
3. Usual care, no smoking advice (not used in MA)
Level of support: low
Outcomes Continuous abstinence at 12 months
Validation: CO < 10 ppm
Notes No placebo. 63% chose patch, 13% inhalator, 11% gum, 8% tablets and 1% nasal spray, 4% declined
use
Study was supported by Pharmacia Consumer Healthcare, Sweden
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were randomised ... using a list generated for each centre, al-
locating equally in random permuted blocks of nine".
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Not relevant to participants, as NRT group chose their own type. Assessment




Unclear risk Losses to follow-up counted as failures. All losses fully detailed in flow chart
Other bias Unclear risk 4% of counselling + NRT group refused NRT, and counselling-only group were






Participants 120 adolescent (age 13 to 17) smokers (≥ 10 cpd), motivated to quit
70% female, average age 15, average cpd 19
Moolchan 2005 
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Interventions 1. Nicotine patch (21 mg, or 14 mg for < 20 cpd) for 6 weeks + placebo gum
2. Nicotine gum (4 mg, or 2 mg for < 24 cpd) for 6 weeks + placebo patch
3. Double placebo
Level of support: high (11 x 45-min individual counselling over 12 weeks)
Outcomes PP abstinence at 6 months
Validation: CO and cotinine
Notes Placebo group contributes twice to MA - too small to affect total
Sustained abstinence at 3 and 6 months could be derived from text, relative effect greater since no
quitters on placebo
Study was funded by National Institute on Drug Abuse, and supported by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomized ... according to an algorithm held by the National Insti-
tute on Drug Abuse Pharmacy, with true replacement of the non-completers".
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes











Participants 364 smokers with smoking-related illness.
Number of cpd not stated. Motivation to quit probably not required.
Interventions 1. Nicotine gum 2 mg for 3 months
2. Placebo gum
Level of support: low
Outcomes Abstinence (not defined) at 6 months
Validation: serum thiocyanate
Notes "Supported partially by FISss 90/0431 and SEPAR". Trial report was abstract only
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Mori 1992 
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Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes










Participants 60 adult smokers.
Average cpd 31
Interventions 1. Nicotine gum (2 mg, 2 months or longer)
2. Non-placebo control group received counselling
Level of support: high
Outcomes Sustained abstinence at 6 months
Validation: CO
Notes Study was supported by Merrell-Dow Pharmaceuticals
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Assignment was done ... by individual randomisation based on their
screen's numbers [or] by group randomisation by worksite unit". 15 members




Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk ITT analyses conducted, with all dropouts and non-compliers included as fail-
ures. But "smoking on one or two occasions in a single day was not considered
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Participants 2485 (1658 in relevant arms) smokers of at least 10 cpd
Interventions 1. NRT patch, 8 weeks. 21 mg for 4 weeks, 14 mg for 2 weeks, 7 mg for 2 weeks
2. No NRT
Level of support: low (internet assisted tobacco treatment)
Outcomes 6 months prolonged abstinence at 9 months
Validation: none
Notes New for 2017 update
Funding: not specified
Data from clinical trials registry so limited information available, for this reason not included in setting
subgroup
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes










Participants 425 unselected smokers. 60% to 70% smoking > 15 cpd
Interventions A. Brief counselling from physician
B. Physician counselling plus nicotine gum
C. Health education from nurse
Level of support: low
Outcomes PP abstinence at 12 months
Validation: CO
Notes Study was supported by the Fondo de Investigaciones Sanitarias de la Seguridad Social
Risk of bias
Nebot 1992 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Not applicable; "each PCT was randomly allocated to perform the three differ-




Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk Only those quit at 2 months were followed up at 12 months. All non-respon-
ders were included as failures
Other bias Unclear risk Unequal assignments to the 3 groups, with nurse and NRT groups outnum-





Recruitment: outpatient settings and physician referrals (primary care subgroup)
Participants 77 low-dependence (FTND ≤ 6) and 96 high-dependence smokers
50% female, average age 42, average cpd 29, FTND 4.7 for low dependence, 8.0 for high dependence
Interventions 1. Nicotine gum 2 mg, ad lib for up to 4 months (participants given prescription for gum, not free)
2. No gum
Level of support: high (4 individual counselling sessions and ALA self-help treatment manuals)
Outcomes Continuous abstinence at 12 months
Validation: saliva cotinine, or CO for gum users
Notes No placebo used. Data collapsed across dependence levels. As predicted by the study, smokers with
lower dependence had lower quit rates with than without gum. The point estimate would be higher if
inclusion restricted to the high-dependence group
Study was supported by National Cancer Institute and National Heart, Lung, and Blood Institute
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Participants stratified on level of nicotine dependence. "Within each of the
high- and low-dependence groups, subjects were randomly assigned"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes
Low risk No placebo - not relevant. But therapist and participant were blinded to FTQ
score (level of dependency), and to match or mismatch status for gum use
Incomplete outcome data
(attrition bias) 
Low risk Dropout rates fully reported
Niaura 1994 
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Participants 62 smokers in relevant arms
50% female, average cpd 28, average age 43.5
Interventions 1. Brief cognitive behavioral relapse prevention (CBRP) , 15-min sessions
2. Intensive CBRP with nicotine gum (2 mg)
3. Intensive CBRP with cue exposure
4. Intensive CBRP with cue exposure + nicotine gum
Level of support: high (5 group sessions within 3 weeks of TQD)
Outcomes Sustained abstinence, 12 months and all previous follow-ups (1, 3, 6 months)
Validation: CO < 8 ppm
Notes 4 vs 3, behavioural support not identical in others. No placebo
Study was supported by Department of Veterans Affairs
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Quote: "Counselors were kept blind to the relapse prevention condition to










Participants 1223 unselected smokers
57% female, average age 35, average cpd 22 to 23
Interventions 1. Advice only
2. Participant-centred counselling
3. Participant-centred counselling and offer of nicotine gum (2 mg) plus minimal or intensive follow-up
by telephone
Level of support: mixed (not used in subgroup analysis)
Ockene 1991 
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Outcomes Sustained abstinence at 12 months (quit at 6 months and 12 months, reported in Ockene 1994)
Validation: none
Notes 69% of group 3 accepted prescription and received at least 1 box of gum
12-month sustained rates, 3 vs 2, used in MA since 2008
Study was funded by the National Cancer Institute
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Physicians opened "a packet containing the intervention materials, which they
received at the beginning of the clinic encounter"
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk Losses and dropouts were included as failures. 62 participants removed from






Participants 152 post-menopausal women (≥ 10 cpd)
Average cpd 22, average age 54/56.6
Interventions 1. Nicotine patch (21 mg for 13 weeks including 4 weeks tapering)
2. Placebo patch
Level of support: high (7 visits including 4 x 2-h group counselling, 1 pre-TQD)
Outcomes PP abstinence at 16 months (12 months post-EOT)
Validation: CO < 8 ppm
Notes Study was supported by The Patrick and Catherine Weldon Donaghue Foundation, The University of
Connecticut Center on Aging, University of Connecticut General Clinical Research Center and the Na-
tional Institute for Health. Pharmaceuticals supplied by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Assignment ratio was 3:5; "152 women were randomized"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
Unclear risk Described as double-blind, but no further information
Oncken 2007 
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Recruitment: volunteers from antenatal clinics
Participants 194 pregnant women smoking at least 1 cpd
Average age 25, average cpd 10 in week before study enrolment, average cpd 18 prepregnancy, mean
FTND < 4
Interventions 1. 2 mg nicotine gum (first 6 weeks: instructed to chew 1 piece for every cigarette usually smoked per
day, not exceeding 20, followed by 6-week tapering period)
2. Placebo gum, dosing and duration as above
Level of support: high. In-person and telephone individual smoking cessation counselling
Outcomes Abstinence at 32 to 34 weeks of gestation and 7-day PP at 6 to12 weeks post-partum (abstinence at 6
weeks post-quit date also reported)
Validation: CO and urinary cotinine
Notes Varying lengths of follow-up. Longest follow-up used in primary analysis
NRT group had significantly higher birth weight and gestational age than placebo group. NRT group sig-
nificantly more likely to attend follow-up visits.
Funded by the National Institutes of Health.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "computerized urn randomization program to balance participant as-
signment in the two treatment groups"
Allocation concealment
(selection bias)
Low risk Urn randomization procedure implies that allocation not known until after en-
rolment
Blinding (performance
bias and detection bias) 
All outcomes




High risk Significantly higher loss to follow-up in placebo group (50% as opposed to
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Methods Country: Spain
Recruitment: hospital inpatients
Participants 1843 hospital inpatients who identified as smokers
88% male, average age 62, average 56 packs/year
Interventions 1. Nicotine patch or gum (max 12 weeks; participant's choice) + CBT
2. CBT only
3. Declined to participate
Level of support: high (standardized 30- to 45-min sessions every 3 days until participant discharged
from hospital; post-discharge participant could have telephone or in-person sessions at 1 week, 15
days, 2, 3, 6, and 12 months)
Outcomes Continuous abstinence from quit day at 12 months
Validation: 34% of participants verified with CO measurement
Notes No placebo. Groups 1 and 2 included in primary analysis under 'choice of NRT'. "No significant outcome
differences between NRT types" (personal communication from author)
717 declined to participate but followed up at 12 months
Funding not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were randomized "using a "computerized algorithm."
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
High risk Participants not blinded; no placebo group. Not specified as to whether study
personnel were blinded. Quote: "...the one-year abstinence in the telephone
follow-up group was self declared and not validated, which may entail bias











Participants 1199 smokers (includes 254 non-attenders), motivated to quit
63% female, average age 42, 46% smoked > 20 cpd
Interventions Factorial design with multiple levels of behavioural support
1. Nicotine patch (21 mg, 14 mg for FTND < 5) 8 weeks including tapering + behavioural support
Otero 2006 
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2. Cognitive behavioural support only
Level of support: Mixed - low = single 20-min session. High = 1, 2, 3 or 4 weekly 1-h sessions. Mainte-
nance or recycling sessions provided at 3, 6, 12 months
Outcomes PP abstinence at 12 months
Validation: none
Notes Contributes to both high- and low-support subgroups
No placebo
Study was supported by the Institute for Global Tobacco Control and the Fogarty International Center
of the National Institutes of Health
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes
High risk 29% of control group participants asked for nicotine patch after the 3-month









Recruitment: primary care (5 family practices in Ontario)
Participants 275 unselected smokers. Primary care attenders aged 18 to 65 years
Number of cpd not stated
Interventions 1. No advice
2. Advice to quit
3. Advice to quit plus offer of nicotine chewing gum prescription (2 mg)
Level of support: low
Outcomes Sustained abstinence at 6 months
Validation: none
Notes 3 vs 1 + 2
No placebo.
Study was funded by the Canadian College of Family Physicians of Canada and by the University of Wa-
terloo Social Sciences and Humanities Research Grant Fund
Risk of bias
Bias Authors' judgement Support for judgement
Page 1986 
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Random sequence genera-
tion (selection bias)
High risk Randomized by day of attendance. Post hoc tests of results by day of atten-
dance showed no interaction
Allocation concealment
(selection bias)
High risk Not applicable
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Single-blinding:
Quote: "subjects were not aware of their treatment group nor the fact that
they were being evaluated against other experimental groups". Follow-up in-
terviewers "remained blind to the patient's experimental group until the final










Participants 297 smokers (≥ 10 cpd), motivated to quit
Stratified according to baseline cotinine levels
40% female, average age 43, average cpd 24 in low-cotinine group (n = 120), 30 in high group (n = 177)
Interventions Stratum A (Baseline cotinine < 250 ng/ml)
1. Nicotine patch (15 mg/16 h, 18 weeks incl taper)
2. Placebo patch
Stratum B (Baseline cotinine > 250 ng/ml)
3. Nicotine patch 15 mg
4. Nicotine patch 25 mg
Level of support: low
Outcomes PP abstinence at 12 months
Validation: CO and plasma cotinine
Notes Stratum A in Comparison 1
Study was funded by Pharmacia
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Losses to follow-up fully reported
Paoletti 1996 
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Recruitment: outpatient chest clinics, volunteers
Participants 62 smokers (> 20 cpd)
94% male, average age 62, average cpd 26
Interventions 1. Nicotine patch (24 mg/24 h for 6 weeks, no weaning)
2. Placebo patch
Level of support: high (weekly visit to outpatient department for assessment, unclear if counselling
was provided)
Outcomes Abstinence at 12 months
Validation: CO < 10 ppm during patch use, but no validation at 12 months
Notes Level of support reclassified as high, 2008 update
Study was funded by Orient Europharma Company Ltd, Taipei, Taiwan
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Randomization was performed by an independent outside facility"
Allocation concealment
(selection bias)
Unclear risk See above
Blinding (performance
bias and detection bias) 
All outcomes










Participants 1504 smokers motivated to quit
58% female, average age 45, average cpd 21.4
Interventions 1. Nicotine lozenge 2 or 4 mg for 12 weeks (based on dose-for-dependence level as in instructions)
2. Nicotine patch (24 h, 21, 14, and 7 mg titrated down over 8 week period post-quit)
3. Bupropion SR (150 mg bid, 1 week pre-quit, 8 weeks post-quit)
Piper 2009 
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4. Lozenge + patch (duration and dosage as above)
5. Bupropion + lozenge (duration and dosage as above)
6. Placebo (5 groups matched to above 5 interventions)
Level of support: high. All participants received 7 one-to-one 10- to 20-min counselling sessions
Outcomes 7-day PP abstinence at 6 months; initial cessation
Validation: CO < 10 ppm
Notes Placebo outcomes not reported by subgroup; outcomes generated by applying overall percentage of
events in placebo group to individual subgroups. 1, 2, 4 and 6 included in primary analysis
Analyses conducted using ITT
Most of the funding from National Institute on Drug Abuse and National Center for Research Resources.
Medication provided to participants at no extra cost by GlaxoSmithKline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Randomization was double-blind and used a block randomization
scheme with sex and self-reported race as the blocking variables."
Allocation concealment
(selection bias)
Low risk Quote: "StaE did not know to which type(s) of medication a participant would
be assigned until the moment of randomization, and study staE were blinded
to whether the medication was active or placebo."
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Quote: "Double blind."
"Study staE were blinded to whether the medication was active or placebo".





Low risk 90 dropouts (out of 1504). Analyses conducted using ITT. Individuals with miss-






Participants 417 women smokers, average cpd 25 to 27
Interventions 1. Group therapy
2. Group therapy plus weight control programme
3. Group therapy plus nicotine gum
4. Group therapy plus weight control programme and nicotine gum
Gum type: 2 mg ad lib
Level of support: high
Outcomes Sustained abstinence at 12 months
Validation: CO
Pirie 1992 
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Notes 3 and 4 compared to 1 and 2
Study was funded by the National Cancer Institute
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Participants were randomized to one of four groups"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes









Recruitment: volunteers from antenatal clinic
Participants 181 pregnant women smoking at least 5 cpd
Average age 27, average cpd pre-pregnancy 19
Interventions 1. CBT
2. CBT + free NRT (choice of patch, gum, lozenge or no NRT. Patch: 16 h, encouraged to use for 6 weeks,
dose based on woman's smoking level, < 10 cpd = 7 mg/day, 10 to 14 cpd = 14 mg/day, ≥ 15 cpd = 21
mg/day; gum or lozenge: 2 mg for every cpd)
Level of support: high (6 one-to-one counselling sessions)
Outcomes 7-day PP at 38 weeks of gestation and 3 months post-partum
Validation: salivary cotinine
Notes Varying lengths of follow-up
Recruitment suspended early when interim analysis found higher rate of negative birth outcomes in
CBT+NRT arm; not statistically different when adjusted for previous history of birth outcomes in final
analysis
6 in NRT group opted to use no NRT; 4 in CBT-only arm reported use of NRT
Funded by the National Cancer Institute
Risk of bias
Bias Authors' judgement Support for judgement
Pollak 2007 
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Random sequence genera-
tion (selection bias)
Low risk Quote: "computerised random number generator"
Allocation concealment
(selection bias)
Low risk Quote: "each support specialist had a handheld device that contained a ran-
domization list"
Blinding (performance
bias and detection bias) 
All outcomes




Low risk All women lost to follow-up considered smokers; similar numbers in both
groups




Methods Country: New Zealand
Recruitment: community volunteers
Participants 121 women smokers (> 10 cpd) (excludes dropouts not starting programme)
Interventions NRT as adjunct to either CBT or exercise programmes, collapsed for this review
1. Nicotine patch (21 mg/24 h for 10 weeks, no weaning)
2. No patch
Level of support: high (36 x 45-min session over 12 weeks of group CBT or supervised vigorous exercise,
starting 6 weeks before TQD)
Outcomes Continuous abstinence since TQD at 12 months from end of programme
Validation: CO < 10 ppm, cotinine < 10 ng/mL
Notes No placebo
Study was funded by the National Heart Foundation of New Zealand, and supported by GlaxoSmithK-
line
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes




Low risk "Analyses were conducted by intent to treat". Missing data on smoking absti-
nence were counted as failures. % losses reported
Prapavessis 2007 
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Participants 229 adult smokers, 80% smoking > 5 cpd
Interventions 1. Nicotine gum (4 mg) for 3 weeks
2. Placebo gum for 3 weeks
Level of support: high (group therapy)
Outcomes PP abstinence at 6 months
Validation: none
Notes Study was supported by AB Leo and Co, Helsinborg, Sweden
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "Neither the subjects nor the course leaders were aware who received










Participants 450 adult smokers (350 in included arms)
Average cpd 15 to 21
Interventions 1. Smokescreen programme plus nicotine gum, dose and duration not stated
2. Smokescreen programme alone
3. Brief advice and gum (not included in MA)
Level of support: high (5 visits during first 3 months)
Outcomes Continuous abstinence (from week 1) at 12 months
Validation: expired CO < 14 ppm
Notes No placebo
Continuous abstinence rates from Richmond 1993 paper used from 2007. Group 3 not included
Study was funded by the Department of Health, Housing and Community Services, Community Health
Anti-Tuberculosis Association, Glaxo Australia, and the Drug and Alcohol Directorate, NSW Department
of Health
Richmond 1993 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Quote: "random weekly assignment"
Allocation concealment
(selection bias)
High risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes












Interventions 1. Nicotine patch (24 h, 22 mg/24 h, 10 weeks incl tapering)
2. Placebo patch
Level of support: high (group therapy)
Outcomes Sustained abstinence at 12 months (reported in Richmond 1997, which also reports 3-year follow-up,
not used in MA)
Validation: CO
Notes 3-year abstinence 21/153 vs 8/152, OR 2.9 - higher than at 12 months
Study was funded by Marion Merrell Dow, and supported by the Drug and Alcohol Directorate, NSW De-
partment of Health, and the Lifestyle Unit, Prince of Wales Hospital, Sydney
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Treatment and control patches were arranged in random order by
Marion Merrell Dow, Sydney, then issued sequentially to patients as they at-
tended"; married couples were assigned to same condition
Allocation concealment
(selection bias)
Low risk See above
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind
Incomplete outcome data
(attrition bias) 
Low risk Losses to follow-up included as failures. Dropout rates fully reported
Richmond 1994 
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Recruitment: primary care (occupational health centres)
Participants 121 smokers
> 10 cpd, > 1 year, 43% female
Interventions 1. Nicotine gum (2 mg and 4 mg) + advice
2. Advice only (no placebo)
Level of support: low
Outcomes Abstinence at 6 months (not defined)
Validation: not described
Notes Study funding and support not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes









Recruitment: primary care - consecutive attenders admitting to being cigarette smokers and consent-
ing to participate at 6 general practices
Participants 2106 unselected adult smokers
average cpd 17.5
Interventions 1. No intervention
2. Advised to stop smoking plus provided with a "give up smoking" booklet
3. As group 2, plus offer of nicotine gum prescription, individual therapy, single visit, 1 minimal con-
tent, 1 more intensive content, untrained therapist
Level of support: low
Russell 1983 
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Outcomes Sustained abstinence at 4 months and 12 months
Validation: 66% of those claiming to have quit validated with CO
Notes 3 vs 2 + 1 used in comparison. Using only 2 as control has negligible effect on point estimate
Only 53% of group 3 tried the gum
Use of quit rates adjusted for estimated validation failure and protocol violation would increase rela-
tive effect of gum
Study was funded by the Medical Research Council, and the AB Leo Research Foundation, Sweden
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Participants assigned "according to their week of attendance"
Allocation concealment
(selection bias)
High risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not stated. Correct procedure was not followed by 10.4% in Grp 1, 15.4% in




Low risk 16 deaths and 152 who moved away were excluded from analyses. 327 with no






Participants 220 adult smokers
average cpd 28 to 29
Interventions 1. Nicotine patch (15 mg/16 h, 12 weeks + 6 weeks tapering)
2. Placebo patch
Level of support: high (physician advice, 8 visits during treatment period)
Outcomes Sustained abstinence at 12 months
Validation: CO
Notes Study was funded by National Institute on Drug Abuse, Kabi Pharmacia AB and Parke-Davis
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Subjects were sequentially and randomly assigned"
Allocation concealment
(selection bias)
Unclear risk Not stated
Sachs 1993 
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Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk Dropout rates not fully reported, but all participants included in ITT analyses






Participants 265 adolescents (12 to 18 years old), smoking ≥ 7 cpd, motivated to quit
52.9% female, mean age 16.5, mean cpd 16.7
Interventions 1. 24-h patch, dose and length depending on baseline cpd. If > 20 cpd, 3 weeks 21 mg/day, 3 weeks 14
mg/day; 3 weeks 7 mg/day; if < 20 cpd, 3 weeks 14 mg/day, 3 weeks 7 mg/day
2. Control: placebo patch control, otherwise identical to intervention
Level of support: low (one-oE "short behavioral intervention aimed at quitting smoking (e.g. prepara-
tions and expectations)" at study start)
Outcomes 30-day PP abstinence at 12 months
Verification: salivary cotinine measured using a NicAlert saliva strip (Nymox)
Notes New for 2017 update
Funding: ZonMw – The Netherlands Organization for Health Research and Development; Novartis pro-
vided study medication and placebo
Risk of bias and some data extraction from Fanshawe 2017
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomized according to a computer-generated randomization list
by the pharmacy of the University Medical Centre to either (1) active study




Unclear risk Quote: "participants and research assistants were blind to treatment alloca-
tion"; however, does not specify how this occurred
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Loss to follow-up not reported by trial arm, but 10.1% overall at 12 months
Scherphof 2014 
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Participants 60 heavy smokers (> 1 pack/day)
60% female, average age 40/37, average cpd 35/31
Interventions Study A (clinic support):
1. Nicotine gum, (2 mg duration not stated)
2. Placebo gum
Level of support: high (individual support at multiple clinic assessment visits, daily during week 1,
weekly to week 5)
Outcomes Sustained abstinence at 12 months
Validation: CO
Notes Reported in same papers as Schneider 1983b. Shared study ID until 2008. Schneider 1983 provides de-
mographic data so now used as primary reference
Jarvik 1984 reports outcomes by dependency score for 48/60 participants
Study was funded by National Institute on Drug Abuse and by the Medical Research Service of the Vet-
erans Administration
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "subjects were randomly assigned"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes










Participants 36 heavy smokers (> 1 pack/day)
no demographic details
Interventions Study B (pilot dispensary study):
1. Nicotine gum, (2 mg, duration not stated)
2. Placebo gum
Level of support: low (weekly laboratory visits for 5 weeks but no support provided)
Outcomes Sustained abstinence at 12 months
Schneider 1983b 
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Validation: CO
Notes Reported in same papers as Schneider 1983a. Shared study ID until 2008
Study was funded by National Institute on Drug Abuse and by the Medical Research Service of the Vet-
erans Administration
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "subjects were randomly assigned"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes









Recruitment: community volunteers (radio and newspaper ads)
Participants 255 adults with no serious illness, motivated to quit, smoking > 15 cpd for > 2 years with baseline CO
level > 20 ppm average cpd 28 to 29
Interventions 1. Nicotine nasal spray
2. Placebo spray
Nicotine dosage: 0.5 mg of nicotine per spray. No fewer than 8 and no more than 32 doses/day for 6
weeks, with free use for further 6 months
Level of support: high (repeated clinic visits for assessment)
Outcomes Sustained abstinence at 12 months
Validation: CO < 8 ppm.
Notes Study was funded by Veteran Affairs and Pharmacia (Sweden)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Subjects were randomly assigned to conditions"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Quote: "the trial was double-blind". Participant guesses reported as confirma-
tion of blinding success
Schneider 1995 
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Participants 223 adult smokers (≥10 cpd)
37% female, average age 44, average cpd 29/26 (significantly higher in active group)
Interventions 1. Nicotine inhaler (4 to 20 inhalers per day) for up to 6 months, with weaning from 3 months
2. Placebo inhaler
Level of support: high (repeated clinic visits for assessment)
Outcomes Sustained abstinence at 12 months
Validation: CO and salivary cotinine
Notes Study was funded by Veteran Affairs and by Pharmacia & Upjohn (Sweden)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Quote: "An independent "randomizer" packaged drug from the list."
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "Subjects and all personnel connected with the trial (including the PI)













Notes Excluded study, but contributing data on adverse events
Schnoll 2010 
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Methods Country: Italy
Recruitment: primary care - consecutive patients attending 44 general practices
Participants 923 practice attenders aged 20 to 60
average cpd not stated
Therapists: GPs who had undergone a 3-h training session
Interventions 1. Advice and leaflet
2. Repeated counselling (follow-up at 1, 3, 6, 9 months)
3. Repeated counselling plus prescription for nicotine gum unless contraindicated, dose not stated, up
to 3 months
4. Repeated counselling plus spirometry
Level of support: high
Outcomes Sustained abstinence at 12 months
Validation: urinary cotinine
Notes 3 vs 1 + 2 + 4.
Study was supported by SIMG (Italian Association of General Practice), and by Serono SPA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a predetermined randomized sequence of the four interventions"
Allocation concealment
(selection bias)
Low risk Quote: "a package of closed numbered envelopes ... was provided to each GP".
Research staE checked the integrity of the process
Blinding (performance
bias and detection bias) 
All outcomes









Methods Country: USA and UK (15 sites)
Recruitment: community volunteers
Participants 917 smokers, motivated to quit, time to first cigarette > 30 mins
58% female, average age 41, cpd 17
Interventions 1. Nicotine lozenge, 2 mg. Recommended dose 1 every 1 to 2 h, min 9, max 20/day for 6 weeks, decreas-
ing 7 to 12 weeks, available as needed 13 to 24 weeks
2. Placebo lozenge, same schedule
Level of support: high (brief advice at 4 visits in 4 weeks from enrolment)
Outcomes Continuous abstinence at 12 months (sustained from 2 weeks, no slips allowed)
Validation: CO ≤ 10 ppm at all follow-ups. (only abstainers continued in study)
Shi>man 2002 (2 mg) 
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Notes Dose based on dependence level. Low-dependence group here. High-dependence group in Shiffman
2002 (4 mg).
Study was supported by GlaxoSmithKline Consumer Healthcare
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "smokers were randomized" after stratification for dependency by time
to first cigarette of the day
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Only abstainers were followed up. "Participants who did not appear for a visit
were counted as treatment failures". Losses fully reported
Shi>man 2002 (2 mg)  (Continued)
 
 
Methods Country: USA and UK (15 sites)
Recruitment: community volunteers
Participants 901 smokers, time to first cigarette < 30 mins
55% female, average age 44, cpd 26
Interventions 1. Nicotine lozenge, 4 mg. Recommended dose 1 every 1 to 2 h, min 9, max 20/day for 6 weeks, decreas-
ing 7 to 12 weeks, available as needed 13 to 24 weeks
2. Placebo lozenge, same schedule
Outcomes Continuous abstinence at 12 months (sustained from 2 weeks, no slips allowed)
Validation: CO ≤ 10 ppm at all follow-ups (only abstainers continued in study)
Notes Dose based on dependence level. High-dependence group here. Low-dependence group in Shiffman
2002 (2 mg)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk See above (Shiffman 2002 (2 mg))
Allocation concealment
(selection bias)
Unclear risk See above
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk See above
Incomplete outcome data
(attrition bias) 
Low risk See above
Shi>man 2002 (4 mg) 
Nicotine replacement therapy versus control for smoking cessation (Review)
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All outcomes





Participants 1636 smokers wishing to quit by gradual reduction (RTQ technique)
64% female, average age 42, average cpd 9.4, average FTND 4.4
Interventions 1. Nicotine gum 2 mg. Instructed to gradually reduce smoking while increasing gum use for up to 8
weeks. Post-quit instructed to use 1 piece every 1 to 2 h for first 6 weeks; 1 every 2 to 4 h for next 3
weeks; 1 every 4 to 8 hours for final 3 weeks
2. Placebo gum, same schedule as above
Level of support: low (designed to simulate OTC setting)
Outcomes Abstinence at 6 months from start of treatment (initial abstinence had to be achieved within 8 weeks of
start of treatment, so duration of abstinence was at least 4 months)
Validation: CO ≤ 10 ppm
Notes Included in main analyses
Dose based on dependence level. Participants read labelling which recommended 4 mg dose for smok-
ers of > 25 cpd and selected appropriate dose. Low-dependence group here. High-dependence group
reported in Shiffman 2009 (4 mg).
Funding provided by GlaxoSmithKline Consumer Healthcare
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "using a 1:1 computer-generated randomization scheme, balanced
across study sites and generated separately for the 2- and 4-mg groups"
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk Those who had not succeeded at 28 days follow-up not followed up at 6
months. All missing data considered to be smoking




Shi>man 2009 (4 mg) 
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Recruitment: community volunteers
Participants 1661 smokers wishing to quit by gradual reduction (RTQ technique)
50% female, average age 46, average cpd 32, average FTND 6.9
Interventions 1. Nicotine gum 4 mg. Instructed to gradually reduce smoking while increasing gum use for up to 8
weeks. Post-quit instructed to use 1 piece every 1 to 2 hours for first 6 weeks; 1 every 2 to 4 hours for
next 3 weeks; 1 every 4 to 8 hours for final 3 weeks
2. Placebo gum, same schedule as above
Level of support: low (designed to simulate OTC setting)
Outcomes Abstinence at 6 months from start of treatment (initial abstinence had to be achieved within 8 weeks of
start of treatment, so duration of abstinence was at least 4 months)
Validation: CO ≤ 10 ppm
Notes Dose based on dependence level. High-dependence group here. Low-dependence group reported in
Shiffman 2009 (2 mg).
Funding provided by GlaxoSmithKline Consumer Healthcare
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk See above (Shiffman 2009 (2 mg))
Allocation concealment
(selection bias)
Unclear risk See above
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk See above





Participants 1200 smokers considered by GP to be highly dependent and motivated to give up
average cpd 23 to 24
Interventions 1. Nicotine patch standard dose (15 mg/16 h for 18 weeks)
2. Nicotine patch with dose increase to 25 mg at 1 week if required
3. Placebo patch group
The nicotine patch groups were further randomized to gradual tapering or abrupt withdrawal at week
12
Level of support: high (physician advice and brief support at 1, 3, 6, 12 weeks)
Stapleton 1995 
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Outcomes Sustained abstinence at 12 months
Validation: CO
Notes The dose increase after 1 week did not affect cessation, 1 + 2 vs 3 in comparison 1
Study was funded by Kabi Pharmacia (Sweden)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Numbered packages
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "Both subjects and their doctors or nurses were blind to whether the
dose increase was real or placebo". Study conduct throughout was monitored










Recruitment: methadone-maintained treatment centres in New England
Participants 315 adult methadone-maintained smokers, smoking 10+ cpd, willing to set a quit date within the 1st
week
Mean age 39.9, 47.6% female, 78.5% white, mean cpd 20, mean FTND 5.7
Interventions 1. Combination NRT: 24-week course of NRT patch (42 mg for > 30 cpd, 21 mg if < 30 cpd), + ad lib nico-
tine gum (4 mg) as needed
2. Varenicline: 24-week course of varenicline tablets, 1st week titrated
3. Placebo: 24-week course of identical tablets and regimen
Level of support: high (all received standardized 15-min session of advice to quit (5As model) and made
monthly visits for support and top-up medication)
Outcomes 7-day PP at 6 months (continuous abstinence also reported from 2 weeks to 6 months but unclear if
this was biochemically verified)
Validation: CO < 8 ppm; urinary cotinine in varenicline and placebo participants claiming abstinence
Notes New for 2017 update. Analysis uses only 1 v 3
Funding: NCI grant RO1 CA129226; MDS supported by a NIDA mid-career investigator award K24
DA000512
Risk of bias and some data extraction from Cahill 2016
Risk of bias
Stein 2013 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "Quote: Participants were randomized to treatment after completing the base-
line assessment". No further information
Allocation concealment
(selection bias)
Unclear risk No information
Blinding (performance
bias and detection bias) 
All outcomes










Recruitment: smoking cessation clinic
Participants 227 smokers, motivated to quit. Average cpd 25 to 27
Interventions 1. Nicotine nasal spray, maximum 40 mg/day
2. Placebo spray
Level of support: High (4 weeks group support)
Outcomes Sustained abstinence at 12 months
Validation: CO
Notes Follow-up beyond 1 year reported in Stapleton 1998
Study was funded by the Medical Research Council and by the Imperial Cancer Research Fund
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes
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Methods Country: Denmark
Recruitment: customers seeking to buy nicotine patches OTC at 42 pharmacies
Participants 522 smokers of > 10 cpd. Smokers of > 20 cpd used a higher-dose patch than lower-rate smokers
50% female, average age 39
Interventions 1. Nicotine patch (24 h). > 20/day smokers used 21 mg for 4 weeks, 14 mg for 4 weeks, 7 mg for 4 weeks.
Smokers of < 20/day used 14 mg for first 8 weeks, 7 mg for 4 weeks
2. Placebo patches
Level of support: Low (brief instructions on patch use at baseline, visit to collect further patches at 4
and 8 weeks, no behavioural support)
Outcomes Abstinence at 6 months - no reported smoking in the last 4 weeks, by telephone interview with neutral
independent assessor
Validation: none
Notes Study was partly funded by Ciba-Geigy
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Placebo patches contained "a pharmacologically negligible amount of nico-





Low risk Quote: "Participants lost to follow-up (n = 19) were classified as smokers".




Methods Country: USA (9 sites)
Recruitment: community volunteers (treated at smoking cessation clinics)
Participants 808 unselected smokers
60% female, average age 43, average cpd 31
Interventions 1. Nicotine patch (21 mg/24 h, 6 weeks+)
2. Nicotine patch 14 mg
3. Placebo patch
Abstainers at end of week 6 entered a randomized blinded trial of weaning
Level of support: high (group therapy, 6+ sessions)
Outcomes Sustained abstinence at 6 months
Validation: CO
Notes 2 trials pooled and data relating to a 7 mg patch group used in only 1 trial omitted
Long-term (4 to 5 year) follow-up data reported for 7/9 sites (Daughton 1999). Data not used in MA -
point estimate would be higher
TNSG 1991 
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Study was supported by Alza Corp
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated: "patients were ... randomized", but members of same household




Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Quote: "All participants were included in outcome evaluations except for the
excluded members of couples (49 participants) and nine participants with ma-







Participants 180 (in relevant arms)
18 to 26 years old, smoked daily for at least past month, smoked > 100 cigarettes in life, light smokers
(as per Heaviness of Smoking Index based on cpd and time to first cigarette) only included in this re-
view
52% female, median age 21, median cpd 10
Interventions 1. NRT patch (10 mg/16 h) for 8 weeks
2. Placebo
Level of support: high (individual smoking cessation counselling of 30 mins (and planned for week 52))
Outcomes 7-day PP at 6 months (Methods section also states 12 months follow-up but results not reported)
Validation: none
Notes New for 2017 update
Funding: Ministry of Social Affairs and Health, Finland; Finnish Research Foundation of the Pulmonary
Disease; Finnish Medical Society Duodecim
Participants were assessed as light or heavy smokers. Light smokers were randomized to placebo or
10 mg NRT patches. Heavy smokers were randomized to varenicline or 15 mg NRT patches. First com-
parison is eligible for inclusion in this review (NRT vs no NRT). Second comparison is not (NRT vs vareni-
cline). Cannot combine NRT 15 mg group with 10 mg group – different populations randomized
Risk of bias
Tuisku 2016 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “After assessment… at the baseline visit, simple randomisation with
a computer-generated random list… was used to allocate study subjects into
the different treatment groups”
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding (performance
bias and detection bias) 
All outcomes
High risk Quote: “The placebo patch was not identical to the nicotine patch" “the study




Low risk Dropouts: 22/86 for placebo, 18/94 for NRT






Participants 113 low- to medium-dependence smokers, motivated to quit (19 or less on Horn-Russell scale)
56% female, average age 45, average cpd 20
60 highly-dependent smokers
58% female, average age 45, average cpd 26 to 28
Interventions Group A: Low/medium dependence
1. Nicotine gum (2 mg) for 16 weeks
2. Placebo
Group B: High dependence
1. Nicotine gum 4 mg for 6 weeks then 2 mg
2. Nicotine gum 2 mg
Level of support: high (informal group support, 6 sessions)
Outcomes Sustained abstinence at 12 months (24 months also reported)
Validation: CO
Notes Group A in comparison 1
Abstinence at 24 months 17/60 vs 5/53, OR 3.8, relative effect greater than at 12 months
Study was supported by AB Leo (Sweden) and H. Lundbeck A.S. (Denmark)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Participants stratified by dependence, then "subjects on each list were then
randomly assigned to treatment in blocks of two"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
Unclear risk Gum was packaged and produced to be indistinguishable between 2 mg, 4 mg
and placebo
Tønnesen 1988 
Nicotine replacement therapy versus control for smoking cessation (Review)














Low risk All participants who attended 1st counselling session were included in analy-







Participants 289 smokers (≥ 10 cpd)
70% female, average age 45, average cpd 22
Interventions 1. Nicotine patch (15 mg/16 h for 12 weeks with tapering)
2. Placebo patch
Level of support: high (7 clinic visits including a few minutes of advice)
Outcomes Sustained abstinence at 12 months (also reported 24 months in Tønnesen 1992, 3 years in Mikkelsen
1994)
Validation: CO
Notes Classification of support corrected to high in 2008 update
Study was supported in part by Kabi Pharmacia Therapeutics
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "subjects were sequentially and randomly assigned to either active




Low risk Quote: "Patches were packaged and labeled with consecutive numbers"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "The placebo patches were identical to the active patches in appear-
ance, packaging and labeling, but contained no nicotine"




Low risk All who attended the 1st session were included in the analyses. Losses to fol-






Participants 286 smokers (≥ 10 cpd)
60% female, average age 39, average cpd 20
Interventions 1. Nicotine inhaler (2 to 10/day) up to 6 months
2. Placebo inhaler
Tønnesen 1993 
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Level of support: high (brief advice at 8 clinic visits, 0, 1, 2, 3, 6,12, 24, 52 weeks)
Outcomes Sustained abstinence at 12 months (from week 2, paper also reports with-slips outcome)
Validation: CO
Notes Study was supported by Kabi Pharmacia Therapeutics
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The randomization code for assignment to either active or placebo in-
haler was generated by a computer program"
Allocation concealment
(selection bias)
Low risk See above
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "The placebo inhaler contained only the additive and was identical in





Low risk Quote: "Subjects unavailable for follow-up were assumed to be smokers". Re-
lapsers were dropped from the study, but were all contacted at 1 year. 6 were





Recruitment: referrals to lung clinic
Participants 446 smokers ≥ 10 cpd
52% female, average age 49, average cpd 18
Interventions 1. 5 mg nicotine patch (placebo)
2. 15 mg (16 h) nicotine patch for 12 weeks (up to 9 months on request)
3. Nicotine inhaler (4 to 12/day ad lib)
4. Combination, 15 mg patch and inhaler
Level of support: high (Physician advice at baseline, brief (15 minute) nurse counselling at 2, 6 weeks,
3, 6, 9, 12 months)
Outcomes Sustained abstinence at 12 months, (from week 2, paper also reports PP and with-slips rates)
Validation: CO < 10 ppm at all visits
Notes In main comparison for patch vs placebo but not inhaler
Study funding and support not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a computer-generated list with random numbers"
Allocation concealment
(selection bias)
Unclear risk Not stated
Tønnesen 2000 
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Blinding (performance
bias and detection bias) 
All outcomes









Recruitment: lung clinic patients and newspaper adverts
Participants 370 smokers (at least 1 cpd) with COPD (Mean FEV1 was 56% of predicted)
52% female, average age 61, average cpd 20 (8% < 7/day), 71% had previously tried NRT
Interventions 2 x 2 factorial trial of lozenge and behavioural support
1. Nicotine sublingual tablet (2 mg), recommended dose depended on baseline cpd, from min 3 to max
40 per day
2. Placebo
Level of support: high: Either 4 clinic visits (0, 2 weeks, 6, 12 months) and 6 phone calls, total time 2½
h, or 7 visits (0, 2, 4, 8, 12 weeks) and 5 calls, total 4½ h
Outcomes Sustained abstinence at 12 months (from 2 weeks)
Validation: CO < 10 ppm at all visits
Notes New for 2008 update
Behavioural support arms collapsed. Both involved multiple clinic visits
Study was funded by the Danish Medical Research Council, and supported by Pfizer Consumer Health-
care (Sweden)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were allocated to one of the four treatment groups using a
block randomization list at each center"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes








Methods Country: Germany (2 sites) and Denmark (1 site)
Tønnesen 2012 
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Recruitment: community volunteers
Participants 479 adult smokers of ≥ 1 cpd, motivated to quit
56% male, average age 47, average cpd 22.7, average FTND 5.3
Interventions 1. Active: weeks 1 to 6: 1 to 2 sprays when participants would normally have smoked a cigarette or ex-
perienced a craving, up to 4 sprays/hour and 64 sprays/day. Tapered down weeks 7 to 12 (end of week
9 instructed to be using half as much as in weeks 1 to 6, reducing to max 4 sprays/day by week 12). Oc-
casional use (max 4 sprays/day) permitted weeks 13 to 24. 1 mg/spray oral nicotine spray (in develop-
ment, name not provided)
2. Control: placebo on same schedule
Level of support: high. General written and oral advice (< 10 mins) at study start and < 3 mins at subse-
quent visits up to and including week 24 (9 visits total)
Outcomes Prolonged abstinence from week 2 to 52 (also recorded AEs and prolonged abstinence to weeks 6 and
24)
Validation: CO < 10 ppm
Notes Funded by McNeil AB, Sweden
Setting: smoking cessation clinics
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Subject randomization list stratified by study site”
Allocation concealment
(selection bias)
Low risk Quote: "The supply or resupply of study medication to a subject was deter-
mined via an Interactive Voice Response System involving a dispenser pack
number randomization list. Both randomization lists were computer-generat-
ed."
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "Double blind....The supply or resupply of study medication to a subject
was determined via an Interactive Voice Response System...the placebo was
identical in appearance, but contained capsaicin instead of nicotine to mimic




Low risk Similar percentage lost in both groups (151/318 active, 81/161 placebo). 9%
of active group and 7.5% of placebo group withdrew due to adverse events.





Recruitment: volunteers working in a university health and safety department
Participants 47 smokers (excludes 5 who did not attend at least 2 sessions)
72% female, average age 36, cpd 24 to 26
Interventions 1. Nicotine gum (2 mg)
2. No gum
Villa 1999 
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Level of support: high (8 weekly group sessions, 5 before TQD. Reduction prior to quitting)




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Los participantes fueron distribuidos aleatoriamente"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes










Participants 247 smokers (≥ 10 cpd), motivated to quit
59% female, average age 45, average cpd 1 to 20
Interventions 1. Nicotine sublingual tablet, 2 mg. Recommended dosage 1/h for smokers with FTND < 7, 2/h for scores
≥ 7. After 3 months treatment, tapering period of 3 months if necessary
2. Placebo tablet
Level of support: high (brief 5-mins counselling at study visits (0, 1, 2, 3, 6 weeks, 3, 6 months)
Outcomes Sustained abstinence at 12 months (from week 2, paper also reports with-slips rates)
Validation: CO < 10 ppm
Notes Study was supported by Pharmacia & Upjohn Consumer Health Care
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Subjects were randomized... using a computer program".
Allocation concealment
(selection bias)
Unclear risk Not stated
Wallstrom 2000 
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Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "All medication was dispensed by staE who were not involved in treat-










Recruitment: primary care centres (3 clinics were operated by NGOs for low-middle income patients,
4th clinic is private)
Participants 269 smokers (≥ 5 cpd, > 1 year)
22% female, average age 40, average cpd 28, mean FTND 5.8
Interventions 1. Nicotine patch, 24 h for 6 weeks. Participants who smoked ≥ 10 cpd given 2 weeks at 21 mg, 2 weeks
14 mg, 2 weeks 7 mg. Participants who smoked 5 to 9 cpd given 4 weeks 14 mg, 2 weeks 7 mg
2. Placebo on same schedule
Level of support: high (3 x 30 mins individual face-to-face counselling plus 5 x 10-min phone calls, from
4 days prior to TQD to 45 days post-TQD)
Outcomes Prolonged abstinence at 12 months
Validation: CO < 10 ppm
Notes New for 2017 update
N quit extrapolated from percentages given
Funding: "This work was supported by PHS grant 1R01DA024876"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Quote: “Allocation assignments were contained in opaque, sequentially-num-
bered envelopes and were maintained in the biostatistics unit of the SCTS,
a facility geographically separated from the clinics. A statistician, not other-
wise involved in the trial, made each allocation after receiving a request from
a cessation coordinator, prepared the treatment package, including patches,
and had it delivered to the clinic. Patients, interventionists and data collectors
were blind to allocation”
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: “Patients, interventionists and data collectors were blind to allocation”
placebo-controlled: “62% of those on NRT correctly guessed treatment group,
compared to 40% on placebo”. However, no effect detected so judged as low
risk of bias for this domain
Ward 2013 
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Participants 158 smokers motivated to quit (excludes 1 participant who used nicotine gum throughout)
57% female, average age 41, average cpd 30
Interventions 1. Nicotine patch (25 mg/24 h, 6 weeks incl weaning)
2. Placebo patches
Level of support: high (brief counsellor support at 3 clinic visits, 4 telephone counselling sessions, self-
help materials)
Outcomes Sustained abstinence at 6 months (from 2 weeks post-TQD)
Validation: CO < 8 ppm
Notes Study was supported by TBS Laboratories, Piscataway, NJ
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Quote: "At all times, the subjects and study staE were masked to the treatment




Low risk Dropouts fully reported
Westman 1993 
Nicotine replacement therapy versus control for smoking cessation (Review)













Recruitment: volunteers, antenatal clinic
Participants 250 pregnant women who continued to smoke after 1st trimester
Average age 28, average cpd 14; 43% primiparous
Interventions 1. Nicotine patch (15 mg/16 h, tapering to 10 mg, 11 weeks total)
2. Placebo patch
Level of support: high. 4 x 15- to 20-min sessions of midwife counselling at 0, 4,11 weeks from enrol-
ment, and 4 weeks before expected delivery
Outcomes Abstinence at 4 weeks prior to delivery and at 1 year post-partum (telephone interview). (Rates at 3
months post-partum also reported)
Validation: Cotinine < 26 ng/ml at 4 weeks pre-delivery visit only
Notes First long-term study of nicotine patch in pregnancy. Compliance with patch use was low. Only 17% of
active and 8% of placebo used all patches. Data used in Analysis 5.1 from 2012 is abstinence at 4th pre-
natal visit rather than continuous abstinence from 2nd to 4th prenatal visit, for consistency with Cole-
man 2015. The effect estimate is not altered
Study was funded by the Danish Cancer Society and the Department of Health, and supported by Phar-
macia & Upjohn
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomization. Quote: "Pharmacia & Upjohn ... generated the random-
ization list, supplied the patches with randomization numbers, and kept the




Low risk Quote: "Women ... were assigned consecutive numbers on the randomization
list"
Blinding (performance
bias and detection bias) 
All outcomes










Recruitment: 167 primary care clinics
Participants 467 'current regular smokers' attending primary care clinic for any reason and willing to consider treat-
ment in next 7 days
48% male, average age 43, average cpd 20
Interventions 1. Minimal intervention (not used in review)
Wittchen 2011 
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2. CBT
3. CBT + bupropion SR (9 to 12 weeks, 150 mg;1/day for first 6 days; 2/day thereafter)
4. CBT + NRT for 9 to 12 weeks, participant's choice of patch (7 mg to 52.5 mg), gum (2 or 4 mg) or spray
(10 mg/ml)
Level of support: high for 2, 3 and 4 (1 excluded from analysis). 4 to 5 one-on-one counselling sessions
for 20 to 30 mins
Outcomes Abstinence at 12 months (from EOT)
Validation: none
Notes 4 vs 2 included in primary analyses. 1 not used as results vs NRT would be confounded with CBT
Participants covered all costs for pharmaceutical treatments
Sponsored by the Federal Ministry of Education and Research; additional support provided by Glax-
oSmithKline GmbH & Co and Pharmacia GmbH
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Generated by the study center"; used to put 4 different coloured ques-
tionnaires in random order
Allocation concealment
(selection bias)
High risk No concealment
Quote: "questionnaires were distributed consecutively to all attending pa-
tients on the target days by nurses. Thus, the assignment of patients was en-
tirely dependent on the consecutive attendance of patients and the random
assignment of a color. Doctors were not allowed to interfere with this study
procedure." But numbers allocated to groups very uneven and discussion
states: "Random checks of this procedure [randomization] and quality assur-
ance tests by study monitors revealed that in some cases in the latter part of
the study treatment was based on patient and physician preferences."
Blinding (performance
bias and detection bias) 
All outcomes




Low risk Similar number of dropouts between groups; participants lost to follow-up






Participants 116 smokers (excludes 10 early treatment dropouts evenly distributed across conditions)
54% female, average age 29 to 35, average cpd 25 to 27
Interventions 1. Rapid smoking + support counselling
2. Rapid smoking + skills training
3. Nicotine gum 2 mg, average 10 pieces/day, duration not stated + skills training
Zelman 1992 
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4. Nicotine gum + support counselling
Level of support: high (6 x 60- to 75-min group sessions over 2 weeks, starting on quit day)
Outcomes Sustained abstinence at 12 months (not more than 2 consecutive days of smoking)
Validation: Independent observer report
Notes No placebo. Group support variants collapsed; 3 and 4 compared to 1 and 2
Study was funded by National Institutes of Health
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "subjects were randomly assigned"
Allocation concealment
(selection bias)
Unclear risk Not stated
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk Early dropout rates reported, but not included in the analyses. 4 12-month
dropouts included as smokers
Zelman 1992  (Continued)
AE = adverse event; ALA = American Lung Association; C = control; CBT = cognitive behavioural therapy; CO = carbon monoxide in exhaled
air; cpd = cigarettes per day; COPD = chronic obstructive pulmonary disease; EOT = end of treatment; FTND = Fagerström Test for Nicotine
Dependence; FTQ = Fagerström Tolerance Questionnaire; I = intervention; ITT = intention to treat; MA = meta-analysis; RTQ = reduce-to-
quit; OTC = over-the-counter; PP = point prevalence; SC = smoking cessation; TQD = target quit date
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Adelman 2009 Study of nicotine nasal spray in adolescents. 12 weeks follow-up
Allen 2005 Short-term study of effect of nicotine patch on weight change during early abstinence
Allen 2011 Trial of NRT for reduction of agitation and aggression in smokers with schizophrenia
Aubin 2006 Short-term study of the effect of different types of nicotine patch on sleep and smoking urges
Batra 2005 Trial of nicotine gum for smoking reduction in people not making a quit attempt. See Cochrane Re-
view of harm reduction interventions, Lindson-Hawley 2016
Berlin 2011 Trial of standard NRT dosing vs dose adaptation according to salivary cotinine
Bock 2010 Trial of computer software quit programme, treatment group offered free NRT. Control group could
also use NRT (unsubsidized)
Bolliger 2000a Trial of nicotine inhaler for smoking reduction in people not making a quit attempt. See Cochrane
Review of harm reduction interventions, Lindson-Hawley 2016
Bolliger 2007 Pilot study, not powered to detect efficacy differences between gum, inhaler and mouth spray
Nicotine replacement therapy versus control for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Study Reason for exclusion
Brantmark 1973a Double-blind gum/placebo only for 1st week of clinic, then both groups offered active gum during
6-month follow-up period
Caldwell 2016 All arms received pharmacotherapy
Carpenter 2003 Compared 2 methods of reducing smoking. Control group also offered NRT if a quit attempt
planned
Carpenter 2011 Measured effect of providing NRT samples on participants not initially motivated to quit. Partici-
pants were encouraged but not required to make a practice quit attempt. Intervention participants
were provided with up to 2 boxes of nicotine lozenges
Chan 2010 Measured effect of counselling + 2 weeks free NRT. No data on whether control group also using
NRT; unclear if outcome due to counselling or free NRT
Chan 2011 Measured effect of adherence counselling as opposed to effect of NRT itself
Chou 2004 Only 3 months follow-up
Christen 1984 Only 15 weeks follow-up
Cohen 1989a Primarily a trial of training dentists. Included in Cochrane Review of training of health professionals
(Carson 2012)
Cohen 1989b Primarily a trial of training doctors. Included in Cochrane Review of training of health professionals
(Carson 2012)
Croghan 2007 Provides a short-term comparison between nicotine patch, bupropion, and combination therapy.
Initial failures randomized to retreatment so no long-term control group
Cummings 2011 Compared provision of free NRT, but participants able to use additional NRT as desired
Dey 1999 Compared free and paid prescription for nicotine patch. Only 14 weeks follow-up
Donny 2009 Endpoint not cessation
Ebbert 2009 Study of NRT for smokeless tobacco users
Ebbert 2010 Study of mailed NRT for smokeless tobacco users
Elan Pharm 88-02 No long-term follow-up. Long-term follow-up for 1 site included as Hurt 1990
Elan Pharm 90-03 No long-term follow-up. Long-term follow-up for 1 site included as Fiore 1994a
Etter 2004 Trial of a choice of NRT products for smoking reduction in people not making a quit attempt. See
Cochrane Review of harm reduction interventions, Lindson-Hawley 2016
Fagerström 1993 Endpoint withdrawal symptoms, not cessation
Fagerström 1997 Short-term cross-over trial of different types of NRT. For 2 weeks smokers could choose a method,
for other 2 they were randomly assigned to one of gum, patch, spray, inhaler or tablet. Smoking re-
duction assessed
Fagerström 2000 Short-term cross-over trial comparing 2 nicotine delivery devices
Nicotine replacement therapy versus control for smoking cessation (Review)
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Study Reason for exclusion
Ferguson 2012 Study of offer of free NRT via NHS Quitline services. Control group had access to and used free NRT
and other stop-smoking medications at high levels; study conditions were very similar for both
groups
Finland unpublished Only 3-month follow-up. Comparison of patch and nasal spray (n = 51) versus nasal spray alone (n
= 50). Sustained abstinence rates 18% in each group. Used in a sensitivity analysis of combination
therapies
Foulds 1993 Follow-up less than 6 months
Garvey 2006 Not enough information currently available (abstract only)
Glover 1992 Follow-up less than 6 months
Gross 1989 Study of weight gain. Abstinence outcomes not reported
Guo 2006 Only 3 months follow-up
Hajek 1999 Follow-up less than 6 months
Hanson 2003 Follow-up only 10 weeks; primary outcomes were withdrawal, craving, safety and compliance
among adolescents
Haustein 2003 Trial of nicotine gum for smoking reduction in people not making a quit attempt. See Cochrane Re-
view of harm reduction interventions, Lindson-Hawley 2016
Hoch 2006 Not enough information currently available (abstract only)
Hotham 2006 RCT of nicotine patch as adjunct to counselling for pregnant smokers. Only 20 people in each con-
dition, with high withdrawal and low compliance.
Hughes 1989b No long-term follow-up, primarily a trial of the effect of instructions
Hurt 1995 Analysis of prior nicotine patch studies (to determine if recovering alcoholic smokers were more
nicotine-dependent than non-alcoholics and whether the efficacy of nicotine patch therapy was
comparable)
Hurt 2003 All participants received nicotine patch
Jarvik 1984 Reports subgroup analysis by level of nicotine dependence. See Schneider 1983a for main out-
comes
Jibrail 2010 Only 12 weeks follow-up. Study of NRT for smoking abstinence and relationship between c-reactive
protein and depressed mood during nicotine abstinence
Kapur 2001 Only 12 weeks follow-up. Trial of nicotine patch in pregnant smokers. 30 participants
Korberly 1999 Insufficient data in unpublished abstracts to include
Kozak 1995 Open-label study in which smokers with higher nicotine dependence scores were given higher
patch doses
Kras 2010 Study of NRT and hypericum perforatum extract. Only 10 weeks follow-up
Krumpe 1989 Only 10 weeks follow-up
Nicotine replacement therapy versus control for smoking cessation (Review)
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Study Reason for exclusion
Krupski 2016 All arms received pharmacotherapy
Kupecz 1996 Participants were randomized by month of treatment to group therapy with nicotine patch (n = 21)
or gum (n = 17)
Landfeldt 1998 Only 12 weeks follow-up reported in abstract
Leischow 1996b Only 10 weeks follow-up
Levin 1994 Only 9 weeks follow-up
Lin 1996 Only 8 weeks follow-up
Marsh 2005 Only 3 months follow-up, safety study comparing 4 mg lozenge to 4 mg gum
McCarthy 2006 Only 3 months follow-up, study of withdrawal symptoms
McRobbie 2010 Short-term cross-over study assessing withdrawal symptoms and user satisfaction
Meier 1990 Short-term follow-up. Compared dependence individualized to standard dose patch.
Merz 1993 Only 3 months follow-up
Miller 2009 1377 low-income smokers with quitline and subsidized NRT. Participants informed what group they
would be in when first invited to participate
Millie 1989 Only 2 months follow-up
Minneker 1989 Only 9 weeks follow-up
Molander 2000 Cross-over study with 2-day smoke-free periods
Mooney 2005 All participants used nicotine gum
Mulligan 1990 Only 6 weeks follow-up
Nackaerts 2009 Insufficient data in published abstract to include (longest follow-up reported in abstract 1m); NRT
delivered for maximum 7 days
NCT00000437 3-month follow-up only. Thank you to Barbara Mason for confirming
Okuyemi 2007 Intervention combined nicotine gum and multiple sessions of motivational interviewing
Oncken 2009 Study of short-term effects of NRT in pregnant smokers
Piper 2016 All arms received pharmacotherapy
Pomerleau 2003 Compared extended treatment (18 weeks) to 10-week treatment with nicotine patch. No follow-up
beyond 18 weeks
Rennard 2006 Trial of nicotine inhaler for smoking reduction in people not making a quit attempt. See Cochrane
Review of harm reduction interventions, Lindson-Hawley 2016
Rey 2009 All study participants received nicotine nasal spray. Comparison between different types of instruc-
tional guidance for dosing
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Study Reason for exclusion
Rigotti 2009 Assessed effectiveness of adding NRT to rimonabant which has not been licensed for smoking ces-
sation and results may not be generalizable
Roddy 2006 Only 13 weeks follow-up. At this point there were no quitters in either the treatment or control
group. There were particularly high losses to follow-up (64% overall) and low compliance (median
duration of patch use 1 week)
Rose 1990 Only 3 weeks follow-up
Rubinstein 2008 Only 12 weeks follow-up
Sachs 1995 Only 6 weeks follow-up
Schlam 2016 All arms received pharmacotherapy
Schneider 2004 Short-term cross-over study
Schneider 2008 Outcome was craving and withdrawal, not abstinence
Schnoll 2015 All arms received pharmacotherapy
Shahab 2011 Short-term cross-over trial of withdrawal symptom relief
Shiffman 2000a Compared 10 and 6 weeks of patch treatment without longer follow-up. Main outcome was craving
and withdrawal
Shiffman 2000b Comparison between 24-h and 16-h patches. Assessment of craving and abstinence over 2 weeks
Shiffman 2002a Only 10 weeks follow-up
Shiffman 2002b Not a randomized trial. Compared prescription and OTC patch in different populations using differ-
ent methods
Shiffman 2006 Only 6 weeks follow-up. High-dose (35 mg) patch
Stapleton 2011 Only 12 weeks follow-up
Sun 2009 Only 3 months follow-up
Sussman 2004 Presents Project EX program for adolescent tobacco use cessation. Mentions trial of nicotine gum
vs herbal gum but insufficient detail provided
Sutherland 1999 Only 3 months follow-up. Comparison of patch and nasal spray (n = 104) versus patch alone (n =
138) or nasal spray alone (n = 138). Used in a sensitivity analysis of combination therapies
Sutherland 2005 Only 12 weeks follow-up
Sutton 1987 Control group received no treatment so effect of nicotine gum is confounded with the brief coun-
selling
Sutton 1988 Control group received no treatment so effect of nicotine gum is confounded with the behavioural
support
Thorsteinsson 2001 No long-term follow-up reported
Nicotine replacement therapy versus control for smoking cessation (Review)
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Study Reason for exclusion
Tsukahara 2010 Follow-up less than 6 months. Direct comparison of varenicline and nicotine patch for smoking ces-
sation
Tundulawessa 2010 Only 4 weeks follow-up
Tzivoni 1998 Follow-up less than 6 months
Tønnesen 1996 All study participants received nicotine nasal spray. Comparison between ad lib and fixed schedule
dosing
Uyar 2005 Unpublished, insufficient detail in abstract on nicotine patch dose, length of treatment, level of
support
Velicer 2006 Participants were sent nicotine patches if they were assessed as potentially ready to quit. They did
not have to set a quit date
Vial 2002 Treatment groups differed from control in amount of counselling as well as use of NRT
Vikhireva 2003 Trial of free choice of NRT product vs assigned NRT product from the outcome; no control group
Warner 2005 Goal of intervention was relief of stress and withdrawal postoperatively
Wennike 2003a Trial of nicotine gum for smoking reduction in people not making a quit attempt. See Cochrane Re-
view of harm reduction interventions, Lindson-Hawley 2016
Williams 2007 Only short-term outcomes reported in conference abstract. Trial terminated early when no benefit
of higher dose detected in interim analysis
Wiseman 2005 2-week cross-over study
Working Group 1994 Follow-up less than 6 months
h = hour; OTC = over the counter;
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Double-blind, placebo-controlled trial of nicotine nasal spray as an aid for smoking cessation in
schizophrenia
Methods RCT
Participants 60 individuals with schizophrenia
Interventions Nicotine nasal spray or placebo spray with behavioural intervention
Outcomes Abstinence at 12 months
Starting date August 2009
Contact information Mia H Zimmerman, hanosma@umdnj.edu
Notes  
NCT01010477 
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Trial name or title A smoking cessation trial in HIV-infected patients in South Africa (JHU)
Methods RCT
Participants HIV-infected patients in South Africa
Interventions 1. intensive anti-smoking counseling + NRT (patches)
2. intensive anti-smoking counseling only
Outcomes 6-month and 12-month cessation, CO-validated
Starting date March 2014





Trial name or title Effect of pre-op NRT on peri-operative complications and long-term abstinence: a pilot trial in pa-
tients undergoing CABG surgery
Methods Single site, double-blind RCT
Participants Smokers of > 5 cpd scheduled for CABG surgery
Interventions 1. NRT patch
2. Placebo
Outcomes Smoking cessation (CO-validated) at time of surgery and 6 month post-op; peri-operative compli-
cations
Starting date Oct 2017
Contact information Evyanne Wooding, ewooding@ottawaheart.ca
Notes  
NCT02918500 
CABG = coronary artery bypass graO; RCT = randomized controlled trial
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Comparison 1.   Any type of NRT versus placebo/no NRT control





Statistical method Effect size
1 Smoking cessation at 6+
months follow up
133 64640 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [1.49, 1.61]
1.1 Gum 56 22581 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [1.40, 1.60]
1.2 Patch 51 25754 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [1.53, 1.75]
1.3 Inhalator 4 976 Risk Ratio (M-H, Fixed, 95% CI) 1.90 [1.36, 2.67]
1.4 Intranasal spray 4 887 Risk Ratio (M-H, Fixed, 95% CI) 2.02 [1.49, 2.73]
1.5 Tablets/lozenges 8 4439 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.32, 1.74]
1.6 Oral spray 1 479 Risk Ratio (M-H, Fixed, 95% CI) 2.48 [1.24, 4.94]
1.7 Choice of NRT product 7 8288 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.25, 1.52]
1.8 Patch and inhalator 1 245 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.57, 1.99]
1.9 Patch and lozenge 1 308 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [1.01, 3.31]
1.10 Patch and gum 2 259 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.64, 2.06]
1.11 Patch, gum and lozenge 1 424 Risk Ratio (M-H, Fixed, 95% CI) 15.0 [2.00, 112.54]
 
 
Analysis 1.1.   Comparison 1 Any type of NRT versus placebo/no
NRT control, Outcome 1 Smoking cessation at 6+ months follow up.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.1.1 Gum  
Ahluwalia 2006 53/378 42/377 1.28% 1.26[0.86,1.84]
Areechon 1988 56/99 37/101 1.11% 1.54[1.13,2.1]
Blondal 1989 30/92 22/90 0.68% 1.33[0.84,2.13]
Br Thor Society 1983 39/410 111/1208 1.71% 1.04[0.73,1.46]
Campbell 1987 13/424 9/412 0.28% 1.4[0.61,3.25]
Campbell 1991 21/107 21/105 0.64% 0.98[0.57,1.69]
Clavel 1985 24/205 6/222 0.17% 4.33[1.81,10.38]
Clavel-Chapelon 1992 47/481 42/515 1.23% 1.2[0.81,1.78]
Cooper 2005 17/146 15/147 0.45% 1.14[0.59,2.2]
Fagerström 1982 30/50 23/50 0.7% 1.3[0.9,1.9]
Fagerström 1984 28/96 5/49 0.2% 2.86[1.18,6.94]
Fee 1982 23/180 15/172 0.47% 1.47[0.79,2.71]
Fortmann 1995 110/552 84/522 2.62% 1.24[0.96,1.6]
García 1989 21/68 5/38 0.19% 2.35[0.96,5.72]
Garvey 2000 75/405 17/203 0.69% 2.21[1.34,3.64]
Gilbert 1989 11/112 9/111 0.27% 1.21[0.52,2.81]
Favours control 1000.01 100.1 1 Favours NRT
Nicotine replacement therapy versus control for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Gross 1995 37/131 6/46 0.27% 2.17[0.98,4.79]
Hall 1985 18/41 10/36 0.32% 1.58[0.84,2.97]
Hall 1987 30/71 14/68 0.43% 2.05[1.2,3.52]
Hall 1996 24/98 28/103 0.83% 0.9[0.56,1.44]
Harackiewicz 1988 12/99 7/52 0.28% 0.9[0.38,2.15]
Herrera 1995 30/76 13/78 0.39% 2.37[1.34,4.18]
Hjalmarson 1984 31/106 16/100 0.5% 1.83[1.07,3.13]
Huber 1988 13/54 11/60 0.32% 1.31[0.64,2.68]
Hughes 1989a 23/210 6/105 0.24% 1.92[0.81,4.56]
Hughes 1990 15/59 5/19 0.23% 0.97[0.4,2.31]
Jamrozik 1984 10/101 8/99 0.25% 1.23[0.5,2.98]
Jarvis 1982 22/58 9/58 0.27% 2.44[1.23,4.85]
Jensen 1991 49/211 19/82 0.83% 1[0.63,1.59]
Killen 1984 16/44 6/20 0.25% 1.21[0.56,2.63]
Killen 1990 129/600 112/617 3.35% 1.18[0.94,1.49]
Llivina 1988 61/113 28/103 0.89% 1.99[1.39,2.84]
Malcolm 1980 6/73 3/121 0.07% 3.32[0.86,12.85]
McGovern 1992 51/146 40/127 1.3% 1.11[0.79,1.56]
Moolchan 2005 8/46 2/40 0.06% 3.48[0.78,15.44]
Mori 1992 30/178 22/186 0.65% 1.42[0.86,2.37]
Nakamura 1990 13/30 5/30 0.15% 2.6[1.06,6.39]
Nebot 1992 5/106 13/319 0.2% 1.16[0.42,3.17]
Niaura 1994 5/84 4/89 0.12% 1.32[0.37,4.77]
Niaura 1999 1/31 2/31 0.06% 0.5[0.05,5.23]
Ockene 1991 40/402 33/420 0.98% 1.27[0.82,1.97]
Oncken 2008 11/100 9/94 0.28% 1.15[0.5,2.65]
Page 1986 9/93 13/182 0.27% 1.35[0.6,3.05]
Pirie 1992 75/206 50/211 1.5% 1.54[1.14,2.08]
Puska 1979 29/116 21/113 0.65% 1.35[0.82,2.21]
Richmond 1993 17/200 14/150 0.49% 0.91[0.46,1.79]
Roto 1987 19/54 7/60 0.2% 3.02[1.38,6.61]
Russell 1983 81/729 78/1377 1.64% 1.96[1.46,2.64]
Schneider 1983a 9/30 6/30 0.18% 1.5[0.61,3.69]
Schneider 1983b 1/13 3/23 0.07% 0.59[0.07,5.11]
Segnan 1991 22/294 37/629 0.72% 1.27[0.76,2.12]
Shiffman 2009 (2 mg) 24/819 9/817 0.27% 2.66[1.24,5.69]
Shiffman 2009 (4 mg) 101/830 24/831 0.73% 4.21[2.73,6.51]
Tønnesen 1988 23/60 12/53 0.39% 1.69[0.94,3.06]
Villa 1999 11/21 10/26 0.27% 1.36[0.72,2.57]
Zelman 1992 23/58 18/58 0.55% 1.28[0.78,2.1]
Subtotal (95% CI) 10596 11985 34.12% 1.49[1.4,1.6]
Total events: 1732 (NRT), 1196 (Control)  
Heterogeneity: Tau2=0; Chi2=91.05, df=55(P=0); I2=39.59%  
Test for overall effect: Z=11.56(P<0.0001)  
   
1.1.2 Patch  
Abelin 1989 17/100 11/99 0.34% 1.53[0.76,3.1]
Ahluwalia 1998 35/205 24/205 0.73% 1.46[0.9,2.36]
Anthenelli 2016 320/2038 191/2035 5.8% 1.67[1.41,1.98]
Buchkremer 1988 11/42 16/89 0.31% 1.46[0.74,2.86]
Campbell 1996 24/115 17/119 0.51% 1.46[0.83,2.57]
Cinciripini 1996 12/32 7/32 0.21% 1.71[0.78,3.79]
Favours control 1000.01 100.1 1 Favours NRT
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Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Coleman 2012 49/521 40/529 1.2% 1.24[0.83,1.86]
Cummins 2016 44/637 38/633 1.16% 1.15[0.76,1.75]
Cunningham 2016 14/500 5/499 0.15% 2.79[1.01,7.7]
Daughton 1991 28/106 4/52 0.16% 3.43[1.27,9.28]
Daughton 1998 25/184 16/185 0.48% 1.57[0.87,2.84]
Davidson 1998 33/401 16/401 0.49% 2.06[1.15,3.69]
Ehrsam 1991 7/56 2/56 0.06% 3.5[0.76,16.12]
Fiore 1994a 15/44 9/44 0.27% 1.67[0.82,3.4]
Fiore 1994b 10/57 4/55 0.12% 2.41[0.8,7.24]
Gallagher 2007 1/60 4/60 0.12% 0.25[0.03,2.17]
Glavas 2003a 13/56 9/56 0.27% 1.44[0.67,3.1]
Glavas 2003b 29/80 12/80 0.36% 2.42[1.33,4.39]
Hays 1999 62/636 14/322 0.56% 2.24[1.28,3.94]
Heydari 2012 23/92 6/91 0.18% 3.79[1.62,8.88]
Hughes 1999 171/779 34/260 1.55% 1.68[1.19,2.36]
Hughes 2003 13/61 8/54 0.26% 1.44[0.65,3.2]
Hurt 1990 8/31 6/31 0.18% 1.33[0.52,3.39]
Hurt 1994 33/120 17/120 0.52% 1.94[1.15,3.29]
ICRF 1994 76/842 53/844 1.61% 1.44[1.03,2.01]
Jorenby 1999 24/244 9/160 0.33% 1.75[0.83,3.66]
Joseph 1996 29/294 35/290 1.07% 0.82[0.51,1.3]
Killen 1997 23/212 21/212 0.64% 1.1[0.63,1.92]
Kornitzer 1995 19/150 10/75 0.4% 0.95[0.47,1.94]
Lerman 2015 69/418 50/408 1.54% 1.35[0.96,1.89]
Lewis 1998 6/62 7/123 0.14% 1.7[0.6,4.84]
Moolchan 2005 9/34 2/40 0.06% 5.29[1.23,22.85]
NCT00534404 194/830 109/828 3.31% 1.78[1.43,2.2]
Oncken 2007 19/57 28/95 0.64% 1.13[0.7,1.83]
Otero 2006 193/597 122/602 3.69% 1.6[1.31,1.94]
Paoletti 1996 15/60 4/60 0.12% 3.75[1.32,10.64]
Perng 1998 9/30 3/32 0.09% 3.2[0.96,10.71]
Piper 2009 90/262 8/37 0.43% 1.59[0.84,3]
Prapavessis 2007 13/59 7/62 0.21% 1.95[0.84,4.55]
Richmond 1994 29/153 14/152 0.43% 2.06[1.13,3.74]
Sachs 1993 28/113 10/107 0.31% 2.65[1.35,5.19]
Scherphof 2014 6/136 8/129 0.25% 0.71[0.25,1.99]
Stapleton 1995 77/800 19/400 0.77% 2.03[1.24,3.3]
Sønderskov 1997 20/251 14/267 0.41% 1.52[0.78,2.94]
TNSG 1991 111/537 31/271 1.25% 1.81[1.25,2.62]
Tuisku 2016 19/94 13/86 0.41% 1.34[0.7,2.54]
Tønnesen 1991 24/145 6/144 0.18% 3.97[1.67,9.43]
Tønnesen 2000 9/104 2/109 0.06% 4.72[1.04,21.32]
Ward 2013 17/134 16/135 0.48% 1.07[0.56,2.03]
Westman 1993 16/78 2/80 0.06% 8.21[1.95,34.51]
Wisborg 2000 19/124 18/126 0.54% 1.07[0.59,1.94]
Subtotal (95% CI) 13773 11981 35.43% 1.64[1.53,1.75]
Total events: 2160 (NRT), 1131 (Control)  
Heterogeneity: Tau2=0; Chi2=65.44, df=50(P=0.07); I2=23.59%  
Test for overall effect: Z=14.23(P<0.0001)  
   
1.1.3 Inhalator  
Hjalmarson 1997 35/123 22/124 0.66% 1.6[1,2.57]
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Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Leischow 1996a 12/110 6/110 0.18% 2[0.78,5.14]
Schneider 1996 15/112 9/111 0.27% 1.65[0.75,3.62]
Tønnesen 1993 22/145 7/141 0.22% 3.06[1.35,6.93]
Subtotal (95% CI) 490 486 1.34% 1.9[1.36,2.67]
Total events: 84 (NRT), 44 (Control)  
Heterogeneity: Tau2=0; Chi2=1.93, df=3(P=0.59); I2=0%  
Test for overall effect: Z=3.73(P=0)  
   
1.1.4 Intranasal spray  
Blondal 1997 20/79 13/78 0.4% 1.52[0.81,2.84]
Hjalmarson 1994 34/125 18/123 0.55% 1.86[1.11,3.11]
Schneider 1995 23/128 10/127 0.3% 2.28[1.13,4.6]
Sutherland 1992 30/116 11/111 0.34% 2.61[1.38,4.95]
Subtotal (95% CI) 448 439 1.59% 2.02[1.49,2.73]
Total events: 107 (NRT), 52 (Control)  
Heterogeneity: Tau2=0; Chi2=1.63, df=3(P=0.65); I2=0%  
Test for overall effect: Z=4.53(P<0.0001)  
   
1.1.5 Tablets/lozenges  
Dautzenberg 2001 25/211 18/222 0.53% 1.46[0.82,2.6]
Fraser 2014 151/518 139/516 4.23% 1.08[0.89,1.32]
Glover 2002 22/120 12/121 0.36% 1.85[0.96,3.56]
Piper 2009 87/260 8/36 0.43% 1.51[0.8,2.84]
Shiffman 2002 (2 mg) 82/459 44/458 1.34% 1.86[1.32,2.62]
Shiffman 2002 (4 mg) 67/450 28/451 0.85% 2.4[1.57,3.65]
Tønnesen 2006 26/185 5/185 0.15% 5.2[2.04,13.25]
Wallstrom 2000 28/123 19/124 0.57% 1.49[0.88,2.52]
Subtotal (95% CI) 2326 2113 8.46% 1.52[1.32,1.74]
Total events: 488 (NRT), 273 (Control)  
Heterogeneity: Tau2=0; Chi2=24.39, df=7(P=0); I2=71.31%  
Test for overall effect: Z=5.97(P<0.0001)  
   
1.1.6 Oral spray  
Tønnesen 2012 44/318 9/161 0.36% 2.48[1.24,4.94]
Subtotal (95% CI) 318 161 0.36% 2.48[1.24,4.94]
Total events: 44 (NRT), 9 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.57(P=0.01)  
   
1.1.7 Choice of NRT product  
Graham 2017 366/2630 312/2660 9.42% 1.19[1.03,1.37]
Johns 2017 27/100 16/100 0.49% 1.69[0.97,2.93]
Kralikova 2009 39/209 9/105 0.36% 2.18[1.1,4.32]
Molyneux 2003 10/91 4/91 0.12% 2.5[0.81,7.68]
Ortega 2011 305/924 193/919 5.87% 1.57[1.35,1.84]
Pollak 2007 24/122 8/59 0.33% 1.45[0.69,3.03]
Wittchen 2011 22/103 27/175 0.61% 1.38[0.83,2.3]
Subtotal (95% CI) 4179 4109 17.19% 1.37[1.25,1.52]
Total events: 793 (NRT), 569 (Control)  
Heterogeneity: Tau2=0; Chi2=10.41, df=6(P=0.11); I2=42.34%  
Test for overall effect: Z=6.34(P<0.0001)  
   
Favours control 1000.01 100.1 1 Favours NRT
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Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.1.8 Patch and inhalator  
Hand 2002 20/136 15/109 0.51% 1.07[0.57,1.99]
Subtotal (95% CI) 136 109 0.51% 1.07[0.57,1.99]
Total events: 20 (NRT), 15 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.21(P=0.83)  
   
1.1.9 Patch and lozenge  
Piper 2009 107/267 9/41 0.47% 1.83[1.01,3.31]
Subtotal (95% CI) 267 41 0.47% 1.83[1.01,3.31]
Total events: 107 (NRT), 9 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.98(P=0.05)  
   
1.1.10 Patch and gum  
Hasan 2014 13/40 15/41 0.45% 0.89[0.49,1.62]
Stein 2013 11/133 1/45 0.05% 3.72[0.49,28.03]
Subtotal (95% CI) 173 86 0.49% 1.15[0.64,2.06]
Total events: 24 (NRT), 16 (Control)  
Heterogeneity: Tau2=0; Chi2=2, df=1(P=0.16); I2=50.04%  
Test for overall effect: Z=0.46(P=0.64)  
   
1.1.11 Patch, gum and lozenge  
Heydari 2013 15/212 1/212 0.03% 15[2,112.54]
Subtotal (95% CI) 212 212 0.03% 15[2,112.54]
Total events: 15 (NRT), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.63(P=0.01)  
   
Total (95% CI) 32918 31722 100% 1.55[1.49,1.61]
Total events: 5574 (NRT), 3315 (Control)  
Heterogeneity: Tau2=0; Chi2=220.2, df=135(P<0.0001); I2=38.69%  
Test for overall effect: Z=21.25(P<0.0001)  
Test for subgroup differences: Chi2=23.05, df=1 (P=0.01), I2=56.61%  
Favours control 1000.01 100.1 1 Favours NRT
 
 
Comparison 2.   Subgroup: Definition of abstinence





Statistical method Effect size
1 Nicotine gum. Smoking cessation 56 22581 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [1.40, 1.60]
1.1 Sustained 12 months 32 13737 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [1.31, 1.56]
1.2 Sustained 6 months 8 4187 Risk Ratio (M-H, Fixed, 95% CI) 2.77 [2.14, 3.59]
1.3 PP/uncertain 12 months 8 2501 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [1.12, 1.55]
1.4 PP/uncertain 6 months 8 2156 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [1.20, 1.68]
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Statistical method Effect size
2 Nicotine patch: Smoking cessation 49 23976 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [1.52, 1.75]
2.1 Sustained 12 months 21 7622 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.34, 1.74]
2.2 Sustained 6 months 9 8613 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.51, 1.92]
2.3 PP/uncertain 12 months 9 3856 Risk Ratio (M-H, Fixed, 95% CI) 1.66 [1.44, 1.93]
2.4 PP/uncertain 6 months 10 3885 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [1.32, 2.04]
 
 
Analysis 2.1.   Comparison 2 Subgroup: Definition of abstinence, Outcome 1 Nicotine gum. Smoking cessation.
Study or subgroup Nicotine gum Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.1.1 Sustained 12 months  
Niaura 1999 1/31 2/31 0.18% 0.5[0.05,5.23]
Schneider 1983b 1/13 3/23 0.19% 0.59[0.07,5.11]
Harackiewicz 1988 12/99 7/52 0.82% 0.9[0.38,2.15]
Hall 1996 24/98 28/103 2.43% 0.9[0.56,1.44]
Richmond 1993 17/200 14/150 1.42% 0.91[0.46,1.79]
Campbell 1991 21/107 21/105 1.89% 0.98[0.57,1.69]
Jensen 1991 49/211 19/82 2.43% 1[0.63,1.59]
Br Thor Society 1983 39/410 111/1208 5% 1.04[0.73,1.46]
Cooper 2005 17/146 15/147 1.33% 1.14[0.59,2.2]
Killen 1990 129/600 112/617 9.82% 1.18[0.94,1.49]
Clavel-Chapelon 1992 47/481 42/515 3.61% 1.2[0.81,1.78]
Gilbert 1989 11/112 9/111 0.8% 1.21[0.52,2.81]
Killen 1984 16/44 6/20 0.73% 1.21[0.56,2.63]
Ockene 1991 40/402 33/420 2.87% 1.27[0.82,1.97]
Segnan 1991 22/294 37/629 2.1% 1.27[0.76,2.12]
Zelman 1992 23/58 18/58 1.6% 1.28[0.78,2.1]
Niaura 1994 5/84 4/89 0.35% 1.32[0.37,4.77]
Blondal 1989 30/92 22/90 1.98% 1.33[0.84,2.13]
Campbell 1987 13/424 9/412 0.81% 1.4[0.61,3.25]
Schneider 1983a 9/30 6/30 0.53% 1.5[0.61,3.69]
Pirie 1992 75/206 50/211 4.39% 1.54[1.14,2.08]
Tønnesen 1988 23/60 12/53 1.13% 1.69[0.94,3.06]
Hjalmarson 1984 31/106 16/100 1.46% 1.83[1.07,3.13]
Hughes 1989a 23/210 6/105 0.71% 1.92[0.81,4.56]
Russell 1983 81/729 78/1377 4.8% 1.96[1.46,2.64]
Llivina 1988 61/113 28/103 2.61% 1.99[1.39,2.84]
Garvey 2000 75/405 17/203 2.01% 2.21[1.34,3.64]
Herrera 1995 30/76 13/78 1.14% 2.37[1.34,4.18]
Jarvis 1982 22/58 9/58 0.8% 2.44[1.23,4.85]
Fagerström 1984 28/96 5/49 0.59% 2.86[1.18,6.94]
Moolchan 2005 8/46 2/40 0.19% 3.48[0.78,15.44]
Clavel 1985 24/205 6/222 0.51% 4.33[1.81,10.38]
Subtotal (95% CI) 6246 7491 61.25% 1.43[1.31,1.56]
Favours control 500.02 100.1 1 Favours NRT
Nicotine replacement therapy versus control for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Study or subgroup Nicotine gum Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total events: 1007 (Nicotine gum), 760 (Control)  
Heterogeneity: Tau2=0; Chi2=47.87, df=31(P=0.03); I2=35.24%  
Test for overall effect: Z=7.93(P<0.0001)  
   
2.1.2 Sustained 6 months  
Hughes 1990 15/59 5/19 0.67% 0.97[0.4,2.31]
Page 1986 9/93 13/182 0.78% 1.35[0.6,3.05]
Gross 1995 37/131 6/46 0.79% 2.17[0.98,4.79]
García 1989 21/68 5/38 0.57% 2.35[0.96,5.72]
Nakamura 1990 13/30 5/30 0.44% 2.6[1.06,6.39]
Shiffman 2009 (2 mg) 24/819 9/817 0.8% 2.66[1.24,5.69]
Malcolm 1980 6/73 3/121 0.2% 3.32[0.86,12.85]
Shiffman 2009 (4 mg) 101/830 24/831 2.13% 4.21[2.73,6.51]
Subtotal (95% CI) 2103 2084 6.4% 2.77[2.14,3.59]
Total events: 226 (Nicotine gum), 70 (Control)  
Heterogeneity: Tau2=0; Chi2=12.78, df=7(P=0.08); I2=45.22%  
Test for overall effect: Z=7.7(P<0.0001)  
   
2.1.3 PP/uncertain 12 months  
McGovern 1992 51/146 40/127 3.81% 1.11[0.79,1.56]
Nebot 1992 5/106 13/319 0.58% 1.16[0.42,3.17]
Fortmann 1995 110/552 84/522 7.68% 1.24[0.96,1.6]
Huber 1988 13/54 11/60 0.93% 1.31[0.64,2.68]
Villa 1999 11/21 10/26 0.79% 1.36[0.72,2.57]
Fee 1982 23/180 15/172 1.36% 1.47[0.79,2.71]
Hall 1985 18/41 10/36 0.95% 1.58[0.84,2.97]
Hall 1987 30/71 14/68 1.27% 2.05[1.2,3.52]
Subtotal (95% CI) 1171 1330 17.37% 1.31[1.12,1.55]
Total events: 261 (Nicotine gum), 197 (Control)  
Heterogeneity: Tau2=0; Chi2=4.3, df=7(P=0.74); I2=0%  
Test for overall effect: Z=3.27(P=0)  
   
2.1.4 PP/uncertain 6 months  
Oncken 2008 11/100 9/94 0.83% 1.15[0.5,2.65]
Jamrozik 1984 10/101 8/99 0.72% 1.23[0.5,2.98]
Ahluwalia 2006 53/378 42/377 3.74% 1.26[0.86,1.84]
Fagerström 1982 30/50 23/50 2.05% 1.3[0.9,1.9]
Puska 1979 29/116 21/113 1.89% 1.35[0.82,2.21]
Mori 1992 30/178 22/186 1.91% 1.42[0.86,2.37]
Areechon 1988 56/99 37/101 3.26% 1.54[1.13,2.1]
Roto 1987 19/54 7/60 0.59% 3.02[1.38,6.61]
Subtotal (95% CI) 1076 1080 14.98% 1.42[1.2,1.68]
Total events: 238 (Nicotine gum), 169 (Control)  
Heterogeneity: Tau2=0; Chi2=4.81, df=7(P=0.68); I2=0%  
Test for overall effect: Z=4.07(P<0.0001)  
   
Total (95% CI) 10596 11985 100% 1.49[1.4,1.6]
Total events: 1732 (Nicotine gum), 1196 (Control)  
Heterogeneity: Tau2=0; Chi2=91.05, df=55(P=0); I2=39.59%  
Test for overall effect: Z=11.56(P<0.0001)  
Test for subgroup differences: Chi2=25.26, df=1 (P<0.0001), I2=88.12%  
Favours control 500.02 100.1 1 Favours NRT
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Analysis 2.2.   Comparison 2 Subgroup: Definition of abstinence, Outcome 2 Nicotine patch: Smoking cessation.
Study or subgroup Nicotine patch Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.2.1 Sustained 12 months  
Abelin 1989 17/100 11/99 1.05% 1.53[0.76,3.1]
Campbell 1996 24/115 17/119 1.59% 1.46[0.83,2.57]
Cinciripini 1996 12/32 7/32 0.66% 1.71[0.78,3.79]
Daughton 1998 25/184 16/185 1.51% 1.57[0.87,2.84]
Ehrsam 1991 7/56 2/56 0.19% 3.5[0.76,16.12]
Hurt 1990 8/31 6/31 0.57% 1.33[0.52,3.39]
Hurt 1994 33/120 17/120 1.61% 1.94[1.15,3.29]
ICRF 1994 76/842 53/844 5.02% 1.44[1.03,2.01]
Jorenby 1999 24/244 9/160 1.03% 1.75[0.83,3.66]
Joseph 1996 29/294 35/290 3.34% 0.82[0.51,1.3]
Killen 1997 23/212 21/212 1.99% 1.1[0.63,1.92]
Kornitzer 1995 19/150 10/75 1.26% 0.95[0.47,1.94]
Oncken 2007 19/57 28/95 1.99% 1.13[0.7,1.83]
Prapavessis 2007 13/59 7/62 0.65% 1.95[0.84,4.55]
Richmond 1994 29/153 14/152 1.33% 2.06[1.13,3.74]
Sachs 1993 28/113 10/107 0.97% 2.65[1.35,5.19]
Stapleton 1995 77/800 19/400 2.4% 2.03[1.24,3.3]
Tønnesen 1991 24/145 6/144 0.57% 3.97[1.67,9.43]
Tønnesen 2000 9/104 2/109 0.19% 4.72[1.04,21.32]
Ward 2013 17/134 16/135 1.51% 1.07[0.56,2.03]
Wisborg 2000 19/124 18/126 1.69% 1.07[0.59,1.94]
Subtotal (95% CI) 4069 3553 31.15% 1.52[1.34,1.74]
Total events: 532 (Nicotine patch), 324 (Control)  
Heterogeneity: Tau2=0; Chi2=28.39, df=20(P=0.1); I2=29.54%  
Test for overall effect: Z=6.29(P<0.0001)  
   
2.2.2 Sustained 6 months  
Ahluwalia 1998 35/205 24/205 2.28% 1.46[0.9,2.36]
Anthenelli 2016 320/2038 191/2035 18.13% 1.67[1.41,1.98]
Coleman 2012 49/521 40/529 3.77% 1.24[0.83,1.86]
Daughton 1991 28/106 4/52 0.51% 3.43[1.27,9.28]
Davidson 1998 33/401 16/401 1.52% 2.06[1.15,3.69]
Hughes 1999 171/779 34/260 4.84% 1.68[1.19,2.36]
Hughes 2003 13/61 8/54 0.81% 1.44[0.65,3.2]
TNSG 1991 111/537 31/271 3.91% 1.81[1.25,2.62]
Westman 1993 16/78 2/80 0.19% 8.21[1.95,34.51]
Subtotal (95% CI) 4726 3887 35.94% 1.7[1.51,1.92]
Total events: 776 (Nicotine patch), 350 (Control)  
Heterogeneity: Tau2=0; Chi2=10.01, df=8(P=0.26); I2=20.06%  
Test for overall effect: Z=8.59(P<0.0001)  
   
2.2.3 PP/uncertain 12 months  
Buchkremer 1988 11/42 16/89 0.97% 1.46[0.74,2.86]
Glavas 2003a 13/56 9/56 0.85% 1.44[0.67,3.1]
Hays 1999 62/636 14/322 1.76% 2.24[1.28,3.94]
Heydari 2012 23/92 6/91 0.57% 3.79[1.62,8.88]
Lerman 2015 69/418 50/408 4.8% 1.35[0.96,1.89]
Favours control 500.02 100.1 1 Favours NRT
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Study or subgroup Nicotine patch Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Otero 2006 193/597 122/602 11.52% 1.6[1.31,1.94]
Paoletti 1996 15/60 4/60 0.38% 3.75[1.32,10.64]
Perng 1998 9/30 3/32 0.28% 3.2[0.96,10.71]
Scherphof 2014 6/136 8/129 0.78% 0.71[0.25,1.99]
Subtotal (95% CI) 2067 1789 21.92% 1.66[1.44,1.93]
Total events: 401 (Nicotine patch), 232 (Control)  
Heterogeneity: Tau2=0; Chi2=12.71, df=8(P=0.12); I2=37.05%  
Test for overall effect: Z=6.76(P<0.0001)  
   
2.2.4 PP/uncertain 6 months  
Cummins 2016 44/637 38/633 3.62% 1.15[0.76,1.75]
Cunningham 2016 14/500 5/499 0.47% 2.79[1.01,7.7]
Fiore 1994a 15/44 9/44 0.85% 1.67[0.82,3.4]
Fiore 1994b 10/57 4/55 0.39% 2.41[0.8,7.24]
Glavas 2003b 29/80 12/80 1.14% 2.42[1.33,4.39]
Lewis 1998 6/62 7/123 0.45% 1.7[0.6,4.84]
Moolchan 2005 9/34 2/40 0.17% 5.29[1.23,22.85]
Piper 2009 90/262 8/37 1.33% 1.59[0.84,3]
Sønderskov 1997 20/251 14/267 1.29% 1.52[0.78,2.94]
Tuisku 2016 19/94 13/86 1.29% 1.34[0.7,2.54]
Subtotal (95% CI) 2021 1864 10.99% 1.64[1.32,2.04]
Total events: 256 (Nicotine patch), 112 (Control)  
Heterogeneity: Tau2=0; Chi2=8.82, df=9(P=0.45); I2=0%  
Test for overall effect: Z=4.49(P<0.0001)  
   
Total (95% CI) 12883 11093 100% 1.63[1.52,1.75]
Total events: 1965 (Nicotine patch), 1018 (Control)  
Heterogeneity: Tau2=0; Chi2=61.81, df=48(P=0.09); I2=22.35%  
Test for overall effect: Z=13.32(P<0.0001)  
Test for subgroup differences: Chi2=1.59, df=1 (P=0.66), I2=0%  
Favours control 500.02 100.1 1 Favours NRT
 
 
Comparison 3.   Subgroup: Level of behavioural support





Statistical method Effect size
1 Nicotine gum. Smoking cessa-
tion
55 21759 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [1.40, 1.61]
1.1 Low intensity support 17 11257 Risk Ratio (M-H, Fixed, 95% CI) 1.66 [1.46, 1.88]
1.2 High intensity individual sup-
port
18 6891 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [1.18, 1.49]
1.3 High intensity group-based
support
20 3611 Risk Ratio (M-H, Fixed, 95% CI) 1.57 [1.40, 1.76]
2 Nicotine patch. Smoking cessa-
tion
49 23657 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [1.56, 1.79]
Nicotine replacement therapy versus control for smoking cessation (Review)









Cochrane Database of Systematic Reviews





Statistical method Effect size
2.1 Low intensity support 15 7310 Risk Ratio (M-H, Fixed, 95% CI) 1.76 [1.54, 2.02]
2.2 High intensity individual sup-
port
25 12709 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [1.47, 1.81]
2.3 High intensity group-based
support
10 3638 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [1.43, 1.90]
 
 
Analysis 3.1.   Comparison 3 Subgroup: Level of behavioural support, Outcome 1 Nicotine gum. Smoking cessation.
Study or subgroup Nicotine gum Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.1.1 Low intensity support  
Br Thor Society 1983 39/410 111/1208 5.13% 1.04[0.73,1.46]
Campbell 1987 13/424 9/412 0.83% 1.4[0.61,3.25]
Fagerström 1984 28/96 5/49 0.6% 2.86[1.18,6.94]
Fortmann 1995 110/552 84/522 7.88% 1.24[0.96,1.6]
Gilbert 1989 11/112 9/111 0.82% 1.21[0.52,2.81]
Harackiewicz 1988 12/99 7/52 0.84% 0.9[0.38,2.15]
Hughes 1989a 23/210 6/105 0.73% 1.92[0.81,4.56]
Hughes 1990 15/59 5/19 0.69% 0.97[0.4,2.31]
Jamrozik 1984 10/101 8/99 0.74% 1.23[0.5,2.98]
Mori 1992 30/178 22/186 1.96% 1.42[0.86,2.37]
Nebot 1992 5/106 13/319 0.59% 1.16[0.42,3.17]
Page 1986 9/93 13/182 0.8% 1.35[0.6,3.05]
Roto 1987 19/54 7/60 0.61% 3.02[1.38,6.61]
Russell 1983 81/729 78/1377 4.93% 1.96[1.46,2.64]
Schneider 1983b 1/13 3/23 0.2% 0.59[0.07,5.11]
Shiffman 2009 (2 mg) 24/819 9/817 0.82% 2.66[1.24,5.69]
Shiffman 2009 (4 mg) 101/830 24/831 2.19% 4.21[2.73,6.51]
Subtotal (95% CI) 4885 6372 30.36% 1.66[1.46,1.88]
Total events: 531 (Nicotine gum), 413 (Control)  
Heterogeneity: Tau2=0; Chi2=42.62, df=16(P=0); I2=62.45%  
Test for overall effect: Z=7.74(P<0.0001)  
   
3.1.2 High intensity individual support  
Ahluwalia 2006 53/378 42/377 3.84% 1.26[0.86,1.84]
Areechon 1988 56/99 37/101 3.34% 1.54[1.13,2.1]
Campbell 1991 21/107 21/105 1.93% 0.98[0.57,1.69]
Clavel-Chapelon 1992 47/481 42/515 3.7% 1.2[0.81,1.78]
Cooper 2005 17/146 15/147 1.36% 1.14[0.59,2.2]
Fagerström 1982 30/50 23/50 2.1% 1.3[0.9,1.9]
Garvey 2000 75/405 17/203 2.07% 2.21[1.34,3.64]
Gross 1995 37/131 6/46 0.81% 2.17[0.98,4.79]
Jensen 1991 49/211 19/82 2.5% 1[0.63,1.59]
Killen 1990 129/600 112/617 10.08% 1.18[0.94,1.49]
Malcolm 1980 6/73 3/121 0.21% 3.32[0.86,12.85]
Moolchan 2005 8/46 2/40 0.2% 3.48[0.78,15.44]
Favours control 200.05 50.2 1 Favours NRT
Nicotine replacement therapy versus control for smoking cessation (Review)
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Study or subgroup Nicotine gum Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nakamura 1990 13/30 5/30 0.46% 2.6[1.06,6.39]
Niaura 1994 5/84 4/89 0.35% 1.32[0.37,4.77]
Oncken 2008 11/100 9/94 0.85% 1.15[0.5,2.65]
Richmond 1993 17/200 14/150 1.46% 0.91[0.46,1.79]
Schneider 1983a 9/30 6/30 0.55% 1.5[0.61,3.69]
Segnan 1991 22/294 37/629 2.15% 1.27[0.76,2.12]
Subtotal (95% CI) 3465 3426 37.94% 1.32[1.18,1.49]
Total events: 605 (Nicotine gum), 414 (Control)  
Heterogeneity: Tau2=0; Chi2=17.42, df=17(P=0.43); I2=2.39%  
Test for overall effect: Z=4.8(P<0.0001)  
   
3.1.3 High intensity group-based support  
Blondal 1989 30/92 22/90 2.03% 1.33[0.84,2.13]
Clavel 1985 24/205 6/222 0.53% 4.33[1.81,10.38]
Fee 1982 23/180 15/172 1.4% 1.47[0.79,2.71]
García 1989 21/68 5/38 0.59% 2.35[0.96,5.72]
Hall 1985 18/41 10/36 0.97% 1.58[0.84,2.97]
Hall 1987 30/71 14/68 1.3% 2.05[1.2,3.52]
Hall 1996 24/98 28/103 2.49% 0.9[0.56,1.44]
Herrera 1995 37/76 17/78 1.53% 2.23[1.38,3.61]
Hjalmarson 1984 31/106 16/100 1.5% 1.83[1.07,3.13]
Huber 1988 13/54 11/60 0.95% 1.31[0.64,2.68]
Jarvis 1982 22/58 9/58 0.82% 2.44[1.23,4.85]
Killen 1984 16/44 6/20 0.75% 1.21[0.56,2.63]
Llivina 1988 61/113 28/103 2.67% 1.99[1.39,2.84]
McGovern 1992 51/146 40/127 3.9% 1.11[0.79,1.56]
Niaura 1999 1/31 2/31 0.18% 0.5[0.05,5.23]
Pirie 1992 75/206 50/211 4.51% 1.54[1.14,2.08]
Puska 1979 29/116 21/113 1.94% 1.35[0.82,2.21]
Tønnesen 1988 23/60 12/53 1.16% 1.69[0.94,3.06]
Villa 1999 11/21 10/26 0.82% 1.36[0.72,2.57]
Zelman 1992 23/58 18/58 1.64% 1.28[0.78,2.1]
Subtotal (95% CI) 1844 1767 31.69% 1.57[1.4,1.76]
Total events: 563 (Nicotine gum), 340 (Control)  
Heterogeneity: Tau2=0; Chi2=25.32, df=19(P=0.15); I2=24.96%  
Test for overall effect: Z=7.64(P<0.0001)  
   
Total (95% CI) 10194 11565 100% 1.5[1.4,1.61]
Total events: 1699 (Nicotine gum), 1167 (Control)  
Heterogeneity: Tau2=0; Chi2=90.9, df=54(P=0); I2=40.6%  
Test for overall effect: Z=11.6(P<0.0001)  
Test for subgroup differences: Chi2=7.36, df=1 (P=0.03), I2=72.83%  
Favours control 200.05 50.2 1 Favours NRT
 
 
Analysis 3.2.   Comparison 3 Subgroup: Level of behavioural support, Outcome 2 Nicotine patch. Smoking cessation.
Study or subgroup Nicotine patch Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.2.1 Low intensity support  
Favours control 500.02 100.1 1 Favours NRT
Nicotine replacement therapy versus control for smoking cessation (Review)
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Study or subgroup Nicotine patch Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Abelin 1989 17/100 11/99 1.03% 1.53[0.76,3.1]
Cunningham 2016 14/500 5/499 0.46% 2.79[1.01,7.7]
Daughton 1991 28/106 4/52 0.5% 3.43[1.27,9.28]
Daughton 1998 25/184 16/185 1.48% 1.57[0.87,2.84]
Davidson 1998 33/401 16/401 1.48% 2.06[1.15,3.69]
Glavas 2003a 13/56 9/56 0.84% 1.44[0.67,3.1]
Glavas 2003b 29/80 12/80 1.11% 2.42[1.33,4.39]
Hays 1999 62/636 14/322 1.72% 2.24[1.28,3.94]
Killen 1997 23/212 21/212 1.95% 1.1[0.63,1.92]
Lewis 1998 6/62 7/123 0.44% 1.7[0.6,4.84]
NCT00534404 194/830 109/828 10.13% 1.78[1.43,2.2]
Otero 2006 57/189 39/194 3.57% 1.5[1.05,2.14]
Paoletti 1996 15/60 4/60 0.37% 3.75[1.32,10.64]
Scherphof 2014 6/136 8/129 0.76% 0.71[0.25,1.99]
Sønderskov 1997 20/251 14/267 1.26% 1.52[0.78,2.94]
Subtotal (95% CI) 3803 3507 27.1% 1.76[1.54,2.02]
Total events: 542 (Nicotine patch), 289 (Control)  
Heterogeneity: Tau2=0; Chi2=13.9, df=14(P=0.46); I2=0%  
Test for overall effect: Z=8.3(P<0.0001)  
   
3.2.2 High intensity individual support  
Ahluwalia 1998 35/205 24/205 2.23% 1.46[0.9,2.36]
Anthenelli 2016 320/2038 191/2035 17.74% 1.67[1.41,1.98]
Campbell 1996 24/115 17/119 1.55% 1.46[0.83,2.57]
Coleman 2012 49/521 40/529 3.68% 1.24[0.83,1.86]
Ehrsam 1991 7/56 2/56 0.19% 3.5[0.76,16.12]
Fiore 1994b 10/57 4/55 0.38% 2.41[0.8,7.24]
Gallagher 2007 1/60 4/60 0.37% 0.25[0.03,2.17]
Heydari 2012 23/92 6/91 0.56% 3.79[1.62,8.88]
Hurt 1990 8/31 6/31 0.56% 1.33[0.52,3.39]
Hurt 1994 33/120 17/120 1.58% 1.94[1.15,3.29]
ICRF 1994 76/842 53/844 4.91% 1.44[1.03,2.01]
Jorenby 1999 24/244 9/160 1.01% 1.75[0.83,3.66]
Joseph 1996 29/294 34/290 3.18% 0.84[0.53,1.34]
Kornitzer 1995 19/150 10/75 1.24% 0.95[0.47,1.94]
Moolchan 2005 9/34 2/40 0.17% 5.29[1.23,22.85]
Perng 1998 9/30 3/32 0.27% 3.2[0.96,10.71]
Piper 2009 90/262 8/37 1.3% 1.59[0.84,3]
Sachs 1993 28/113 10/107 0.95% 2.65[1.35,5.19]
Stapleton 1995 77/800 19/400 2.35% 2.03[1.24,3.3]
Tuisku 2016 19/94 13/86 1.26% 1.34[0.7,2.54]
Tønnesen 1991 24/145 6/144 0.56% 3.97[1.67,9.43]
Tønnesen 2000 9/104 2/109 0.18% 4.72[1.04,21.32]
Ward 2013 17/134 16/135 1.48% 1.07[0.56,2.03]
Westman 1993 16/78 2/80 0.18% 8.21[1.95,34.51]
Wisborg 2000 19/124 18/126 1.66% 1.07[0.59,1.94]
Subtotal (95% CI) 6743 5966 49.52% 1.63[1.47,1.81]
Total events: 975 (Nicotine patch), 516 (Control)  
Heterogeneity: Tau2=0; Chi2=42.61, df=24(P=0.01); I2=43.68%  
Test for overall effect: Z=9.4(P<0.0001)  
   
3.2.3 High intensity group-based support  
Favours control 500.02 100.1 1 Favours NRT
Nicotine replacement therapy versus control for smoking cessation (Review)
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Study or subgroup Nicotine patch Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Buchkremer 1988 11/42 16/89 0.95% 1.46[0.74,2.86]
Cinciripini 1996 12/32 7/32 0.65% 1.71[0.78,3.79]
Fiore 1994a 15/44 9/43 0.84% 1.63[0.8,3.32]
Hughes 1999 171/779 34/260 4.73% 1.68[1.19,2.36]
Hughes 2003 13/61 8/54 0.79% 1.44[0.65,3.2]
Oncken 2007 19/57 28/95 1.95% 1.13[0.7,1.83]
Otero 2006 136/408 83/408 7.7% 1.64[1.29,2.07]
Prapavessis 2007 13/59 7/62 0.63% 1.95[0.84,4.55]
Richmond 1994 29/153 14/152 1.3% 2.06[1.13,3.74]
TNSG 1991 111/537 31/271 3.82% 1.81[1.25,2.62]
Subtotal (95% CI) 2172 1466 23.38% 1.65[1.43,1.9]
Total events: 530 (Nicotine patch), 237 (Control)  
Heterogeneity: Tau2=0; Chi2=3.55, df=9(P=0.94); I2=0%  
Test for overall effect: Z=6.88(P<0.0001)  
   
Total (95% CI) 12718 10939 100% 1.67[1.56,1.79]
Total events: 2047 (Nicotine patch), 1042 (Control)  
Heterogeneity: Tau2=0; Chi2=61.01, df=49(P=0.12); I2=19.68%  
Test for overall effect: Z=14.27(P<0.0001)  
Test for subgroup differences: Chi2=0.87, df=1 (P=0.65), I2=0%  
Favours control 500.02 100.1 1 Favours NRT
 
 
Comparison 4.   Subgroup: Recruitment/treatment setting





Statistical method Effect size
1 Community volunteer (treatment
provided in medical setting)
65 24597 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [1.53, 1.72]
1.1 Nicotine gum 28 8336 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [1.28, 1.53]
1.2 Nicotine patch 27 11214 Risk Ratio (M-H, Fixed, 95% CI) 1.74 [1.59, 1.91]
1.3 Nicotine inhalator 2 443 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [0.98, 3.27]
1.4 Nicotine tablet/lozenge 7 3405 Risk Ratio (M-H, Fixed, 95% CI) 1.95 [1.61, 2.36]
1.5 Nicotine intranasal spray 2 412 Risk Ratio (M-H, Fixed, 95% CI) 1.85 [1.16, 2.95]
1.6 Combination of NRT 1 308 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [1.01, 3.31]
1.7 Nicotine oral spray 1 479 Risk Ratio (M-H, Fixed, 95% CI) 2.48 [1.24, 4.94]
2 Smoking clinic 12 3300 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.48, 1.96]
2.1 Nicotine gum 6 1283 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [1.30, 1.91]
2.2 Nicotine inhalator 2 533 Risk Ratio (M-H, Fixed, 95% CI) 1.96 [1.30, 2.95]
Nicotine replacement therapy versus control for smoking cessation (Review)
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Statistical method Effect size
2.3 Nicotine intranasal spray 2 475 Risk Ratio (M-H, Fixed, 95% CI) 2.15 [1.44, 3.20]
2.4 Nicotine patch 2 1009 Risk Ratio (M-H, Fixed, 95% CI) 1.61 [1.18, 2.19]
3 Primary care 24 11974 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [1.33, 1.69]
3.1 Nicotine gum 16 7277 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [1.35, 1.85]
3.2 Nicotine patch 7 4419 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [1.15, 1.71]
3.3 Choice of NRT products 1 278 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [0.83, 2.30]
4 Hospitals 13 7037 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [1.24, 1.55]
4.1 Nicotine gum 3 2194 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.86, 1.43]
4.2 Nicotine patch 6 2492 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [1.10, 1.78]
4.3 Combination of NRT 2 326 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.64, 1.52]
4.4 Choice of NRT products 2 2025 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [1.36, 1.86]
5 Community volunteer (treatment
provided in 'over-the-counter' set-
ting)
9 13163 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [1.26, 1.55]
5.1 Nicotine gum 2 3297 Risk Ratio (M-H, Fixed, 95% CI) 3.79 [2.60, 5.52]
5.2 Nicotine patch 5 3542 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [1.38, 2.55]
5.3 Tablets/lozenges 1 1034 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.89, 1.32]
5.4 Choice of product 1 5290 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [1.03, 1.37]
6 Antenatal clinic 4 1675 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.92, 1.62]
6.1 Nicotine gum 1 194 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.50, 2.65]
6.2 Nicotine patch 2 1300 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.85, 1.66]
6.3 Choice of NRT products 1 181 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.69, 3.03]
 
 
Analysis 4.1.   Comparison 4 Subgroup: Recruitment/treatment setting,
Outcome 1 Community volunteer (treatment provided in medical setting).
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.1.1 Nicotine gum  
Ahluwalia 2006 53/378 42/377 2.86% 1.26[0.86,1.84]
Favours control 1000.01 100.1 1 Favours NRT
Nicotine replacement therapy versus control for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Areechon 1988 56/99 37/101 2.5% 1.54[1.13,2.1]
Blondal 1989 30/92 22/90 1.51% 1.33[0.84,2.13]
Clavel 1985 24/205 6/222 0.39% 4.33[1.81,10.38]
Clavel-Chapelon 1992 47/481 42/515 2.76% 1.2[0.81,1.78]
Cooper 2005 17/146 15/147 1.02% 1.14[0.59,2.2]
Fortmann 1995 110/552 84/522 5.88% 1.24[0.96,1.6]
Garvey 2000 75/405 17/203 1.54% 2.21[1.34,3.64]
Gross 1995 37/131 6/46 0.6% 2.17[0.98,4.79]
Hall 1985 18/41 10/36 0.73% 1.58[0.84,2.97]
Hall 1987 30/71 14/68 0.97% 2.05[1.2,3.52]
Hall 1996 24/98 28/103 1.86% 0.9[0.56,1.44]
Herrera 1995 30/76 13/78 0.87% 2.37[1.34,4.18]
Huber 1988 13/54 11/60 0.71% 1.31[0.64,2.68]
Hughes 1990 15/59 5/19 0.52% 0.97[0.4,2.31]
Killen 1984 16/44 6/20 0.56% 1.21[0.56,2.63]
Killen 1990 129/600 112/617 7.52% 1.18[0.94,1.49]
Malcolm 1980 6/73 3/121 0.15% 3.32[0.86,12.85]
McGovern 1992 51/146 40/127 2.91% 1.11[0.79,1.56]
Moolchan 2005 8/46 2/40 0.15% 3.48[0.78,15.44]
Nakamura 1990 13/30 5/30 0.34% 2.6[1.06,6.39]
Niaura 1999 1/31 2/31 0.14% 0.5[0.05,5.23]
Pirie 1992 75/206 50/211 3.36% 1.54[1.14,2.08]
Puska 1979 29/116 21/113 1.45% 1.35[0.82,2.21]
Schneider 1983a 9/30 6/30 0.41% 1.5[0.61,3.69]
Schneider 1983b 1/13 3/23 0.15% 0.59[0.07,5.11]
Villa 1999 11/21 10/26 0.61% 1.36[0.72,2.57]
Zelman 1992 23/58 18/58 1.23% 1.28[0.78,2.1]
Subtotal (95% CI) 4302 4034 43.72% 1.4[1.28,1.53]
Total events: 951 (NRT), 630 (Control)  
Heterogeneity: Tau2=0; Chi2=33.51, df=27(P=0.18); I2=19.43%  
Test for overall effect: Z=7.27(P<0.0001)  
   
4.1.2 Nicotine patch  
Anthenelli 2016 320/2038 191/2035 13.02% 1.67[1.41,1.98]
Buchkremer 1988 11/42 16/89 0.7% 1.46[0.74,2.86]
Cinciripini 1996 12/32 7/32 0.48% 1.71[0.78,3.79]
Daughton 1991 28/106 4/52 0.37% 3.43[1.27,9.28]
Fiore 1994a 15/44 9/44 0.61% 1.67[0.82,3.4]
Fiore 1994b 10/57 4/55 0.28% 2.41[0.8,7.24]
Glavas 2003a 13/56 9/56 0.61% 1.44[0.67,3.1]
Glavas 2003b 29/80 12/80 0.82% 2.42[1.33,4.39]
Hughes 1999 171/779 34/260 3.47% 1.68[1.19,2.36]
Hughes 2003 13/61 8/54 0.58% 1.44[0.65,3.2]
Hurt 1990 8/31 6/31 0.41% 1.33[0.52,3.39]
Hurt 1994 33/120 17/120 1.16% 1.94[1.15,3.29]
Jorenby 1999 24/244 9/160 0.74% 1.75[0.83,3.66]
Killen 1997 23/212 21/212 1.43% 1.1[0.63,1.92]
Kornitzer 1995 19/150 10/75 0.91% 0.95[0.47,1.94]
Moolchan 2005 9/34 2/40 0.13% 5.29[1.23,22.85]
Oncken 2007 19/57 28/95 1.43% 1.13[0.7,1.83]
Otero 2006 193/597 122/602 8.28% 1.6[1.31,1.94]
Paoletti 1996 15/60 4/60 0.27% 3.75[1.32,10.64]
Favours control 1000.01 100.1 1 Favours NRT
Nicotine replacement therapy versus control for smoking cessation (Review)
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Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Perng 1998 9/30 3/32 0.2% 3.2[0.96,10.71]
Piper 2009 90/262 8/37 0.95% 1.59[0.84,3]
Prapavessis 2007 13/59 7/62 0.46% 1.95[0.84,4.55]
Richmond 1994 29/153 14/152 0.96% 2.06[1.13,3.74]
Sachs 1993 28/113 10/107 0.7% 2.65[1.35,5.19]
TNSG 1991 111/537 31/271 2.81% 1.81[1.25,2.62]
Tønnesen 1991 24/145 6/144 0.41% 3.97[1.67,9.43]
Westman 1993 16/78 2/80 0.13% 8.21[1.95,34.51]
Subtotal (95% CI) 6177 5037 42.31% 1.74[1.59,1.91]
Total events: 1285 (NRT), 594 (Control)  
Heterogeneity: Tau2=0; Chi2=29.29, df=26(P=0.3); I2=11.22%  
Test for overall effect: Z=11.94(P<0.0001)  
   
4.1.3 Nicotine inhalator  
Leischow 1996a 12/110 6/110 0.41% 2[0.78,5.14]
Schneider 1996 15/112 9/111 0.62% 1.65[0.75,3.62]
Subtotal (95% CI) 222 221 1.02% 1.79[0.98,3.27]
Total events: 27 (NRT), 15 (Control)  
Heterogeneity: Tau2=0; Chi2=0.09, df=1(P=0.76); I2=0%  
Test for overall effect: Z=1.9(P=0.06)  
   
4.1.4 Nicotine tablet/lozenge  
Dautzenberg 2001 25/211 18/222 1.19% 1.46[0.82,2.6]
Glover 2002 22/120 12/121 0.81% 1.85[0.96,3.56]
Piper 2009 87/260 8/36 0.96% 1.51[0.8,2.84]
Shiffman 2002 (2 mg) 82/459 44/458 3% 1.86[1.32,2.62]
Shiffman 2002 (4 mg) 67/450 28/451 1.91% 2.4[1.57,3.65]
Tønnesen 2006 26/185 5/185 0.34% 5.2[2.04,13.25]
Wallstrom 2000 28/123 19/124 1.29% 1.49[0.88,2.52]
Subtotal (95% CI) 1808 1597 9.5% 1.95[1.61,2.36]
Total events: 337 (NRT), 134 (Control)  
Heterogeneity: Tau2=0; Chi2=7.88, df=6(P=0.25); I2=23.84%  
Test for overall effect: Z=6.81(P<0.0001)  
   
4.1.5 Nicotine intranasal spray  
Blondal 1997 20/79 13/78 0.89% 1.52[0.81,2.84]
Schneider 1995 23/128 10/127 0.68% 2.28[1.13,4.6]
Subtotal (95% CI) 207 205 1.57% 1.85[1.16,2.95]
Total events: 43 (NRT), 23 (Control)  
Heterogeneity: Tau2=0; Chi2=0.73, df=1(P=0.39); I2=0%  
Test for overall effect: Z=2.59(P=0.01)  
   
4.1.6 Combination of NRT  
Piper 2009 107/267 9/41 1.06% 1.83[1.01,3.31]
Subtotal (95% CI) 267 41 1.06% 1.83[1.01,3.31]
Total events: 107 (NRT), 9 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.98(P=0.05)  
   
4.1.7 Nicotine oral spray  
Tønnesen 2012 44/318 9/161 0.81% 2.48[1.24,4.94]
Subtotal (95% CI) 318 161 0.81% 2.48[1.24,4.94]
Favours control 1000.01 100.1 1 Favours NRT
Nicotine replacement therapy versus control for smoking cessation (Review)
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Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total events: 44 (NRT), 9 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.57(P=0.01)  
   
Total (95% CI) 13301 11296 100% 1.62[1.53,1.72]
Total events: 2794 (NRT), 1414 (Control)  
Heterogeneity: Tau2=0; Chi2=89.74, df=67(P=0.03); I2=25.34%  
Test for overall effect: Z=15.92(P<0.0001)  
Test for subgroup differences: Chi2=18.68, df=1 (P=0), I2=67.88%  
Favours control 1000.01 100.1 1 Favours NRT
 
 
Analysis 4.2.   Comparison 4 Subgroup: Recruitment/treatment setting, Outcome 2 Smoking clinic.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.2.1 Nicotine gum  
Fagerström 1982 30/50 23/50 9.77% 1.3[0.9,1.9]
Fee 1982 23/180 15/172 6.51% 1.47[0.79,2.71]
Hjalmarson 1984 31/106 16/100 6.99% 1.83[1.07,3.13]
Jarvis 1982 22/58 9/58 3.82% 2.44[1.23,4.85]
Jensen 1991 49/211 19/82 11.62% 1[0.63,1.59]
Llivina 1988 61/113 28/103 12.44% 1.99[1.39,2.84]
Subtotal (95% CI) 718 565 51.15% 1.58[1.3,1.91]
Total events: 216 (NRT), 110 (Control)  
Heterogeneity: Tau2=0; Chi2=8.15, df=5(P=0.15); I2=38.61%  
Test for overall effect: Z=4.66(P<0.0001)  
   
4.2.2 Nicotine inhalator  
Hjalmarson 1997 35/123 22/124 9.3% 1.6[1,2.57]
Tønnesen 1993 22/145 7/141 3.01% 3.06[1.35,6.93]
Subtotal (95% CI) 268 265 12.32% 1.96[1.3,2.95]
Total events: 57 (NRT), 29 (Control)  
Heterogeneity: Tau2=0; Chi2=1.83, df=1(P=0.18); I2=45.25%  
Test for overall effect: Z=3.23(P=0)  
   
4.2.3 Nicotine intranasal spray  
Hjalmarson 1994 34/125 18/123 7.7% 1.86[1.11,3.11]
Sutherland 1992 30/116 11/111 4.77% 2.61[1.38,4.95]
Subtotal (95% CI) 241 234 12.48% 2.15[1.44,3.2]
Total events: 64 (NRT), 29 (Control)  
Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%  
Test for overall effect: Z=3.74(P=0)  
   
4.2.4 Nicotine patch  
Heydari 2012 23/92 6/91 2.56% 3.79[1.62,8.88]
Lerman 2015 69/418 50/408 21.49% 1.35[0.96,1.89]
Subtotal (95% CI) 510 499 24.05% 1.61[1.18,2.19]
Total events: 92 (NRT), 56 (Control)  
Heterogeneity: Tau2=0; Chi2=4.97, df=1(P=0.03); I2=79.86%  
Favours control 1000.01 100.1 1 Favours NRT
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Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Test for overall effect: Z=3.01(P=0)  
   
Total (95% CI) 1737 1563 100% 1.7[1.48,1.96]
Total events: 429 (NRT), 224 (Control)  
Heterogeneity: Tau2=0; Chi2=18.11, df=11(P=0.08); I2=39.27%  
Test for overall effect: Z=7.34(P<0.0001)  
Test for subgroup differences: Chi2=2.46, df=1 (P=0.48), I2=0%  
Favours control 1000.01 100.1 1 Favours NRT
 
 
Analysis 4.3.   Comparison 4 Subgroup: Recruitment/treatment setting, Outcome 3 Primary care.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.3.1 Nicotine gum  
Campbell 1987 13/424 9/412 2.29% 1.4[0.61,3.25]
Fagerström 1984 28/96 5/49 1.66% 2.86[1.18,6.94]
García 1989 21/68 5/38 1.61% 2.35[0.96,5.72]
Gilbert 1989 11/112 9/111 2.26% 1.21[0.52,2.81]
Harackiewicz 1988 12/99 7/52 2.3% 0.9[0.38,2.15]
Hughes 1989a 23/210 6/105 2% 1.92[0.81,4.56]
Jamrozik 1984 10/101 8/99 2.02% 1.23[0.5,2.98]
Nebot 1992 5/106 13/319 1.62% 1.16[0.42,3.17]
Niaura 1994 5/84 4/89 0.97% 1.32[0.37,4.77]
Ockene 1991 40/402 33/420 8.08% 1.27[0.82,1.97]
Page 1986 9/93 13/182 2.2% 1.35[0.6,3.05]
Richmond 1993 17/200 14/150 4.01% 0.91[0.46,1.79]
Roto 1987 19/54 7/60 1.66% 3.02[1.38,6.61]
Russell 1983 81/729 78/1377 13.52% 1.96[1.46,2.64]
Segnan 1991 22/294 37/629 5.9% 1.27[0.76,2.12]
Tønnesen 1988 23/60 12/53 3.19% 1.69[0.94,3.06]
Subtotal (95% CI) 3132 4145 55.31% 1.58[1.35,1.85]
Total events: 339 (NRT), 260 (Control)  
Heterogeneity: Tau2=0; Chi2=14.54, df=15(P=0.49); I2=0%  
Test for overall effect: Z=5.67(P<0.0001)  
   
4.3.2 Nicotine patch  
Abelin 1989 17/100 11/99 2.77% 1.53[0.76,3.1]
Daughton 1998 25/184 16/185 4% 1.57[0.87,2.84]
Ehrsam 1991 7/56 2/56 0.5% 3.5[0.76,16.12]
ICRF 1994 76/842 53/844 13.26% 1.44[1.03,2.01]
Joseph 1996 29/294 35/290 8.82% 0.82[0.51,1.3]
Stapleton 1995 77/800 19/400 6.34% 2.03[1.24,3.3]
Ward 2013 17/134 16/135 3.99% 1.07[0.56,2.03]
Subtotal (95% CI) 2410 2009 39.68% 1.4[1.15,1.71]
Total events: 248 (NRT), 152 (Control)  
Heterogeneity: Tau2=0; Chi2=9.66, df=6(P=0.14); I2=37.89%  
Test for overall effect: Z=3.37(P=0)  
   
4.3.3 Choice of NRT products  
Favours control 1000.01 100.1 1 Favours NRT
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Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Wittchen 2011 22/103 27/175 5.01% 1.38[0.83,2.3]
Subtotal (95% CI) 103 175 5.01% 1.38[0.83,2.3]
Total events: 22 (NRT), 27 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.26(P=0.21)  
   
Total (95% CI) 5645 6329 100% 1.5[1.33,1.69]
Total events: 609 (NRT), 439 (Control)  
Heterogeneity: Tau2=0; Chi2=25.3, df=23(P=0.33); I2=9.09%  
Test for overall effect: Z=6.63(P<0.0001)  
Test for subgroup differences: Chi2=0.95, df=1 (P=0.62), I2=0%  
Favours control 1000.01 100.1 1 Favours NRT
 
 
Analysis 4.4.   Comparison 4 Subgroup: Recruitment/treatment setting, Outcome 4 Hospitals.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.4.1 Nicotine gum  
Br Thor Society 1983 39/410 111/1208 13.17% 1.04[0.73,1.46]
Campbell 1991 21/107 21/105 4.96% 0.98[0.57,1.69]
Mori 1992 30/178 22/186 5.04% 1.42[0.86,2.37]
Subtotal (95% CI) 695 1499 23.18% 1.11[0.86,1.43]
Total events: 90 (NRT), 154 (Control)  
Heterogeneity: Tau2=0; Chi2=1.27, df=2(P=0.53); I2=0%  
Test for overall effect: Z=0.8(P=0.43)  
   
4.4.2 Nicotine patch  
Ahluwalia 1998 35/205 24/205 5.62% 1.46[0.9,2.36]
Campbell 1996 24/115 17/119 3.91% 1.46[0.83,2.57]
Cummins 2016 44/637 38/633 8.93% 1.15[0.76,1.75]
Lewis 1998 6/62 7/123 1.1% 1.7[0.6,4.84]
Tuisku 2016 19/94 13/86 3.18% 1.34[0.7,2.54]
Tønnesen 2000 9/104 2/109 0.46% 4.72[1.04,21.32]
Subtotal (95% CI) 1217 1275 23.2% 1.4[1.1,1.78]
Total events: 137 (NRT), 101 (Control)  
Heterogeneity: Tau2=0; Chi2=3.53, df=5(P=0.62); I2=0%  
Test for overall effect: Z=2.72(P=0.01)  
   
4.4.3 Combination of NRT  
Hand 2002 20/136 15/109 3.9% 1.07[0.57,1.99]
Hasan 2014 13/40 15/41 3.47% 0.89[0.49,1.62]
Subtotal (95% CI) 176 150 7.37% 0.98[0.64,1.52]
Total events: 33 (NRT), 30 (Control)  
Heterogeneity: Tau2=0; Chi2=0.18, df=1(P=0.67); I2=0%  
Test for overall effect: Z=0.07(P=0.94)  
   
4.4.4 Choice of NRT products  
Molyneux 2003 10/91 4/91 0.94% 2.5[0.81,7.68]
Ortega 2011 305/924 193/919 45.32% 1.57[1.35,1.84]
Favours control 1000.01 100.1 1 Favours NRT
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Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Subtotal (95% CI) 1015 1010 46.26% 1.59[1.36,1.86]
Total events: 315 (NRT), 197 (Control)  
Heterogeneity: Tau2=0; Chi2=0.65, df=1(P=0.42); I2=0%  
Test for overall effect: Z=5.9(P<0.0001)  
   
Total (95% CI) 3103 3934 100% 1.39[1.24,1.55]
Total events: 575 (NRT), 482 (Control)  
Heterogeneity: Tau2=0; Chi2=14.16, df=12(P=0.29); I2=15.23%  
Test for overall effect: Z=5.78(P<0.0001)  
Test for subgroup differences: Chi2=8.43, df=1 (P=0.04), I2=64.41%  
Favours control 1000.01 100.1 1 Favours NRT
 
 
Analysis 4.5.   Comparison 4 Subgroup: Recruitment/treatment setting, Outcome
5 Community volunteer (treatment provided in 'over-the-counter' setting).
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.5.1 Nicotine gum  
Shiffman 2009 (2 mg) 24/819 9/817 1.66% 2.66[1.24,5.69]
Shiffman 2009 (4 mg) 101/830 24/831 4.41% 4.21[2.73,6.51]
Subtotal (95% CI) 1649 1648 6.07% 3.79[2.6,5.52]
Total events: 125 (NRT), 33 (Control)  
Heterogeneity: Tau2=0; Chi2=1.06, df=1(P=0.3); I2=5.8%  
Test for overall effect: Z=6.95(P<0.0001)  
   
4.5.2 Nicotine patch  
Cunningham 2016 14/500 5/499 0.92% 2.79[1.01,7.7]
Davidson 1998 33/401 16/401 2.94% 2.06[1.15,3.69]
Hays 1999 62/636 14/322 3.42% 2.24[1.28,3.94]
Scherphof 2014 6/136 8/129 1.51% 0.71[0.25,1.99]
Sønderskov 1997 20/251 14/267 2.49% 1.52[0.78,2.94]
Subtotal (95% CI) 1924 1618 11.28% 1.88[1.38,2.55]
Total events: 135 (NRT), 57 (Control)  
Heterogeneity: Tau2=0; Chi2=4.87, df=4(P=0.3); I2=17.86%  
Test for overall effect: Z=4(P<0.0001)  
   
4.5.3 Tablets/lozenges  
Fraser 2014 151/518 139/516 25.61% 1.08[0.89,1.32]
Subtotal (95% CI) 518 516 25.61% 1.08[0.89,1.32]
Total events: 151 (NRT), 139 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.79(P=0.43)  
   
4.5.4 Choice of product  
Graham 2017 366/2630 312/2660 57.04% 1.19[1.03,1.37]
Subtotal (95% CI) 2630 2660 57.04% 1.19[1.03,1.37]
Total events: 366 (NRT), 312 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.38(P=0.02)  
Favours control 1000.01 100.1 1 Favours NRT
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Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
Total (95% CI) 6721 6442 100% 1.4[1.26,1.55]
Total events: 777 (NRT), 541 (Control)  
Heterogeneity: Tau2=0; Chi2=47.15, df=8(P<0.0001); I2=83.03%  
Test for overall effect: Z=6.38(P<0.0001)  
Test for subgroup differences: Chi2=41.41, df=1 (P<0.0001), I2=92.76%  
Favours control 1000.01 100.1 1 Favours NRT
 
 
Analysis 4.6.   Comparison 4 Subgroup: Recruitment/treatment setting, Outcome 6 Antenatal clinic.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.6.1 Nicotine gum  
Oncken 2008 11/100 9/94 11.95% 1.15[0.5,2.65]
Subtotal (95% CI) 100 94 11.95% 1.15[0.5,2.65]
Total events: 11 (NRT), 9 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.33(P=0.74)  
   
4.6.2 Nicotine patch  
Coleman 2012 49/521 40/529 51.14% 1.24[0.83,1.86]
Wisborg 2000 19/124 18/126 23.01% 1.07[0.59,1.94]
Subtotal (95% CI) 645 655 74.15% 1.19[0.85,1.66]
Total events: 68 (NRT), 58 (Control)  
Heterogeneity: Tau2=0; Chi2=0.16, df=1(P=0.69); I2=0%  
Test for overall effect: Z=1.03(P=0.3)  
   
4.6.3 Choice of NRT products  
Pollak 2007 24/122 8/59 13.9% 1.45[0.69,3.03]
Subtotal (95% CI) 122 59 13.9% 1.45[0.69,3.03]
Total events: 24 (NRT), 8 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.99(P=0.32)  
   
Total (95% CI) 867 808 100% 1.22[0.92,1.62]
Total events: 103 (NRT), 75 (Control)  
Heterogeneity: Tau2=0; Chi2=0.42, df=3(P=0.94); I2=0%  
Test for overall effect: Z=1.38(P=0.17)  
Test for subgroup differences: Chi2=0.25, df=1 (P=0.88), I2=0%  
Favours control 1000.01 100.1 1 Favours NRT
 
 
Comparison 5.   NRT in pregnancy





Statistical method Effect size
1 Smoking cessation 6   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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Statistical method Effect size
1.1 Abstinence at end of pregnancy 6 2129 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [1.04, 1.69]
1.2 Abstinence at longest post partum
follow-up
4 1675 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.90, 1.86]
 
 
Analysis 5.1.   Comparison 5 NRT in pregnancy, Outcome 1 Smoking cessation.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
5.1.1 Abstinence at end of pregnancy  
Berlin 2014 11/203 10/199 10.32% 1.08[0.47,2.48]
Coleman 2012 49/521 40/529 40.58% 1.24[0.83,1.86]
El-Mohandes 2013 5/26 0/26 0.51% 11[0.64,189.31]
Oncken 2008 18/100 14/94 14.75% 1.21[0.64,2.29]
Pollak 2007 17/122 1/59 1.38% 8.22[1.12,60.31]
Wisborg 2000 35/124 32/126 32.45% 1.11[0.74,1.68]
Subtotal (95% CI) 1096 1033 100% 1.32[1.04,1.69]
Total events: 135 (NRT), 97 (Control)  
Heterogeneity: Tau2=0; Chi2=6.46, df=5(P=0.26); I2=22.61%  
Test for overall effect: Z=2.25(P=0.02)  
   
5.1.2 Abstinence at longest post partum follow-up  
Coleman 2012 15/521 9/529 19.06% 1.69[0.75,3.83]
Oncken 2008 11/100 9/94 19.8% 1.15[0.5,2.65]
Pollak 2007 24/122 8/59 23.02% 1.45[0.69,3.03]
Wisborg 2000 19/124 18/126 38.11% 1.07[0.59,1.94]
Subtotal (95% CI) 867 808 100% 1.29[0.9,1.86]
Total events: 69 (NRT), 44 (Control)  
Heterogeneity: Tau2=0; Chi2=0.97, df=3(P=0.81); I2=0%  
Test for overall effect: Z=1.39(P=0.16)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.91), I2=0%  
Favours control 2000.005 100.1 1 Favours NRT
 
 
Comparison 6.   Palpitations in NRT vs placebo users




Statistical method Effect size
1 Palpitations/chest pains 15 11074 Odds Ratio (M-H, Fixed, 95% CI) 1.88 [1.37, 2.57]
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Analysis 6.1.   Comparison 6 Palpitations in NRT vs placebo users, Outcome 1 Palpitations/chest pains.
Study or subgroup NRT Placebo Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Bolliger 2000b 1/200 2/200 3.23% 0.5[0.04,5.53]
Brantmark 1973b 3/46 4/42 6.35% 0.66[0.14,3.15]
Bullen 2010 9/249 1/246 1.58% 9.19[1.16,73.07]
CEASE 1999 69/2861 6/714 15.22% 2.92[1.26,6.74]
Gourlay 1995 5/179 3/143 5.27% 1.34[0.32,5.71]
Hays 1999 5/321 2/322 3.19% 2.53[0.49,13.15]
Hjalmarson 1994 9/116 2/107 3.12% 4.42[0.93,20.92]
Oncken 2007 1/57 1/95 1.2% 1.68[0.1,27.37]
Schneider 1995 23/128 10/127 13.38% 2.56[1.17,5.63]
Schnoll 2010 0/182 2/134 4.66% 0.15[0.01,3.05]
Shiffman 2009 (4 mg) 6/1649 6/1648 9.71% 1[0.32,3.11]
Sutherland 1992 26/111 15/103 19.35% 1.79[0.89,3.62]
Sønderskov 1997 1/255 4/267 6.32% 0.26[0.03,2.33]
Tønnesen 1988 1/114 0/47 1.13% 1.26[0.05,31.38]
Wennike 2003b 6/205 4/206 6.29% 1.52[0.42,5.48]
   
Total (95% CI) 6673 4401 100% 1.88[1.37,2.57]
Total events: 165 (NRT), 62 (Placebo)  
Heterogeneity: Tau2=0; Chi2=15.5, df=14(P=0.35); I2=9.66%  
Test for overall effect: Z=3.93(P<0.0001)  
Placebo users 2000.005 100.1 1 NRT users
 
 
A D D I T I O N A L   T A B L E S
 
Type Available doses
Nicotine transdermal patches Worn over 16 hours: 5 mg, 10 mg, 15 mg, 25 mg doses
Worn over 24 hours: 7 mg, 14 mg, 20 mg, 21 mg, 30 mg doses*
Nicotine chewing gum 2 mg and 4 mg doses
Nicotine sublingual tablet 2 mg dose
Nicotine lozenge 1 mg, 1.5 mg, 2 mg and 4 mg doses
Nicotine inhalation cartridge plus mouthpiece Cartridge containing 10 mg
Nicotine metered nasal spray 0.5 mg dose/spray
Nicotine oral spray 1 mg dose/spray
Table 1.   Nicotine replacement therapies available in the UK 
Information extracted from British National Formulary
* 35 mg/24-hour and 53.5 mg/24-hour patches available in other regions.
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A P P E N D I C E S
Appendix 1. Specialized Register search strategy
#1 NRT: TI,AB,KY,XKY,MH,EMT
#2 (nicotine NEAR2 patch*):TI,AB,KY,XKY,MH,EMT
#3 (nicotine NEAR2 gum):TI,AB,KY,XKY,MH,EMT
#4 (nicotine NEAR2 nasal spray):TI,AB,KY,XKY,MH,EMT
#5 (nicotine NEAR2 lozenge*):TI,AB,KY,XKY,MH,EMT
#6 (nicotine NEAR2 tablet*):TI,AB,KY,XKY,MH,EMT
#7 (nicotine NEAR2 sublingual):TI,AB,KY,XKY,MH,EMT
#8 (nicotine NEAR2 inhal*):TI,AB,KY,XKY,MH,EMT
#9 (nicotine NEAR2 replacement):TI,AB,KY,XKY,MH,EMT
#10 (nicotine NEAR3 therap*):TI,AB,KY,XKY,MH,EMT
#11 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
The specialised register was transferred from Reference Manager to the CRS in May 2012. This is the search used for the CRS: KY, XKY, MH
& EMT are keyword fields.
Appendix 2. Glossary of terms
 
Term Definition
Abstinence A period of being quit, i.e. stopping the use of cigarettes or other tobacco products, May be defined
in various ways; see also:
point prevalence abstinence; prolonged abstinence; continuous/sustained abstinence
Biochemical verification Also called 'biochemical validation' or 'biochemical confirmation':
A procedure for checking a tobacco user's report that he or she has not smoked or used tobacco. It
can be measured by testing levels of nicotine or cotinine or other chemicals in blood, urine, or sali-
va, or by measuring levels of carbon monoxide in exhaled breath or in blood.
Bupropion A pharmaceutical drug originally developed as an antidepressant, but now also licensed for smok-
ing cessation; trade names Zyban, Wellbutrin (when prescribed as an antidepressant)
Carbon monoxide (CO) A colourless, odourless highly poisonous gas found in tobacco smoke and in the lungs of people
who have recently smoked, or (in smaller amounts) in people who have been exposed to tobacco
smoke. May be used for biochemical verification of abstinence.
Cessation Also called 'quitting'
The goal of treatment to help people achieve abstinence from smoking or other tobacco use, also
used to describe the process of changing the behaviour
Continuous abstinence Also called 'sustained abstinence'
A measure of cessation often used in clinical trials involving avoidance of all tobacco use since the
quit day until the time the assessment is made. The definition occasionally allows for lapses. This is
the most rigorous measure of abstinence
'Cold Turkey' Quitting abruptly, and/or quitting without behavioural or pharmaceutical support.
Craving A very intense urge or desire [to smoke].
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See: Shiffman et al 'Recommendations for the assessment of tobacco craving and withdrawal in
smoking cessation trials'
Nicotine & Tobacco Research 2004: 6(4): 599-614
Dopamine A neurotransmitter in the brain which regulates mood, attention, pleasure, reward, motivation and
movement
Efficacy Also called 'treatment effect' or 'effect size':
The difference in outcome between the experimental and control groups
Harm reduction Strategies to reduce harm caused by continued tobacco/nicotine use, such as reducing the number
of cigarettes smoked, or switching to different brands or products, e.g. potentially reduced expo-
sure products (PREPs), smokeless tobacco.
Lapse/slip Terms sometimes used for a return to tobacco use after a period of abstinence. A lapse or slip
might be defined as a puE or two on a cigarette. This may proceed to relapse, or abstinence may be
regained. Some definitions of continuous, sustained or prolonged abstinence require complete ab-
stinence, but some allow for a limited number or duration of slips. People who lapse are very likely
to relapse, but some treatments may have their effect by helping people recover from a lapse.
nAChR [neural nicotinic acetylcholine receptors]: Areas in the brain which are thought to respond to nico-
tine, forming the basis of nicotine addiction by stimulating the overflow of dopamine




A smoking cessation treatment in which nicotine from tobacco is replaced for a limited period by
pharmaceutical nicotine. This reduces the craving and withdrawal experienced during the initial
period of abstinence while users are learning to be tobacco-free The nicotine dose can be taken
through the skin, using patches, by inhaling a spray, or by mouth using gum or lozenges.
Outcome Often used to describe the result being measured in trials that is of relevance to the review. For ex-
ample smoking cessation is the outcome used in reviews of ways to help smokers quit. The exact
outcome in terms of the definition of abstinence and the length of time that has elapsed since the
quit attempt was made may vary from trial to trial.
Pharmacotherapy A treatment using pharmaceutical drugs, e.g. NRT, bupropion
Point prevalence abstinence
(PPA)
A measure of cessation based on behaviour at a particular point in time, or during a relatively brief
specified period, e.g. 24 hours, 7 days. It may include a mixture of recent and long-term quitters. cf.
prolonged abstinence, continuous abstinence
Prolonged abstinence A measure of cessation which typically allows a 'grace period' following the quit date (usually of
about two weeks), to allow for slips/lapses during the first few days when the effect of treatment
may still be emerging.
See: Hughes et al 'Measures of abstinence in clinical trials: issues and recommendations'; Nicotine
& Tobacco Research, 2003: 5 (1); 13-25
Relapse A return to regular smoking after a period of abstinence
Secondhand smoke Also called passive smoking or environmental tobacco smoke [ETS]
A mixture of smoke exhaled by smokers and smoke released from smouldering cigarettes, cigars,
pipes, bidis, etc. The smoke mixture contains gases and particulates, including nicotine, carcino-
gens and toxins.
Self-efficacy The belief that one will be able to change one's behaviour, e.g. to quit smoking
  (Continued)
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SPC [Summary of Product
Characteristics]
Advice from the manufacturers of a drug, agreed with the relevant licensing authority, to enable
health professionals to prescribe and use the treatment safely and effectively.
Tapering A gradual decrease in dose at the end of treatment, as an alternative to abruptly stopping treat-
ment
Tar The toxic chemicals found in cigarettes. In solid form, it is the brown, tacky residue visible in a ciga-
rette filter and deposited in the lungs of smokers.
Titration A technique of dosing at low levels at the beginning of treatment, and gradually increasing to
full dose over a few days, to allow the body to get used to the drug. It is designed to limit adverse
events.
Withdrawal A variety of behavioural, affective, cognitive and physiological symptoms, usually transient, which
occur after use of an addictive drug is reduced or stopped.
See: Shiffman et al 'Recommendations for the assessment of tobacco craving and withdrawal in
smoking cessation trials'
Nicotine & Tobacco Research 2004: 6(4): 599-614
  (Continued)
 





P = patch, G = gum, S = spray, I = in-
halator, L = lozenge, T = tablet.










Headache Anthenelli 2016 (P) 233 2022 199 2014 Totals are numbers as-
sessed for adverse events
  Areechon 1988 (G) 1 98 0 101 - 
  Berlin 2014 (P) 12 203 9 199 -
  Blondal 1989 (G) 14 92 14 92 From %
  Coleman 2012 (P) 25 521 16 529 Pregnant women







  Gourlay 1995 (P) 8 315 13 314  -
  Harackiewicz 1988 (G) 6 99 8 85 First 6 weeks
  Hays 1999 (P) 24 321 24 322 Excludes pay group
  Hjalmarson 1994 (S) 27 116 18 107 First 2 weeks
  Hurt 1994 (P) 14 120 21 120  -
  Jarvis 1982 (G) 14 47 17 44  -
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52 159 P vs placebo
P + B vs placebo
  Lerman 2015 (P) 139 418 169 408 Number of events
summed over time, not
number of people
  Lewis 1998 (P) 1 62 1 62 -
  Llivina 1988 (G)                          11 113 8 101 From %






Active vs placebo (Pl + Pl
or lowA+Pl)
  Puska 1979 (G) 20 80 14 74 From %; missing data re-
moved from denomina-
tor
  Sachs 1993 (P) 7 113 5 107  -
  Schneider 1995 (S) 41 128 32 127 From %
  Shiffman 2002 (2 mg) (L)










  Stapleton 1995 (P) 84 761 30 364  -
  Stein 2013 (P) 10 104 6 33 -
  Sutherland 1992 (S) 49 111 41 103  -
  Tønnesen 1991 (P) 6 145 6 144 From %
  Ward 2013 (P) < 5% 134 < 5% 135 -
  EX Batra 2005 (G) 43 184 52 180  -







  EX Ebbert 2009 (L) 10 136 7 134 Smokeless (from %)
  EX Hanson 2003 (P) 27 50 34 50 adolescents
  EX Mulligan 1990 (P) 1 39 0 36 - 
  EX Rigotti 2009 (P) 31 367 22 362 All were on rimonabant
  EX Schnoll 2010 (P) 0 182 2 134 At 12 weeks
  EX Stapleton 2011 (S) 320 506 154 255  -
             
  (Continued)
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Ahluwalia 1998 (P) 0 174 1 168  -
  Anthenelli 2016 (P) 85 2022 66 2014 Totals are numbers as-
sessed for adverse events
  Areechon 1988 (G) 2 98 0 101  -
  Berlin 2014 (P) < 5% 203 < 5% 199 -







  Gourlay 1995 (P) 5 315 4 314 - 
  Harackiewicz 1988 (G) 9 99 12 85 First 6 weeks
  Hjalmarson 1994 (S) 24 116 16 107 First 2 weeks
  Hughes 1989a (G) 71 210 18 105 From %
  Jarvis 1982 (G) 15 47 11 44  




10 159 P vs placebo
P + B vs placebo
  Lerman 2015 (P) 42 418 56 408 Number of events
summed over time, not
number of people
  Lewis 1998 (P) 0 62 1 62 -
  Puska 1979 (G) 16 80 16 74 From %;
  Sachs 1993 (P) 1 113 0 107  -
  Schneider 1995 (S) 61 128 69 127 From %
  Stapleton 1995 (P) 46 761 24 364  -
  Stein 2013 (P) 5 104 1 33 -
  Sutherland 1992 (S) 61 111 50 103 - 
  Tønnesen 1991 (P) 6 145 0 144 From %
  Ward 2013 (P) <5% 134 <5% 135 -
  EX Hanson 2003 (P) 20 50 22 50 adolescents
  EX Mulligan 1990 (P) 1 39 0 36  -
  EX Oncken 2009 (P, S) P3 7 3 7 Pregnant women
  (Continued)
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S0 7
  EX Rigotti 2009 (P) 25 367 16 362 All were on rimonabant
  EX Schnoll 2010 (P) 2 182 1 134 At 12 weeks
  EX Stapleton 2011 (S) 308 506 139 255  -




Ahluwalia 1998 (P) 1 174 3 168  -
  Anthenelli 2016 (P) Nausea 199 2022 137 2014 Totals are numbers as-
sessed for adverse events
  Areechon 1988 (G) 2 98 2 101  -
  EX Batra 2005 (G) 19 184 11 180  -










  Campbell 1996 (P) 14 115 4 119 -
  Coleman 2012 (P) 16 521 19 529 Pregnant women
  Dautzenberg 2001 (L) 7 214 11 222  -
  Garvey 2000 (G) 11 209 1 69 (2 mg + 4 mg) %
  Glover 2002 (T) 14 120 3 121  -
  Gourlay 1995 (P) 10 315 7 314  -
  Harackiewicz 1988 (G) 17 99 6 85 First 6 weeks
  Hays 1999 (P) 19 321 16 322 Excludes pay group
  Heydari 2012 (P) Nausea 0 92 0 91 -
  Hjalmarson 1994 (S) 16 116 7 107 First 2 weeks
  Hughes 1989a (G) 69 210 18 105 From %
  Hurt 1994 (P) 6 120 3 120  -
  Jarvis 1982 (G) 20 47 9 44  -
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408 Number of events
summed over time, not
number of people
  Lewis 1998 (P) 4 62 3 62 P + counselling vs Pl +
counselling
  Richmond 1994 (P) 9 156 2 157 From %
  Sachs 1993 (P) 4 113 10 107  -
  Schneider 1995 (S) 24 128 11 127 From %
  Schneider 1996 (I) 14 112 13 111  -
  Shiffman 2002 (2 mg) (L)










  Stapleton 1995 (P)
(= Russell 1993)
34 761 12 364  -
  Stein 2013 (P) Nausea 9 104 2 33 -
  Sutherland 1992 (S) 26 111 20 103  -







  Tønnesen 1991 (P) 6 145 1 144 From %
  Tønnesen 1993 (I) 1 145 1 141 severe
  Wallstrom 2000 (T) 30 123 9 124 From %
  Ward 2013 (P) < 5% 134 < 5% 135 -
  EX Bolliger 2000a (I) 9 200 8 200  -


















  EX Rennard 2006 (I) 11 215 5 214  -
  EX Rigotti 2009 (P) 54 367 36 362 All were on rimonabant
  EX Roddy 2006 (P) 2 49 3 49 “Dizziness, nausea or
headache”
  (Continued)
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  EX Schnoll 2010 (P) 1 182 1 134 At 12 weeks (i.e. 4 weeks
on placebo or patch)
  EX Stapleton 2011 (S) 336 506 168 255  -
  EX Tsukahara 2010 (P) 4 16 0 16 V vs Gum, no placebo














  Campbell 1991 (G) 3 107 7 103 From %







  Dautzenberg 2001 (L) 2 214 8 222  -
  Glover 2002 (T) 11 120 6 121  -
  Harackiewicz 1988 (G) 23 99 8 85 First 6 weeks
  Hjalmarson 1984 (G) 25 92 11 91  -
  Hurt 1994 (P) 4 120 6 120  -
  Hughes 1989a (G) 65 210 18 105  -
  Jarvis 1982 (G) 24 47 12 44  -
  Joseph 1996 (P) 5 294 6 290  -


















408 Number of events
summed over time, not
number of people
  Lewis 1998 (P) 1 62 2 62 -
  Llivina 1988 (G)                          11 113 6 101 From %






  Puska 1979 (G) 12 80 13 74 From %
  (Continued)
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  Sachs 1993 (P) 2 113 4 107  -
  Shiffman 2002 (2 mg) (L)










  Shiffman 2009 (2 mg) (G)










  Schneider 1996 (I) 16 112 11 111  -
  Sønderskov 1997 (P) 7 255 9 267 First 4 wks
  Stein 2013 (P) Diarrhoea 0 104 1 33 -







  Wallstrom 2000 (T) 22 123 11 124 From %
  Ward 2013 (P) < 5% 134 < 5% 135 -
  EX Batra 2005 (G) 12 184 5 180  -











  EX Ebbert 2010 (L) 3 30 0 30 Smokeless (from %)
  EX Ebbert 2009 (L) 15 136 1 134 Smokeless (from %)
  EX Molander 2000 (T) 1 20 1 20 -
  EX Mulligan 1990 (P) 3 39 0 36 - 




1 7 Pregnant women
  EX Tsukahara 2010 (P) 14 16 1 16 V vs Gum, no placebo




Ahluwalia 1998 (P) 0 174 0 168 In first week












2014 Totals are numbers as-
sessed for adverse events
  Berlin 2014 (P) 7 203 5 199 -
  (Continued)
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  Dautzenberg 2001 (L) 2 214 3 222  -
  Gourlay 1995 (P) 43 315 19 314  -
  Hays 1999 (P) 30 321 20 322 Excludes pay group
  Heydari 2012 (P) Abnormal dreams 0 92 0 91 -
  Hurt 1994 (P) 9 120 5 120 - 





















  Joseph 1996 (P) 10 294 6 290 - 






408 Number of events
summed over time, not
number of people
  Llivina 1988 (G)                          7 113 10 101 From %
  Oncken 2007 (P) 5 57 2 95  -






  Perng 1998 (P) 2 30 0 32  -
  Puska 1979 (G) 26 80 20 74 From %;
  Richmond 1994 (P) 41 156 25 157 From %
  Sachs 1993 (P) 4 113 5 107  -








  Ward 2013 (P) 11 134 14 135 -







  EX Ebbert 2009 (L) 15 136 1 134 Smokeless (from %)
  EX Ebbert 2010 (L) 0 30 3 30 Smokeless (from %)
  (Continued)
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  EX Hanson 2003 (P) 30 50 23 50 Adolescents
  EX Mulligan 1990 (P) 2 39 0 36  -
  EX Rigotti 2009 (P) 35 367 11 362 All were on rimonabant
  EX Schnoll 2010 (P) 2 182 6 134 At12 weeks
  EX Tsukahara 2010 (P) 6 16 2 16 V vs Gum












  Gourlay 1995 (P) 5 179 3 143 -
  Hays 1999 (P) 5 321 2 322 Excludes pay group
  Hjalmarson 1994 (S) 9 116 2 107 First 2 weeks









408 Number of events
summed over time, not
number of people, there-
fore excluded from meta-
analysis 6.1.
  Oncken 2007 (P) 1 57 1 95  -
  Schneider 1995 (S) 23 128 10 127 From %
  Shiffman 2009 (2 mg) (G)










  Sønderskov 1997 (P)
“cardiac”
1 255 4 267 First 4 weeks
  Sutherland 1992 (S) 26 111 15 103  -














  EX Bolliger 2000a (I) 1 200 2 200  -
  EX Brantmark 1973a (G) 3 46 4 42  -
  EX Bullen 2010 (P,G) 9 249 1 246  -
  EX CEASE 1999 (P) 25 mg 32 1430 6 714 -
  (Continued)
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15 mg 37 1431
  EX Schnoll 2010 (P) 0 182 2 134 At12 weeks (i.e. 4 weeks
on placebo or patch)
  EX Wennike 2003a (G) 6 205 4 206 -
Wisborg 2000 states 5 women had palpitations, but no distribution info
             
Skin reac-
tions
Abelin 1989 (P) 12 156 1 155 Combined studies
  Ahluwalia 1998 (P) 8 174 5 168  -
  Anthenelli 2016 (P) 109 2022 16 2014 Totals are numbers as-
sessed for adverse events
  Berlin 2014 (P) 23 203 8 199 -
  Buchkremer 1988 (P) 6 42 6 43 From %
  Campbell 1996 (P) 54 115 40 119  -
  Coleman 2012 (P) 97 521 28 529 Pregnant women





  Dautzenberg 2001 0 214 2 222  -
  Davidson 1998 (P) 100 401 52 401 From %
  Gourlay 1995 (P) 44 315 27 314  -
  Hays 1999 (P) 124 321 48 322 Excludes pay group
  Hurt 1990 (P) 19 31 10 31 Over 6 weeks



































  Joseph 1996 (P) 6 294 3 290  -
  (Continued)
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1 75 P+G vs Pl
P+PlG vs Pl






408 Number of events
summed over time, not
number of people
  Lewis 1998 (P) 16 62 11 62 -
  Oncken 2007 (P) 8 57 2 95  -





Active vs placebo (Pl+Pl
or lowA+Pl)
  Perng 1998 (P) 7 30 5 32  -
  Richmond 1994 (P) 36 156 19 157 From %
  Sønderskov 1997 (P) 75 255 49 267 First 4 weeks
  Stapleton 1995 (P) 108 761 18 364  -
  Stein 2013 (P) Flushing or sweating 30 104 11 33 -
  Ward 2013 (P) 12 134 16 135 -
















  EX Hanson 2003 (P) 31 50 24 50 adolescents
  EX Levin 1994 (P) 24 31 21 31  -
  EX Mulligan 1990 (P) 10 39 10 36  -




0 7 Pregnant women
  EX Roddy 2006 (P) 16 49 7 49  -







  Ex Schnoll 2010 (P) 1 182 1 134 @12wks
  EX Tsukahara 2010 (P) 0 16 9 16 V vs Gum, no placebo
             
  (Continued)
Nicotine replacement therapy versus control for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Oral/nasal
reactions
Areechon 1988 (G) 1 98 2 101  -
  Berlin 2014 (P) < 5% 203 < 5% 199 -
  Campbell 1991 (G) 9 107 6 105 From %
  Dautzenberg 2001 (L) 5 214 0 222  -
  Garvey 2000 (G) 2 209 0 69 (2 mg + 4 mg)
  Glover 2002 (T) 24 120 23 121 Weeks 1 to 2
  Harackiewicz 1988 (G) 34 99 1 85 First 6 wks
  Hjalmarson 1984 (P) 24 92 14 91  -
  Hjalmarson 1994 (S) 85 116 40 107 First 2 wks
  Hughes 1989a (G) 160 210 56 105 From %
  Jarvis 1982 (G) 28 47 23 44 - 







  Lerman 2015 (P) 173 418 160 408 Number of events
summed over time, not
number of people
  Llivina 1988 (G)                         13 113 4 101 From %
  Perng 1998 (P) 4 30 0 32  -
  Schneider 1995 (S) 125 128 65 127 From %
  Schneider 1996 (I) 47 112 26 111  -
  Shiffman 2002 (2 mg) (L)

















  Sutherland 1992 (S) 105 111 67 103  -







  Tønnesen 1993 (I) 72 145 24 141 From %
  Wallstrom 2000 (T) 66 123 62 124 From %
  (Continued)
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  Ward 2013 (P) < 5% 134 < 5% 135 -
  EX Adelman 2009 (S) 7 20 0 20 Open-label, no spray for
controls
  EX Batra 2005 (G) 8 184 33 180  -
  EX Bolliger 2000a (I) 14 200 4 200  -
  EX Brantmark 1973a (G) 6 46 3 42  -











  EX Molander 2000 (T) 5 20 0 20  -




0 7 Pregnant women
  EX Rigotti 2009 (P) 23 367 24 362 All were on rimonabant
  EX Stapleton 2011 (S) 194 506 135 255  -
             
Hiccups Berlin 2014 (P) < 5% 203 < 5% 199 -
  Blondal 1989 (G) 13 90 0 92  -
  Glover 2002 (T) 18 120 1 121  -
  Harackiewicz 1988 (G) 8 99 1 85 First 6 weeks
  Hjalmarson 1984 (P) 7 92 0 91  -
  Hughes 1989a (G) 103 210 22 105 From %
  Jarvis 1982 (G) 14 47 2 44  -
  Schneider 1996 (I) 3 112 0 111  -
  Shiffman 2002 (2 mg) (L)


















  Wallstrom 2000 (T) 14 123 0 124 From %
  Ward 2013 (P) < 5% 134 < 5% 135 -
  (Continued)
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  EX Batra 2005 (G) 28 184 3 180 - 
  EX Brantmark 1973a (G) 11 46 2 42  -











  EX Molander 2000 (T) 1 20 0 20  -
  (Continued)
 
F E E D B A C K
How should e>icacy be measured?
Summary
The comment (December 2002) states that NRT is not more eEective than abrupt cessation. We summarise the supporting arguments and
our response to each below:
Reply
1. Pierce & Gilpin (Pierce JP, Gilpin EA. Impact of over-the-counter sales on eEectiveness of pharmaceutical aids for smoking cessation.
JAMA 2002;288:1260-4) found no diEerence in long-term cessation rates between those who did and who did not use NRT.
This point is addressed in a letter commenting on the study (Stead LF et al. EEectiveness of over-the-counter nicotine replacement therapy.
JAMA 2002;288:3109-10). The main limitation of their study is that the comparison between groups of people who chose or did not chose
to use NRT, These two groups probably diEer in many respects related to their chance of successful quitting, and it is impossible to adjust
for these possible confounders. Therefore the conclusions of the study are stronger than the evidence justifies.
The criticism authors also cite the Minnesota insurance review (Boyle RG et al. Does insurance coverage for drug therapy aEect smoking
cessation? Health AEairs 2002 Nov-Dec;21:162-8) but it does not seem to give further support to the point made. The main finding of Boyle
et al was that introducing an insurance benefit did not increase use of NRT.
2. In the real-world those relying exclusively upon NRT are relapsing and dying at pre-NRT rates.
This is an assertion which is not supported by evidence.
3. NRT study instruction is designed and sequenced in order to foster device transfer. In fact the placebo group must be deprived of critical
abrupt cessation instructional tips because if given and followed many could have a negative impact upon the active group.
The review does not make the assertion or implication attributed to it. In the studies involving behavioural support as well as active versus
placebo NRT, both active and placebo groups are typically given instructions designed to maximise their chances of success. In these
circumstances NRT if anything shows a larger advantage over placebo than it does in minimal support settings. If it is being asserted that
placebo groups are being deprived of progressive cigarette weaning or some form of lapse management strategy, there is no evidence to
suggest that this approach is eEective.
4. The duration of abstinence for NRT groups should begin from the time they stop using NRT.
In response to this it should be noted that it is cigarettes which are causing the harm to health and the aim is to help people stop smoking.
Secondly, studies that have followed up smokers long-term show that the medication genuinely improves long-term cessation rates and
does not simply set the relapse clock back by the time period when nicotine replacement is being used.
5. There are clinic programmes achieving success rates at least as good as those using NRT.
It is necessary to make direct comparisons ensuring that the same criteria are applied to both groups to be able to draw conclusions.
Finally it must be noted that the Cochrane review shows that NRT is estimated to help some 7% smokers to stop long-term who would not
have stopped had they used a similar approach but without NRT. This eEect is small but given the health benefits from stopping smoking
it is a highly cost-eEective life-preserving medication. That is not to say that other interventions, including a diEerent kind of behavioural
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intervention that was incompatible with NRT could not get better results. However, it is not enough just to assert the possibility; with so
many lives at stake it would be imperative to demonstrate the eEectiveness of such approaches.
Contributors
Comment by John R. Polito. Response by Tim Lancaster & Lindsay Stead on behalf of review authors. Criticism editor Robert West.
How should e>ectiveness be measured
Summary
The comment (October 2003) suggests that randomised controlled trials (RCTs) alone cannot establish the eEectiveness of an intervention
in a population.
Reply
RCTs establish the size of eEect of an intervention in a particular context in a sample who are eligible and willing to receive the intervention.
It always remains possible that the eEect size would be diEerent in a diEerent population under diEerent conditions which is why it is
important to assess in RCTs how representative the samples are, and how far the context of the trial represents the likely clinical scenarios
in which the intervention will be applied. In other words an RCT seeks to achieve internal validity (corresponding to eEicacy) and aspires to
maximise external validity (corresponding to eEectiveness). A 'real-world' comparison of two groups that are not comparable, and where
the diEerences are not adequately controlled for by design or analysis, does not permit attribution of diEerences or similarities in outcome
to the intervention under investigation.
Contributors
Comment by John Pierce. Reply by Lindsay Stead & Tim Lancaster on behalf of review authors.
Criticism Editors: Robert West (internal), Lisa Bero (external).
Impact of failure to assess blinding on validity
Summary
The comment (May 2004) drew attention to a recent paper (Mooney M, White T, Hatsukami D. The blind spot in the nicotine replacement
therapy literature: assessment of the double-blind in clinical trials. Addictive Behaviors 2004; 29(4):673-684) that notes that most NRT trials
do not report whether blinding was maintained, and of those that did, blinding failure was common.
The comment also suggests that smokers failing to quit with an NRT-assisted attempt will not benefit from NRT use in subsequent attempts,
and questions whether people who quit smoking but continue to use NRT should be regarded as having quit or not.
Reply
The issue of possible failure of blinding, and hence of possible bias in estimates of treatment eEect, is a potential problem in many areas
of medicine. Failure to report whether the success of blinding has been tested is widespread (1). There are problems with how best to test
the eEectiveness of blinding. If participants' guesses are influenced by their success in quitting, then apparent breaking of the blind might
be more common where treatment was eEective (2).
Where there is evidence that blinding has failed, there still needs to be an assessment of whether this has lead to bias in eEect estimates.
Mooney's paper makes it clear that there are insuEicient data to try to assess whether there was evidence of a bias in treatment estimates
in the existing trials. There are many potential sources of bias in trials, and we don't have any evidence to suggest that failure of blinding
is more of a problem in trials of NRT. We focus on outcomes at least six months aOer the quit attempt, so that any diEerential eEect of
guessing the treatment assignment on the likelihood of successful quitting would need to be long lasting.
Small amounts of nicotine have been used in placebo products in attempts to improve maintenance of the blind by giving a characteristic
taste or smell. In most cases the amounts are small. If there were suEicient nicotine to be pharmacologically active it would seem more
likely to decrease the eEect of active NRT than inflate the treatment eEect.
We do not think there is evidence to state that an initial failure with NRT means that subsequent attempts will also fail. People who have
a failed quit attempt in a trial seem to have a low chance of success if they immediately try again, as noted in the studies by Gourlay,
and Tonnesen (which was uncontrolled ). A recent study found a similar poor outcome when people who had failed to quit using nicotine
patch were randomized to second line therapy with bupropion or placebo (5). In contrast, two recent studies have found that people who
reported failed quit attempts using NRT do at least as well when enrolled in trials and treated with NRT as do NRT-naïve participants. (6,7).
It is important that smokers realise that their chance of a successful long-term quit from each attempt is low and that NRT, although
increasing the likelihood of success, is not a 'magic bullet', and this point is made in the review.
We do not agree that people who give up smoking cannot regard themselves as quitters whilst they are using NRT. In the context of a history
of chronic smoking over a period of years we do not think that it is a major concern that 6.7% of new gum users may be still using it aOer
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six months. The rate of persistent use appears to fall rapidly, with the same study noting a rate of 2.8% for use aOer a year or more. Rates
of persistent patch use are lower.
References
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Date Event Description
11 January 2019 Amended Signposts added to more comprehensive and updated data on
NRT in pregnancy
 
H I S T O R Y
Protocol first published: Issue 2, 1996
Review first published: Issue 2, 1996
 
Date Event Description
4 September 2018 Amended CENTRAL search date corrected
8 November 2017 New search has been performed Searches updated, 18 new studies added. Review split into NRT
versus control and NRT versus NRT.
8 November 2017 New citation required but conclusions
have not changed
No changes to conclusions for NRT versus control (other compar-
isons moved elsewhere). Review marked as stable. Changes to
authorship.
19 September 2012 New search has been performed Searches updated, 18 new studies added. Table of adverse
events added.
19 September 2012 New citation required but conclusions
have not changed
Additional author. No major changes to conclusions.
22 June 2011 Amended Additional table converted to appendix to correct pdf format
16 April 2008 Amended Converted to new review format.
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Date Event Description
1 November 2007 New citation required and conclusions
have changed
New studies added, some comparisons reorganised, effect mea-
sure changed from odds ratio to risk ratio. Minor changes made
to the conclusions about the evidence for combinations of NRT
types. Authors changed.
7 April 2004 New citation required and minor
changes
Twelve new studies added, no changes to main conclusions. 
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